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Antimicrobial peptides form an important aspect of the innate immune response of
mammals. They function to kill invading microorganisms and in many cases activate
other aspects of the innate and adaptive immune systems. One of the largest families
of antimicrobial peptides is the defensins. In vertebrates, there are three subfamilies
of defensins, termed a, P and 9 based on the connectivity of the six conserved
cysteines. The p-defensins, which are produced mainly by epithelial tissues and
keratinocytes, came to wider interest when it was proposed that their loss of function
might play a role in the pathogenesis of cystic fibrosis (CF) lung disease. Previous
work has suggested that the airway surface liquid (ASL) of primary cultures of
human airway epithelial cells possess salt-sensitive antibacterial activity and that this
is impaired in CF individuals by elevated levels of sodium chloride. Further work
has also suggested that the p-defensins secreted by the airway epithelia might
comprise an important component of this salt-sensitive defence system.
The aim of this project was 1) to characterise the salt-sensitive antibacterial activity of
members of the human and murine p-defensin subfamily, 2) to analyse their activity
as chemoattractants, 3) to establish a cell culture-based system for the production of
p-defensins to allow for greater analysis of their range of activities and 4) to verify
the validity of novel human p-defensins identified by bioinformatics techniques.
In this thesis describes the characterisation of the salt-sensitive activities of synthetic
human P-defensin 2 (DEFB2), mouse p-defensin2 (Defb2), and a novel p-defensin
related 1, Defrl, which lacks the first of the canonical six cysteines are described
against a range of CF-related pathogens. This work has concluded that a) DEFB2,
Defb2 and Defrl display, to varying degrees, salt-sensitive antibacterial activity, b)
The differences observed between the activities of the peptides may represent the
evolution of species-specific profiles of antibacterial activity for specific defensins. c)
That the loss of in Defrl of the first canonical cysteine does not result in loss of
xxi
antibacterial activity and, most interestingly, Defrl also demonstrates activity against
B. cenocepacia - a pathogen normally resistant to the activity of antimicrobials.
Data presented in this thesis also suggests that synthetic Defb2 and Defrl show
chemotactic activity to CD4+ T-lymphocytes and to immature dendritic cells. This
work concludes that, like human P-defensins 1 and 2, the murine p-defensins, Defb2
and Defrl, can act as a bridge between the innate and adaptive immune systems.
In this thesis, expression pattern of five novel human p-defensins in a range of
human tissues is also analysed. Evidence is presented that they are all expressed at
high levels in the testis and that two of these genes are expressed at much lower
levels a variety of other tissues. These data suggest that the p-defensins are an
expanding, and potentially quite large, subfamily of genes, many of which are yet to
be characterised in terms of their expression profile and the antimicrobial and
chemotactic activities.
Chapter 1: Introduction
1.1 The Adaptive and Innate Immune Systems
Organisms defend themselves against pathogens and foreign particles by a
multitude of immune mechanisms. The immune system can be divided into
two aspects: the innate immune system and the adaptive immune system.
Both systems serve to defend the host from microbial challenge.
Adaptive immunity, which responds specifically to a particular type of
pathogen, is mediated by lymphocytes that express an array of receptors (T-
cell receptors and immunoglobulins). Clonal elimination removes T-cells
bearing a receptor that recognises host molecules, and thus establishes self-
tolerance. Clonal expansion, the proliferation of a lymphocyte clone bearing
an antibody or T-cell receptor specific for a particular antigen, permits the
generation of large immune effector cells with reactive receptors that are
targeted against the appropriate invading pathogen or foreign particle.
Furthermore, following activation of the adaptive immune system some
antigen-specific lymphocytes survive, becoming memory cells and thus the
adaptive immune system possesses the ability to mount a more rapid
response to an antigen upon second exposure.
The acquired immune system has arisen relatively recently in evolutionary
terms and was built over the phylogenetically ancient innate immune system.
The adaptive immune system developed before the separation of vertebrates
and invertebrates and many multicellular organisms depend exclusively on
it. It acts effectively without previous exposure to the pathogen and it
confers protection against a broad range of pathogens. The invading
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organisms are recognised by a series of specific pattern recognition receptors
(PRRs), which recognise 'microbial patterns' - those features that are specific
to microorganisms and distinguish them from multicellular organisms. Such
features include the p-1, 3-glucan of fungi, the lipopolysaccharide (LPS) of
Gram-negative bacteria and the phosphoglycan of parasites reviewed in
(Kimbrell and Beutler, 2001).
Many PRRs have been identified in both vertebrates and invertebrates. They
all function to signal the presence of an invading microorganism and to
activate the innate immune system. One of the most powerful weapons of
the plant innate immune system is the hypersensitive response, which is
rapid and localised cell death at the site of infection; other aspects include the
production of reactive oxygen species, cell wall strengthening and the
production of antimicrobial proteins (reviewed in Cohn et al., 2001). In
insects such as Drosophilia the innate immune will include the activation of
haemocytes, which migrate throughout the body and phagocytose or
encapsulate invading microorganisms, and the activation of proteolytic
cascades leading to clotting and melanisation. Furthermore, the fat body of
insects (analogous to the liver) produces an array of antimicrobial peptides.
In vertebrates however, the inflammatory response is the hallmark of an
innate immune reaction. This is characterised by the production of cytokines
and the activation of macrophages and granulocytes such as neutrophils;
these cells invade the infected area and phagocytose microorganisms. Many
cells, both circulating immune-related cells and those of epithelia also possess
the ability to produce a cocktail of antimicrobial peptides, which can directly
kill the invading organisms.
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1.2 Antimicrobial Peptides
An important feature of the innate immune system and one common to
plants, invertebrates and vertebrates is the production of antimicrobial
peptides. Their widespread distribution throughout the plant and animal
kingdom suggests that antimicrobial peptides have served a fundamental
role in the evolution of multicellular organisms. Despite their ancient
lineage, antimicrobial peptides have remained effective components of the
immune system. Moreover, the range and variety of antimicrobial peptides
produced by organisms is vast, and, as their main target is the microbial
membrane, the evolution of resistance is thought to be unlikely, as it would
involve the redesign of the microbes' membrane. Furthermore, the
acknowledgement of these features of antimicrobial peptides has lead to
considerable commercial and academic research into developing a new
generation of therapeutic antibiotics based on these naturally occurring
antimicrobials (Zasloff, 2002).
1.2.1 The Properties and Classification of Antimicrobial Peptides
Most antimicrobial peptides are encoded by single genes; however, the
diversity in the primary structure is so great that the same peptide sequence
is rarely isolated from two different species - even those that are closely
related. Significant conservation in the preproregion of antimicrobial
peptides is found and this suggests constraints exist of the sequences
involved in cellular processing, folding and secretion of the peptides.
However, single mutations in the sequence of the mature antimicrobial
peptides can dramatically alter their activity. For example, the antibacterial
activity of the a-defensin human neutrophil peptide 1 (HNP-1) has
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significant antimicrobial activity against Candida albicans whereas the a-
defensin peptide HNP-3 is almost inactive even though the two peptides
differ by only one amino acid at the N-termini (Lehrer et al, 1988). This is
likely to increase the spectrum of activity of the peptides and may reflect the
host's adaptation to unique microbial environments (Zasloff, 2002).
Although some examples of anionic antimicrobial peptides have been
reported (Brogden et al., 1996; Kalfa and Brogden, 1999), the vast majority of
antimicrobial peptides are cationic and amphipathic in nature. They are
defined by Hancock and Chappie (1999) as being 12 to 50 amino acids in
length with a net positive charge of at least +2 due to an excess of the basic
amino acids arginine, lysine and histidine over acidic amino acids. They also
contain a high percentage of hydrophobic amino acid residues, reflecting the
fact that these peptides interact directly with cell membranes. Despite their
small size and common physical characteristics, cationic antimicrobial
peptides appear to have arisen from multiple, independent sources, possibly
through convergent evolution (Scott and Hancock, 2000; Zasloff, 2002). The
diversity of cationic antimicrobial peptides is so great that it makes
classification difficult. However, this can be done broadly on the basis of
secondary structure. This gives four major classes - p-sheet structures that
are stabilised by two or three disulfide bridges, a-helical peptides, extended
helices (polyprohelices), and looped structures (Figure 1.1 and Table 1.1)
(Falla et al., 1996).
4
Figure 1.1: Structures of the four main classes of antimicrobial peptide, (a) (3-
stranded sheet of human (3-defensin 1; (b) a-helical cecropin- melittin hybrid; (c)
extended coil of indolicidin; (d) looped structure of bactenecin. The backbone of the
structures is shown with positive charges (+), amino-termini (N), and in (a) and (d)
the disulfide bridges are also indicated. In (a) there are three p-strands; their
beginnings and ends are indicated by pairs of one, two or three lines on the
backbone. Figure taken from Hancock (1997a).
5


















Insects, Vertebrates; epithelial cells, leukocytes
Crustacean (Horseshoe crab), haemocytes
Pig, neutrophils
Table 1.1: Classification of Antimicrobial Peptides. Classification is based broadly on
secondary structure. Four classes of peptide are discernable based on the secondary
structure, relevant examples of each type are shown. Information in table adapted from
Diamond (2001), Zasloff (2002) and Hancock (1997).
The most prominent class of antimicrobial peptide is the (3-sheet structure,
stabilised by two to four disulfide bridges and occasionally containing an a-
helical region, this forms a relatively rigid structure with isolated patches of
hydrophilic and hydrophobic amino acids residues. This structure is seen in
peptides such as defensins (Selsted et al.r 1985). a-Helical peptides are also
very common, however, many of these peptides such as the frog magainin
(Zasloff, 1997) and the insect cecropin peptide (Steiner et al, 1981) are linear,
but when they enter a membrane they assume the amphipathic a-helical
structure indicated in Figure 1.1. Less common are the extended coil
peptides; these tend to have a predominance of more or more amino acids.
For example, the pig antimicrobial peptide PR-39 is 39 residues long and
contains 10 arginine residues, which are positively charged at neutral pH,
and 19 proline residues. The final class of peptides have a looped structure
formed by a single disulfide bond. An antimicrobial peptide found in frogs
from Rana esculenta has an a-helical structure similar to the magainins, but
with the addition of single a loop formed by a disulfide bridge at the
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carboxy-terminus, and thus the peptide forms an 'R' shape (Simmaco et al.,
1994). Whereas, the bactenecin is a [3-sheet stabilised by a single disulfide
bond (Romeo et al., 1998). Some antimicrobial peptides are generated by
enzymatic digestion of much larger proteins, for example an antimicrobial
peptide is generated from lactoferrin (Groenink et al., 1999) and CAP18,
which generates the antimicrobial cathelicidin LL37 (Larrick et al., 1995).
1.3 The Defensin Family of Antimicrobial Peptides
One of the largest and most widely studied families of antimicrobial peptides
is that of the defensins reviewed in (Lehrer and Ganz, 1999). Defensins were
originally isolated from rabbit neutrophil granules as a result of experiments
designed to characterise the oxygen-independent antimicrobial activities of
phagocytes (Selsted et al., 1984) and were also later isolated from the granules
of human neutrophils (Ganz et al., 1985). Subsequent studies isolated and
characterised defensin molecules from plants (Broekaert et al., 1995), insects
(Bulet et al., 1999), and many other vertebrate species (Lehrer and Ganz,
2002b). Defensin peptides fit the definition of cationic antimicrobial peptides
stated above; they are approximately 37 amino acids in length, and have a
net positive charge and they possess broad-spectrum antimicrobial activity
against Gram-positive and Gram-negative bacteria, some fungi and
enveloped viruses.
1.3.1 Classification of Defensin Peptides
Small (3-6 kDa), cationic and cysteine-rich antimicrobial peptides have been
termed defensins; the spacing of the cysteines and the arrangement of the
disulfide bridges that stabilise the (3-sheet structure are used to classify
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defensins into different families and subfamilies (Table 1.2 and Figure 1.2)
reviewed in (Ganz and Lehrer, 1994). Defensin peptides isolated from insects
constitute a single family, whereas in vertebrates, defensins form at least
three separate subfamilies: the originally isolated a-defensins (also termed
classical defensins), the subsequently cloned p-defensins (Tang and Selsted,
1993) and the more recently identified 0-defensin subfamily, which to date
contains only a single member (Tang et al., 1999). Insect and vertebrate
defensins all contain six cysteines, however, the spacing and arrangement of
the cysteines differs reviewed in (Yang et al., 2001). In insect defensins, the
cysteines are linked CI to C4, C2 to C5 and C3 to C6. In a-defensins, the
cysteines are linked C1-C6, C2-C4 and C3-C5; the linkage of the cysteines in
P-defensins is C1-C5, C2-C4 and C3-C6. In rhesus 0-defensin 1, the only 0-
defensin isolated to date, the cysteines are linked in the pattern C1-C6, C2-C5
and C3-C4. Defensins have also been isolated form some plant species,
however, these peptides contain eight cysteines, which form four disulfide
bridges, the cysteines are linked C1-C8, C2-C5, C3-C6 and C4-C7 (reviewed
in Yang et al., 2001).
Classification Origin Intramolecular Disulfide Bridges
Family Subfamily N2 Pattern
Plant Defensins - Seeds, leaves 4 C1-C8, C2-C5, C3-C6, C4-C7
Insect Defensins - Fat body, larvae 3 C1-C4, C2-C5, C3-C6
Vertebrate a Avian and mammalian 3 C1-C6 C2-C4, C3-C5
Defensins leukocytes Paneth cells
P Epithelial cells 3 C1-C5, C2-C4, C3-C6
0 Primate leukocytes 3 C1-C6, C2-C5, C3-C4
Table 1.2: Classification of P-defensins. Table details the classification of p-defensins; this
is based upon the origin (organism and tissue) of the peptide as well as the number, spacing
and connectivity of the conserved cysteine residues. N2 indicates the number of disulfide
bridges present in the defensin molecule. Table taken from Yang et al. (2001).
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1.3.2 The Structure of Defensins
Despite the differences in the structure of defensins detailed above, they all
share a similar [3-sheet structure, which is stabilise by the disulfide bonds.
The defensin structure also demonstrates other features common to
antimicrobial peptides: they have a net positive with arginine as the main
basic amino acid, and an amphipathic structure with spatially isolated
hydrophobic and charged regions (Ganz, 1999).
1.3.3.1 Mechanisms of Action
Defensins, and indeed antimicrobial peptides in general, have been described
as membrane-active agents (Hancock and Lehrer, 1998), and they are all
thought to operate by a similar mechanism. The initial, if not only, target of
antimicrobial peptides is the cell membrane, which also forms the basis for
their selectivity. Defensins, being positively charged, interact with the
negatively charged components of microbial membranes. These components
include LPS in Gram-negative bacteria, teichoic acid in Gram-positive
bacteria, since these features are pathogen-associated molecular patterns
(PAMPs) and not found in eukaryotic cells, defensins in general appear to be
specific for prokaryotic membranes (Raj and Dentino, 2002). Furthermore,
bacterial membranes are organised in such a fashion that the outer leaflet of
the membrane is composed of a high proportion of anionic phospholipids
(e.g. phosphatidylglycerol). This contrasts with the membrane of eukaryotic
cells, in which the outer leaflet is composed primarily of Zwitterionic








Figure 1.2: The Cysteine-Cysteine Pairing of the P-Defensin Families. Schematic diagram
representing the connectivity of the different class of P-defensins peptides. The cysteines are
numbered and represented by 'C, dashes (-) separating the cysteines represent the number of
amino acid residues separating the cysteine residues in the peptide.
composed of negatively-charged lipids. This also means that antimicrobial
peptides have a greater affinity for the negatively-charged bacterial
membranes than the neutral membranes of eukaryotic cells. Moreover, the
presence of cholesterol in mammalian membranes also reduces the potency
of antimicrobial peptides, either by stabilisation of the membrane or by a
more direct interference with the peptide-membrane interaction (Matsuzaki,
1999). Several different theories have been proposed to explain the
antimicrobial mechanism of cationic peptides, and the precise mode of
activity of defensins and other cationic peptides remains a subject of
investigation.
The initial attraction between peptide and the target cell is established by the
electrostatic interaction of the positively-charged peptide and the negatively-
charged membrane. However, in Gram-negative bacteria, the peptides must
first cross the outer membrane, and it has been suggested that this initial
uptake occurs via self-promoted uptake (Hancock and Scott, 2000). This
mechanism was first proposed to explain the uptake of polycationic
antibiotics such as the aminoglycosides and polymyxins (Sawyer et al., 1988).
The peptides interact with the polyanionic surface of the outer membrane.
As the peptides have an affinity for LPS that is at least three orders of
magnitude greater than the native divalent cations, they competitively
displace the Ca^ and Mg++ ions (Figure 1.3). Due to their bulk, the peptides
cause disruption of the outer membrane, which 'cracks' and thus permits the
uptake of the peptides into the periplasmic space (Hancock, 1997a).
Interestingly, species belonging to the Burkholderia cepacia complex have been
shown to be inherently resistant to the action of antimicrobial peptides and
this is thought to be due to a nonreactive cell surface (Hancock, 1997a;
Morrison et al., 1998). In bacteria such as those of the B. cepacia complex the
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LPS has low phosphate and high arabinosamine content, which precludes
divalent cations and cationic antimicrobial peptide binding, and therefore
self-promoted uptake ( Hancock and Bell, 1988; Hancock, 1997b).
It is proposed that the peptides cross the periplasmic space, bind in parallel
to the negatively charged outer leaflet of the membrane and cause membrane
thinning of the leaflet. This causes the outer leaflet of the membrane to
expand or bulge relative to the inner leaflet, which generates strain within
the bilayer. The peptides then reorient, undergo a phase transition and insert
into the microbial membrane with the hydrophobic face interacting with the
hydrophobic core of the lipids and the charged surface of the peptide
forming multimeric pores through which ions and other substances may pass
(Figure 1.3). However, it is unclear exactly how the peptides insert, although
it is thought to be driven by the large electrical potential across the bacterial
membrane.
Two different models have been proposed to describe the structure of the
peptide-membrane pore (reviewed in Ganz and Lehrer, 1999). In the barrel-
stave model, the peptides oligomerise like the staves of a barrel and the
complex behaves as a transmembrane protein. In the wormhole model,
however, the peptides are embedded at the interface between the
hydrophobic interior and the charged headgroups. This causes
phospholipids to deform and bend from top to bottom and produces a pore
lined with phospholipid headgroups and peptides (Ludtke et al., 1996).
Several different hypotheses have also been proposed to explain how the
peptides actually kill the target cells (Figure 1.3). One theory suggests that
the killing event is the formation of the channels in the cytoplasmic
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membrane, which is proposed to result in loss of cell viability (Falla et al.,
1996). An alternative theory, however, suggests that the antimicrobial
peptides enter the cells through the disrupted membranes and interact with
intracellular targets such as DNA (Hancock, 1997a).
Another theory has also been proposed to explain the antimicrobial
mechanism of cationic peptides, which emphasises a different aspect of the
peptide-membrane interaction (Huang, 2000). This theory proposes that the
structural aspects of the interaction of peptide and membrane are of
secondary importance, and the formation of wormhole pores is only a
transitory event that transports peptides to the inner leaflet of the membrane,
where they can interact with cellular targets or lead to further destabilisation
of the membrane and its eventual disintegration (Figure 1.3). In this
electrostatic-interaction theory (sometimes called the carpet model), the
peptides aggregate into positively charged patches or carpets on the cell
surface and neutralise the charge of the phospholipid headgroups over the
area around the peptide aggregate. This neutralisation disrupts the integrity
of the lipid bilayer and causes transient gaps to arise, which permits the
passage of ions and larger molecules (Shai et al, 1999; Hoover et al., 2000).
It is of course possible that all of these events are involved in the killing of the
microbe, with the relative importance of the different events varying from






















Leakage of cell contents ?
Intracellular Targets ?
Membrane disintegration ?
Figure 1.3: Schematic diagram showing the antimicrobial peptide's amphipathic structure and
insertion into bacterial membrane.
A) Self-promoted uptake of peptides across the outer membrane must first occur in Gram-negative
bacteria. The positively charged (red) peptide interacts with and displaces Mg++ ions, leading to the
disruption of the outer membrane and peptide uptake. B) The peptides cross the periplasmic space and
the charged face (red) of the peptide interacts with and carpets the outer leaflet of the membrane. This
causes membrane thinning, which causes swelling of the outer leaflet of the membrane (in bold) and
creates strain within the bilayer eventually leading to peptide insertion in the membrane. The peptides
form pores in the bacterial membrane - either in the toroidal or barrel-stave fashion, which results in cell
death either by leakage of cell contents or by interaction of the peptide with intracellular targets such as
DNA. Figure is adapted from Hancock (1997) and Ganz and Lehrer (1999).
1.3.3.2 Mechanisms of Action - Defensins
The work described above was conducted using a-helical peptides such as
magainins and defensin-like p-sheet peptides, however, this mode of action is
proposed to be the mechanism by which most antibacterial peptides
including defensins function (Raj and Dentino, 2002; Zasloff, 2002). One
study demonstrates that treatment of Micrococcus luteus cells with the insect
defensin, defensin A, results in inhibition of respiration and loss of
cytoplasmic potassium and ATP, suggesting that defensins target the
bacterial membrane, and they also form pores in the membrane (Cociancich
et al, 1993). Furthermore, it has also been demonstrated that a-defensins
permeabilise the membranes of Gram-negative bacteria (Lehrer et al., 1989).
It has also been shown that they interact with anionic lipid vesicles, but not
neutral vesicles through electrostatic and hydrophobic forces, which also fits
the pore-formation model (Kagan et al., 1990; Fujii et al., 1993). A physical
model of a human neutrophil a-defensin peptide (HNP3) has been
constructed based on the x-ray structure of HNP3. This model suggested
that 12 a-defensin monomers were arranged to form a membrane-spanning
pore with an inner diameter of approximately 2 nm (Hill et al., 1991).
The electrostatic interactions between defensins and the target cells suggest
that specific membrane bound receptor interaction are unlikely, and this may
explain why the occurrence of resistant bacterial strains is so rare. However,
plant defensins have been shown to interact with specific binding sites on
fungal cells (Thevissen et al., 2000).
The three-dimensional-structure of several p-defensins have recently been
elucidated and this has greatly increased the understanding of how this
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subfamily of defensins may function (Hoover et al., 2000; Hoover et al., 2001;
Bauer et al., 2001). The human p-defensin 4 peptide has been shown to exist
in both dimeric and octomeric (formed by four dimers) (Hoover et al., 2000).
Furthermore, the structural and electrostatic properties for the DEFB4
octomer, which is suggested to be the form bound to bacterial membranes,
does not show any evidence for burial within the microbial membrane or the
formation of membrane-spanning pores. The uniform distribution of
positively-charged residues suggests that DEFB4 disrupts bacterial
membranes by electrostatic interference as opposed to pore formation
(Hoover et al., 2000). Moreover, a uniform pattern of charge distribution is
observed in the crystal structure of another human p-defensin, DEFB1
(Hoover et al., 2001), and an analysis of the charge distribution of two murine
p-defensins, Defb7 and Defb8, also failed to identify distinct hydrophobic
and cationic regions that would be required for pore formation (Bauer et al.,
2001). Taken together these results suggest that the electrostatic-interference
(or carpet) model, as opposed to the pore formation model, may be common
to p-defensin peptides. There appears to be little evidence to support the
mechanism proceeding by formation of membrane-embedded pores, and the
full elucidation of the antimicrobial mechanism will require further
experiments. However, a recent study suggested that DEFB103 forms
functional ion channels in the membrane of Xenopus oocytes (Garcia et al.,
2001a)
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1.3.4 The Mammalian Defensin Subfamilies
In humans, the defensin gene family is located on chromosome 8p23, and in
the mouse at the syntenic region of mouse chromosome 8A4 (Huttner et al.,
1997; Liu et al., 1998; Morrison et al., 1999; Linzmeier et al., 1999; Jia et al.,
2001). The different classes of mammalian defensins have evolved many
differences however they are thought to share a common ancestry (Linzmeier
et al., 1999).
1.3.4.1 The a-Defensin Subfamily
a-Defensins were initially identified in granules of rabbit and human
neutrophils and have subsequently been isolated from many other species
including mice (Selsted et al., 1984; Ganz et al., 1985). a-Defensins are
encoded by genes comprising three exons and are initially synthesised as
prepropeptides (Lehrer et al., 1993). These have an approximately 20 residue
signal sequence for insertion into the endoplasmic reticulum, which is then
cotranslationally removed, and a 40-45 amino acid propiece cleavage of
which generates the functionally mature a-defensin peptide of
approximately 30 amino acid residues. As discussed above the anionic
propiece serves to neutralise the cationicity of the mature peptide and
therefore may afford some protection from autocytotoxicity, and the a-
defensins do not show antibacterial activity until cleavage of the propiece has
occurred (Valore et al., 1996).
Six human a-defensins have been isolated have been isolated to date (Lehrer
and Ganz, 1999). Four of these, human neutrophil peptide (HNP) 1-4, are
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expressed primarily by neutrophils, but expression has also been reported in
B- and yST-lymphocytes, monocytes/macrophages and natural killer cells
(Ganz et al., 1985; Wilde et al., 1989; Agerberth et al., 2000). In contrast,
however, the other two a-defensin peptides, human defensin (HD) 5 and 6,
are constitutively expressed by the secretory Paneth cells, which lie in the
crypts of the gut epithelium. Expression of HD5 also has also been detected
in the vagina and ectocervix and in the inflamed fallopian tube (Quayle et al.,
1998). Moreover, the expression of HD5 was found to peak during the
secretory phase of the menstrual cycle, suggesting that expression may be
regulated by hormones. Therefore, it appears that in humans the a-defensins
contribute to systemic immunity (HNP1-4) and the defence of a limited
number of epithelial surfaces (HD5 and 6). Human neutrophil defensins are
among the most abundant neutrophil protein: HNP1-3 have been shown to
make up 5-7% of total neutrophil protein and up to 50% of the protein
content of the azurophilic granules of neutrophils. Indeed, their importance
in neutrophil-mediated defence is suggested by specific granule deficiency.
In this disease, a disorder of neutrophil development, the concentration of
HNPs can be a low as 10% of the normal value and affected patients suffer
from repeated infections by common bacteria (Johnston et al., 1992).
Furthermore, acquired defensin deficiency is occasionally observed in
patients with chronic myelogenous leukaemia, however, its clinical
consequences have not been explored (Borregaard et al., 1993; reviewed in
Ganz and Lehrer, 1994).
Mouse neutrophils do not express detectable levels of a-defensins
(Eisenhauer and Lehrer, 1992), however mice do have an extended family of
at least seventeen a-defensins (called cryptidins) that have been identified in
the mouse gut and skin (Ouellette and Selsted, 1996; Shirafuji et al., 1999). It
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has recently been demonstrate that the matrix metalloproteinase matrilysin is
required for activation of cryptidins in the gut via removal of the proregion
(which is acidic and functions to neutralise the basic mature peptide).
Peptides isolated from matrilysin knockout mice were demonstrated to have
significantly impaired antimicrobial activity and orally administered bacteria
survived to a greater extent in the matrilysin-deficient mice compared to
wildtype mice. Furthermore, the LDso of Salmonella typhimurium (the dose
required to kill 50% of treated animals) for matrilysin knockout mice was
10% of that for wildtype mice; these data clearly suggesting that defensins
play a significant role in intestinal defence (Wilson et al, 1999).
Mature a-defensins have been shown to possess broad-spectrum salt-
sensitive antibacterial activity against both Gram-positive and Gram-negative
bacteria (Ganz et al., 1985; Miyasaki et al., 1990). Antimicrobial activity has
also been demonstrated against fungi and some enveloped viruses (Daher et
al., 1986; Lehrer et al., 1986; Lehrer et al., 1988). The microbicidal activity has
been shown to be inhibited by high salt-concentrations (Lehrer et al., 1988;
Lehrer et al., 1993). However, killing by a-defensins may occur in phagoctyic
vacuoles or at epithelial surfaces where salt concentrations may be low or
where the concentration of defensin may be high enough to overcome the
inhibition by salt (Ganz and Weiss, 1997).
1.3.4.2 Other Activities of a-Defensins
a-Defensins have also been shown to possess a range of other activities
(Figure 1.4) (reviewed in van Wetering et al., 1999 and in Yang et al., 2001).
Human neutrophil defensins have been shown to enhance phagocytosis by
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macrophages (Ichinose et al., 1996), and human, rabbit and guinea pig a-
defensins have also been shown to induce histamine release and mast cell
degranulation (Yamashita and Saito, 1989; Befus et al., 1999). Human a-
defensins can augment interleukin- (IL) 8 production and mast cell
degranulation and IL-8 increase neutrophil influx into an inflamed area (van
Wetering et al., 1997a; van Wetering et al., 1997b). Recent data has also
shown that HNP1 and 2 are directly chemotactic for immature dendritic cells
and naive T-cells (Yang et al., 2000a). Furthermore, human a-defensins can
bind to complement factor Clq (Panyutich et al., 1994) and either enhance or
suppress activation of complement via the classical pathway, suggesting that
a-defensins may also regulate the complement cascade. A further study has
also been shown to enhance antigen-specific humoural immunity (Lillard., et
al., 1999). Intranasal delivery of human neutrophil peptides with ovalbumin
enhanced ovalbumin-specific IgG antibodies production compared to

















Figure 1.4: The Various activities of Mammalian Defensins. Spider diagram showing the
diverse range of functions displayed by a-defensins; many of these functions have subsequently
been shown for P-defensins. Where appropriate the arrows indicate an increase or decrease in
activity. Figure taken form Yang et at., 2001.
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1.3.4.3 The 0-Defensin Subfamily
A recent study has identified a novel, circular, defensin subfamily expressed
in Rhesus macaque leukocytes (Tang et al, 1999). Rhesus theta-defensin 1
(RTD-1) is formed from two different a-defensin precursors. The precursor
a-defensins are mutated in that they have acquired a stop codon between the
RTD-1 a
Figure 1.5: Posttranslational Processing of RTD1 Precursors. Small arrows
indicate where RTDla and RTDlb are spliced, generating two nonapeptides and then
ligated to produce the circular mature RTD1. Homodimeric 9-defensins have also been
reported Figure adapted from Tang et al., 1999.
third and fourth cysteine. The precursors (called RTDla and RTDlb) are
translated; their ends are spliced and ligated together to produce a circular
defensin (Figure 1.5). The processed peptide has 18 residues, including six
cysteines that form intramolecular disulfide bonds. A recent study has also
identified two homodimeric 0-defensin peptides (Tran et al., 2002). The two
new 0-defensins, termed RTD-2 and RTD-3, are formed from the
21
homodimeric splicing of RTDlb and RTDla respectively. The cellular ratios
of RTD-1, 2 and 3 were 29:1:2, indicating a clear preference for the
heterodimeric RTD-1. However, the antibacterial activities of the three
peptides were found to be broadly similar, except that RTD-2 demonstrated
significantly lower activity against Escherichia coli.
Interestingly, the antibacterial activity of the cyclic RTD-1 was found to be
salt-insensitive in sharp contrast to the salt-sensitive activity of the a-defensin
peptides. It is also noteworthy that synthetic cyclic analogues of the rabbit
neutrophil a-defensin, rNP-1, also retained antibacterial activity in the
presence of salt-concentrations that inhibited the activity of the normal NP-1
peptide (Yu et al, 2000). Moreover, the antimicrobial activity of the acyclic
form of RTD-1 was inhibited by salt. The authors suggested that this was
due to the presence of additional charges at the termini of the open chain
analogue as opposed to overall structural differences (Tang et al., 1999). This
theory was supported when the three-dimensional structures of RTD-1 and
the open-chain analogue of RTD-1 were elucidated. Furthermore, the
structure of RTD-1 reveals that the peptide lacks a pronounced hydrophilic
structure, and this may be an important factor in the salt-insensitive activity
of RTD-1 (Trabi et al., 2001).
1.3.4.4 The (3-Defensin Subfamily
The first p-defensin to be identified was isolated some years after the initial
isolation of a-defensins. It was cloned from cow trachea and termed tracheal
antimicrobial peptide or TAP (Diamond et al., 1991). p-Defensins were
subsequently found in bovine granulocytes (bovine neutrophil P-defensins,
BNBD1-13) (Selsted et al., 1993), and in chicken leukocytes (gallinacin, Gal-la
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and Gall-2) (Harwig et al., 1994). They were distinguished from a-defensins
by the spacing and connectivity of the six cysteines, which in BNBD12 and
HBD4 are linked C1-C5, C2-C4 and C3-C6 (Table 1.2) (Tang and Selsted,
1993; Garcia et al., 2001b). Further studies identified an inducible bovine p-
defensin, expressed in the tongue, called lingual antimicrobial peptide (LAP)
(Schonwetter et al., 1995). Bovine and avian p-defensins show antimicrobial
activity against both Gram-positive and Gram-negative bacteria in vitro at
concentrations of 10-100 pg/ml (Ganz and Lehrer, 1995). A p-defensin has
also been isolated from pigs (pBDl), which was found to be constitutively
expressed at many epithelial surfaces including the respiratory tract, testis,
kidney and digestive tract (Zhang et al., 1998a; Zhang et al., 1999). Functional
analysis of pBD-1 showed that it possesses salt-sensitive antimicrobial
activity at peptide concentrations of 20-100 pg/ml against bacteria such as
Salmonella typhimurium and Listeria monocytogenes and that the protegrin
peptide PR-39 can act synergistically with pBD-1 against S. typhimurium (Shi
et al., 1999). Two p-defensins have also been cloned from rats (termed RBD1
and RBD2). RBD-1 shows high similarity to the human p-defensin 1 and
mouse P-defensin 1 and was abundantly expressed in the kidney, whereas
RBD2 shows greater homology to human P-defensin 4 and is prevalent in the
lung (Jia et al., 1999). Two p-defensins have also been cloned from sheep and
also from goats (Huttner et al., 1998; Zhao et al., 1999). Taken together these
data suggest that the P-defensins are a widely distributed and highly variable
subfamily of antimicrobial peptides expressed at many different epithelial
surfaces.
Until recently research into the activities of p-defensins lagged behind the
study of a-defensins. However, several recent studies which implicated
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dysfunction of human P-defensin 1 in the pathogenesis of cystic fibrosis (CF)
have renewed interest in the study of this class of peptides (Smith et al., 1996;
Goldman et al., 1997; Zabner et al., 1998).
1.3.4.5 Human and Murine P-defensins
The p-defensin genes are located at the same genetic locus as the a-defensins:
8p22-23 in humans and the syntenic region 8A4 in mice (Figure 1.6A and C).
The p-defensins are also produced as prepropeptides. However, unlike a-
defensins the proregion does not appear to function to neutralise the mature
peptide. This may be because p-defensins are not stored in granules prior to
release, whereas the a-defensins are (Ganz and Lehrer, 1995). Moreover, the
cleavage of the propiece does not appear to be necessary for antimicrobial
activity. Indeed Valore et al. (1998) isolated from urine several different
isoforms of DEFB1, ranging in length form 36 to 47 amino acids due to
different amino-terminal truncations. The 36-residue peptide was the most
abundant and also the most potent and least salt-sensitive isoforms, however
the different isoforms demonstrated different levels of activity and
antibacterial profiles. These data suggest that the proregion of DEFB1 may
serve to alter the antibacterial spectra of DEFB1 and thus increase variation.
This study also produced DEFB1 peptide using a baculovirus system and
isolated different N-terminal isoforms from different cell lines, suggesting
that posttranslational processing of DEFB1 may occur in a cell-specific
manner.
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1.3.4.6 The Human P-Defensins
In humans four p-defensins have been characterised in detail (Figure 1.6B),
although the sequences of at least 28 more have been reported (Schutte et al.,
2002). The similarities and sequences of those p-defensins that have been
characterised in detail are indicated in Table 1.4 and Figure 1.6A and B
The first human p-defensin to be identified was originally isolated from
blood filtrate as a 36 amino acid residue peptide with a molecular mass of
3928.6 Da (Bensch et al., 1995). The sequence of the cDNA showed homology
to bovine TAP, BNBD1-12 and chicken gallinacins, including the six-cysteine
motif, and thus was named human p-defensin 1 (HBD1 or DEFB1).
Subsequently, DEFB1 was found to be constitutively expressed high levels in
the pancreas and kidney and at lower levels in the salivary gland, trachea,
prostate, placenta thymus testis and small intestine (Table 1.3) (Zhao et al.,
1996). DEFB1 expression was located in the loops of Henle and collecting
ducts of the kidney (Schnapp et al., 1998). These results suggest that it may
play a role in the defence of epithelial surfaces and mucosa. The DEFB1 gene
is 7 kb in size, with a 6962 bp intron separating two exons, and is located 150
kb from the HNP-1 gene (Liu et al., 1997). DEFB1 has been shown to possess
salt-sensitive antibacterial activity in vitro against Pseudomonas aeruginosa,
Escherichia coli and Staphylococcus aureus (Goldman et al., 1997; Morrison et al.,
1998; Singh et al., 1998), and its salt-sensitive activity has been implicated in
the pathogenesis of CF lung disease (see section 1.3.5) (Goldman et al., 1997).
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The concentration of DEFB1 has been measured by Singh et al., (1998) and
detected at a concentration of 0.1 to 1 ng/ml in the broncheoalveolar lavage
fluid. Studies have also suggested that DEFB1 possess cytotoxic activity
towards mammalian cells, and that DEFB1 may also play a role in the
eradicative processes at epithelia (Zucht et al., 1998).
The second human (3-defensin initially termed HBD2 or DEFB2 was isolated
from psoriatic skin as a 41 residue peptide with 44% identity to DEFB1 (Table
1.4) (Harder et al., 1997). However, as the peptide is the putative orthologue
of mouse (3-defensin 4 (Defb4) this gene was subsequently renamed DEFB4
and that is the name used in this thesis. DEFB4 was found to exhibit highly
effective killing of Gram-negative bacteria E. coli and P. aeruginosa, and also
the yeast Candida albicans, but only a bacteriostatic effect against the Gram-
positive S. aureus. Further studies have shown the antimicrobial activity of
DEFB4 is salt-sensitive, although this sensitivity can be overcome by
increasing the peptide concentration and moreover the activity is 10-fold
greater than that of DEFB1 and is also synergistic with other aspects of the
innate immune system such as lactoferrin and lysozyme (Harder et al., 1997;
Bals et al., 1998b; Singh et al., 1998). Characterisation of synthetic peptide
based on the sequence of DEFB4 is reported in Chapter 3 of this thesis.
DEFB4 is expressed in the skin, lung and trachea and expression is induced
upon exposure to bacteria and inflammatory stimuli and also in individuals
with bacterial pneumonia (Table 1.3) (Harder et al., 1997; Bals et al., 1998b;
Hiratsuka et al., 1998). Expression of DEFB4 has also been detected in several
other tissues including urogenital tract, salivary gland and uterus (reviewed
in Schroder and Harder, 1999). However, Singh et al. (1998) did not detect
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DEFB4 in the broncheoalveolar lavage fluid of healthy individuals, but in
patients with inflammatory lung disease or cystic fibrosis DEFB4 was present
at a concentration of 1-10 ng/ml.
The DEFB4 gene is located approximately 500 to 600 kb centromeric to
DEFB1 (Figure 1.6) and composed of two exons separated by a 1.6 kb intron
(Liu et al., 1998). Moreover, the flanking region of DEFB4 contains four NFkB
sites, these are not found in the DEFB1 gene but are present in TAP and LAP,
which like DEFB4 are upregulated by inflammatory stimuli (Russell et al.,
1996) and DEFB4 expression has been shown to be induced via by Toll-like
receptor (Tlr2) 2 and CD14 (Becker et al., 2000; Birchler et al., 2001).
The third human p-defensin was identified by screening of genomic
sequences using bioinformatics techniques and was initially termed DEFB3,
but subsequently renamed DEFB103 (Garcia et al., 2001a). It was also
independently purified from psoriatic lesional skin and subsequently cloned
from keratinocytes (Harder et al., 2001). The gene for DEFB103 is composed
of two exons, has a small intron of just 943 bp, and encodes a 67 amino acid
peptide (Garcia et al., 2001a). DEFB103 was found to be expressed in the skin,
tonsils, placenta, testis, trachea and oesophagus, and interestingly,
expression was also found in neutrophils (Table 1.3). Expression is up
regulated by interferon (IFN) -y, but not by tumour necrosis factor (TNF-) a,
or interleukin (IL) -la or -6 (Garcia et al., 2001a). DEFB103 has also been
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TISSUE DEFB1 DEFB4 DEFB103 DEFB104
Skin + +++,nd NR NR
Muscle NR NR ++ NR
Lung + +++lnd + +
Trachea + +++Ind ++ ++lnd
Digestive ++ - + +++
Salivary + - NR NR
Kidney +++ - - +
Liver + - + NR
Heart NR NR ++ NR
Testis NR NR +++ +++
TISSUE Defbl Defb2 Defb3 Defb4 Defb6 Defrl
Skin NR NR NR - NR NR
Muscle NR NR NR NR +++ NR
Lung ++ NR ++lnd - - -
T rachea ++ ++,nd ++lnd ++ + -
Digestive NR NR + +++ + NR
Salivary NR NR + - NR NR
Kidney +++ +++ NR - - -
Liver ++ NR ++lnd - - -
Heart + + NR - - ++
Testis NR NR NR NR - +++
Table 1.3: Pattern of expression of human and murine P-defensins. + = detectable expression, - =
expression not detected, lnd = expression up-regulated following proinflammatory stimuli, NR =
expression has not been reported. N.B. Levels of expression are only comparable for each gene and
not between p-defensins.
SIMILARITIY
Defensin DEFB1 DEFB4 DEFB103 DEFB104 Defbl Defb2 Defb3 Defb4 Defb6 Defrl
DEFB1 - 47 36 33* 57 41 41 43 46 47
I DEFB4 44 - 53 41* 42 36 57 59 53 60
D DEFB103 33 45 - 41* 44 37 51 43 46 43
E DEFB104 45* 41* 38* - 38* 36* 46* 30 44 50*
N Defbl 51 36 37 38* - 50 39 39 48 43
T Defb2 34 31 29 36* 41 - 38 45* 42* 50*
I Defb3 36 49 46 39* 33 38 - 66 70 73
T Defb4 34 48 39 28 30 45* 61 - 72 67
Y Defb6 31 37 40 33 34 39* 59 61 - 68
Defrl 40 52 38 32* 36 46* 72 63 60 -
Table 1.4: Percent similarities and percent identities of the different human and murine P-
defensin prepropeptides. For similarity, between two peptides read vertically down and across. For
identity, read across then vertically up. * Indicates that the peptide alignment does not include a
significant length of the peptide sequences. Analyses were performed using the 'bestfit' function of
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shown to possess salt-sensitive antimicrobial activity in vitro against Gram-
negative bacteria such as P. aeruginosa and E. coli, Gram-positive bacteria
such as Streptococcus pyogenes and Staphylococcus carnosus, and also
demonstrates activity against fungi such as Saccharomyces cerevisiae and
C. albicans. Moreover, one study demonstrated that the DEFB103 has highly
potent and salt-resistant antimicrobial activity against S. aureus and reduced
activity was only observed at supraphysiological concentrations of NaCl
(Harder et al, 2001). Most interestingly it was also found to kill the pathogen
Burkholderia cepacia, that is normally resistant to the activity of antimicrobial
peptides (Garcia et al., 2001a).
The fourth (3-defensin to be identified, initially termed DEFB4 and
subsequently renamed DEFB104, was also identified from genomic sequence
analysis (Garcia et al., 2001b). The gene for DEFB104 is composed of two
exons separated by a 4.5 kb intron, and encodes a 43 amino acid peptide.
DEFB104 shows a more limited pattern of expression compared to the other
human p-defensins, which appear to be diffusely expressed throughout
many organs; in contrast expression of DEFB104 appears to be confined to
just the testis, stomach, uterus, thyroid, lung and kidney (Table 1.3).
Interestingly, and like DEFB103 and bovine p-defensins, expression of
DEFB104 was also detected in neutrophils. Expression was up-regulated by
treatment of airway epithelia with Gram-positive or Gram-negative bacteria
and also in response to phorbol 12-myristate 13-acetate (PMA), but not the
inflammatory stimuli that induced expression of DEFB4 (i.e. DEFB2) or
DEFB103. Analysis of the flanking region of the DEFB104 gene shows the
presence of several AP-1 sites, but no NFkB or STAT binding sites were
detected. This study also investigated the linkage of the disulfide bridges in
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the DEFB104 peptide and further supports the p-defensin arrangement
originally seen in BNBD12 (Tang and Selsted, 1993). Functional analysis of
DEFB104 demonstrates that the peptide possesses a salt-sensitive, but specific
spectrum of antimicrobial activity. The minimum inhibitory concentrations
for DEFB104 against Gram-positive bacteria such as E. coli and S. aureus and
the fungi S. cerevisiae were in excess of 100 pg/ml. In contrast, DEFB104
showed strong activity against S. carnosus, and has particularly potent
activity against P. aeruginosa, the MIC of 4.5 pg/ml, which makes this peptide
one of the most active P-defensin against P. aeruginosa.
1.3.4.7 The Murine (3-Defensins
As discussed above, mouse neutrophils do not express a-defensins (although
Paneth cells in the intestine do). However, five murine p-defensin genes
have been identified and reported in some detail, although partial sequences
of a further 43 have also recently been reported (Schutte et al, 2002). The
reported p-defensin genes are located on chromosome 8A4, which is the
syntenic region of the main p-defensins locus, 8p22-23 in humans (Figure
1.6C). The similarities between the different murine p-defensins are shown in
Figure 1.6D and in Table 1.4.
The first murine p-defensin to be identified, Defbl (also referred to as mBD-1),
was simultaneously identified by three separate groups based on homology
to human DEFB1, with which it has 51% identity at the amino acid level
(Table 1.4) (Huttner et al., 1997; Bals et al., 1998a; Morrison et al., 1998), and it
has since been proposed that Defbl is an orthologue of DEFB1. As with the
other p-defensin, the Defbl gene contains two exons, the first encodes the
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signal sequence and part of the proregion, whereas the second encodes the
mature peptide and the remainder of the proregion, separated by a 16 kb
intron. The encoded Defbl peptide is 69 amino acids in length, and
constitutive expression has been detected at high levels in the kidney, and at
lower levels in the lungs, heart, gut, skeletal muscle and also in purified
alveolar macrophages (Table 1.3). Functional analysis of Defbl has
demonstrated that possesses broad-range salt-sensitive antibacterial activity
against P. aeruginosa, E. coli and S. aureus, although the inhibitory effects of
salt could be partially abrogated by increased concentrations of peptide
(Morrison et al, 1998; Bals et al, 1998a). However, this peptide failed to
demonstrate antimicrobial activity against B. cepacia (Morrison et al., 1998).
A second murine p-defensin (Defb2) has also been reported (Morrison et al.,
1999). Expression of Defb2 was detected in the skin, kidney, lungs, trachea
and uterus (Table 1.3). Analysis of the flanking region did not reveal the
presence of any regulatory elements, however unlike Defbl, expression of
Defb2 was found to be induced by inflammatory stimuli; expression was not
detected in primary cultures of murine airway epithelial cells under normal
conditions, but following treatment with bacterial LPS expression of Defb2 is
up-regulated. The Defb2 gene encodes a 71 amino acid peptide that shows
41% identity to Defbl, and 31% identity to DEFB4. Data relating to the
functional characterisation of Defb2 are presented in chapters 3 and 4 of this
thesis.
The murine p-defensin 3 (Defb3, also called mBD3) gene was isolated from
mouse lung using primers based on the sequence of a rat p-defensin (Bals et
al., 1999). The isolated cDNA exhibited greater similarity DEFB4 (57%) than
to DEFB1 (40%) (Table 1.4). Analysis of the gene structure shows that the
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presence of the 1.7kb intron separating two exons, a NFkB site is also present
in the promoter region of the gene. In contrast to other p-defensins, Defb3
contains an additional amino acid residue between the second and third
cysteines. Expression of Defb3 was highest in the salivary glands and
epididymis, but expression was also detected in the lung, ovary, liver and
brain (Table 1.3). Moreover, expression was induced in the liver and airway
epithelia following tracheal installation of P. aeruginosa. Functional analysis
of the Defb3 peptide showed that it possessed salt-sensitive antimicrobial
activity against the Gram-negative bacteria E. coli and P. aeruginosa that
compared favourably to the activity of DEFB4. The authors of this study also
propose that there are two types of P-defensin. Type 1 P-defensins such as
DEFB1 and Defbl show constitutive expression throughout the epithelia of
many mucosal surfaces and possess broad range salt-sensitive antibacterial
activity against an array of bacteria. Type 2 p-defensins, such as DEFB4 and
Defb3, show inducible expression and possess a narrower range antimicrobial
activity, with a tendency to be specific for particular bacteria.
Mouse Defb4 has also been reported and shown to be expressed in only the
oesophagus, tongue and trachea and expression was not induced by
inflammatory stimuli (Table 1.3). The gene comprises two exons separated
by a 2.4 kb intron, and encodes a 63 amino acid peptide. The Defb4 peptide
shares 59% similarity to its putative human orthologue DEFB4 with a much
lower level of identity to Defb2 (Table 1.4). However, no functional data are
yet available on the activities of this peptide.
The fifth murine p-defensin (Defb5) has to date only been reported as a
GenBank database entry (AF318068). Recently however, a sixth p-defensin
has been cloned from mice. Defb6 was isolated form a bacterial artificial
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chromosome (BAC) and the full-length cDNA subsequently cloned from
skeletal muscle. The peptide shows 59% identity to both Defb3 and Defb4
(Table 1.4), and is also expressed at detectable levels in the oesophagus
tongue and trachea (Table 1.3). Moreover, expression of Defb6 is induced in
the lung by LPS (Yamaguchi et al., 2001). Furthermore, Defb6 showed potent
antimicrobial activity against E. coli with an MIC of 20 pg/ml. This activity
was significantly reduced by high levels of salt. The authors argue suggest
that Defb6 plays an important role in maintaining the sterility of skeletal
muscle, and also suggest that the narrow pattern of tissue expression of this
and other (3-defensins may be due to the acquisition of functional adaptations
by specific p-defensins to the microenvironment and invading
microorganisms in specific organs.
Recently, a novel murine p-defensin was isolated from mouse testis. This
defensin related-1 gene (Defrl) deviates from the canonical six cysteine motif
present in all p-defensins isolated to date (Morrison et al., 2002a). However,
surprisingly, Bauer et al., recently reported the crystal structure for a murine
P-defensin peptide, Defb8, that shows very high levels of identity (98%) to
Defrl over the entire length of the genomic sequence (Bauer et al., 2001). The
Defb8 gene encodes a peptide that differs from Defrl at only three amino acid
residues, one of which restores the characteristic six-cysteine motif to Defb8.
This suggests that Defb8 and Defrl are sequence variants of the same gene.
However, Defb8 transcripts could not be detected from C57B1/6N or
C577B1/6J mice by Dr Gillian Morrison who first cloned Defrl working in this
laboratory. Moreover, the public database of the mouse genome, which is
based on genomic sequence of C57B1/6 mice, also identifies the Defrl peptide
as having only five cysteines, and this further suggests that the Defrl is the
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only form of this gene present. The Defrl gene contains two exons and an
intron of 1.3 kb; analysis of the Defrl nucleotide sequence showed greater
similarity to Defb3-Defb7 (similarities greater than 70%) than to Defbl or
Defb2 (similarities less than 50%) (Table 1.4). Defrl was most highly
expressed in the testis and heart, and at lower levels in the uterus (Table 1.3),
however despite the identification of an NFkB site in the promoter region of
Defrl, intratracheal instillation of P. aeruginosa did not induce expression of
Defrl. Data pertaining to the partial functional characterisation of Defrl is
presented in Chapters 3 and 4 of this thesis.
A recent genome-wide computational search for p-defensin sequences
identified a further 27 novel human and 43 new mouse p-defensin second
exon sequences in addition to the four human and 6 murine p-defensins
described above (Schutte et al, 2002). a-Defensin sequences were not
searched for and there may exist a number of a-defensin sequence yet to be
identified. This analysis revealed these potential p-defensin genes to be
located to five syntenic chromosomal loci. Six novel, potential human p~
defensin genes were located to the known P-defensin cluster at 8p22-23; all
previous p-defensins had been located to that region, a different cluster was
also located to 8p23-22. However this region was not contiguous with the
main p-defensin cluster and therefore may represent a separate cluster. More
surprisingly, Schutte et al. identified a further five P-defensin exon 2
sequences located on chromosome 6pl2, and a two other clusters were
located to chromosome 20 (20pl3 and 20qll.l). In the mouse novel gene
sequences were found in region 8A4, where previous p-defensins have been
identified, but also in additional clusters on chromosomes 1,14 and two on 2.
Interestingly, these chromosomal locations are syntenic with the regions
identified in the human genome; moreover, within each cluster the gene
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sequences and organisation were similar, which suggests that each cluster
arose from a common ancestor and subsequent divergence of sequence with
maintenance of function.
The identification of so many potential p-defensin genes in one study
resulted in the reassignment of p-defensin gene names. The human and
murine p-defensin genes were reassigned so that the numerical epithet of a
particular gene represents the putative orthologous sequence in these two
species, in each case the murine p-defensins retain their original name and
the human p-defensin gene names are correspondingly reassigned. For
example, human DEFB1 is the putative orthologue of mouse Defbl and
therefore the names are retained; however, it has been proposed that human
DEFB2 is the orthologue of murine Defb4, thus human DEFB2 was renamed
as DEFB4 and the previously identified human DEFB4, for which no murine
orthologue has been identified, was renamed DEFB104. This classification
system {i.e. the addition of '10' before the original gene number) is used when
there is no clear orthologue identified in the mouse for a given human gene.
For example, no murine orthologue has been identified for human DEFB3
and consequently whereas murine Defb3 retains that name, DEFB3 is
renamed DEFB103. The nomenclature used in the studies presented in this
thesis incorporate these names changes.
1.3.4.8 The Evolution of Defensins
The subfamilies of mammalian defensins share some similar characteristics
such as their small size, cationicity and the high proportion of cysteines,
however, there also appears to be substantial differences between these
different families in terms of their patterns of expressions. The question has
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been proposed therefore as to whether they have descended from a common
ancestral gene by duplication and divergence reviewed in (Hughes, 1999).
The similarities between the a- and (3-defensins are that the primary
structures show a high proportion of cationic residues and six conserved
cysteines and that the resulting three-dimensional structures show striking
overall similarity. However, the cysteines are the only residues that can be
said to be conserved between a- and p-defensins although, the connectivity
and spacing of the two defensin subfamilies is different (Figure 1.2) and there
are few other conserved residues found in all families of defensins. Thus, it
has been argued that the defensin subfamilies are unrelated and have
evolved by convergent evolution. However, there is also evidence that the
defensins have evolved from an ancestral gene, Liu et al (1997) have shown
that the a-defensin and p-defensin loci are located within 100-150 kb of each
other and propose that this is 'strong direct evidence for evolutionary link;
however, linkage in itself is not evidence of a common evolutionary origin.
For example, the TAP transporter genes are linked to the major
histocompatibility complex (MHC) gene in vertebrates. This link the predates
the divergence of bony fishes and tetrapods (Takami et al., 1997); these genes
are not evolutionarily linked to MHC class I genes although their products
interact functionally. It is possible that the defensin genes originated
separately but that their linkage in the genome has been selectively favoured
(Hughes, 1997; Hughes, 1999). Notwithstanding these considerations,
evidence from structural and sequence analysis appears to support the
existence of an evolutionary link between the defensin subfamilies (reviewed
in Hughes, 1999). Perhaps the strongest evidence is seen in the region
between the third and fourth cysteines, the number of residues in this region
(11) is constant - except in a few murine a-defensins, which have 10.
Moreover, there are other conserved residues; across many defensins, there is
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a glycine and threonine immediately before the fourth cysteine and
furthermore, in most cases the residue after sixth cysteine is often positively
charged (arginine or lysine).
Gene duplication is a key step in the process by which new genes, such as the
defensins, evolve new functions. It has been suggested that gene duplication
is followed by a period in which one copy of the gene is functionally
redundant and this results in the accumulation and random fixation of
neutral or nearly neutral mutations; by chance such mutations may fit a
redundant gene for a new function (Ohno, 1973). However, there is evidence
from other gene families that duplication and subsequent functional
redundancy is not followed by random accumulation of mutations. Rather
evidence suggests that positive Darwinian selection leads to acquisition of
new functions for the products of the daughter genes (Hughes, 1994). It has
also been proposed that duplication of a multifunctional ancestral gene may
permit the daughter genes to specialise to one of the functions of the
ancestral gene. For example, it is thought that eosinophil cationic protein
(ECP) and eosinophil-derived neurotoxin (EDN), which belong to the
ribonuclease superfamily, have evolved from a single EDN-like ancestral
gene even though these two genes possess different activities. EDN
functions as an antiviral agent via ribonucleolytic destruction of retroviral
genomes; in contrast, ECP functions as a membranolytic cationic protein with
only low levels of RNase activity. Whilst it is possible that the
membranolytic activity of ECP was acquired after duplication, it has also
been proposed that the ancestral gene possessed both membranolytic activity
and RNase activity and that subsequent duplication allowed one gene to
evolve into the ECP gene with potent membranolytic activity (Zhang et al,
1998b).
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The theory that a-defensins have evolved by positive selection was tested by
analysing the rates of synonymous and nonsynonymous nucleotide
substitutions (Hughes and Yeager, 1997). In most proteins, the majority of
nonsynonymous substitutions (i.e. those changing the encoded amino acid)
will be deleterious to protein function and therefore quickly eliminated. In
contrast, synonymous substitutions (which do not alter the residue encoded)
are selectively neutral (or nearly so). Therefore, in most proteins the rate of
synonymous substitutions will be in excess of nonsynonymous substitutions.
However, analysis of the sequence of mature a-defensin peptides revealed
that the rate of nonsynonymous substitutions exceeded synonymous
substitutions. This highly unusual pattern of amino acid substitution
suggests that diversification of the a-defensins is selectively favoured. There
is also evidence of the same pattern of evolution in bovine and sheep P-
defensins (Hughes and Yeager, 1997; Hughes, 1999).
1.3.4.9 Three-Dimensional Structure of (3-Defensins
The three-dimensional structures of DEFB1, DEFB2, DEFB103, Defb7 and
Defb8 have recently been reported (Hoover et al., 2000; Harder et al., 2001;
Bauer et al., 2001; Schibli et al., 2002). All the P-defensins have shown similar
structures. The peptides consists of three anti-parallel p-strands similar to
that of the a-defensins, however all human and murine p-defensins analysed
to date have an a-helical structure at the N-terminus (Figure 1.7) that is
absent from a-defensins and bovine p-defensins (Hill et al., 1991;
Zimmermann et al., 1995). Also in contrast to a-defensins, many of the
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Figure 1.7: Schematic Diagram of the Three-Dimensional Crystal structure of a DEFB1
monomer. The a-helix is represented in green and the three anti-parallel (3-sheets ((31, (32, 03)
are shown in blue. The crystal structure of the DEFB4 monomer showed strking similarity to the
DEFB1 structure. Figure taken from (Hoover et al., 2001).
P-defensins analysed appear to lack a defined amphipathic structure, with no
clearly identifiable pattern of charged and hydrophobic residues on the
surface with the accommodation of a wide range of different amino acid
residues at most sequence positions (Bauer et al., 2001). It has been proposed
that this feature of p-defensin structure suggests that p-defensins
antimicrobial activity is mediated by the 'carpet model' rather than through
the formation of stable functional barrel-stave pores (Hoover et al., 2000).
The structures of some p-defensins show a capacity for oligomerisation. For
example, DEFB4 monomers form dimers via interaction of the first p-sheets
and they also show a quaternary arrangement of four dimers to produce a
higher order structure of DEFB4 molecules (Hoover et al., 2000). The authors
propose that the octomer is the form that interacts with bacterial membranes.
Whilst DEFB1 dimers were observed in the crystal structure, there was no
evidence however of higher order structures such as the DEFB4 octomer
(Hoover et al., 2001). Separate studies have suggested that whilst DEFB103
forms amphipathic dimers via the second p-sheet, DEFB4 and DEFB1 exist
only as monomers. The authors suggest that the detection of DEFB4 the
higher order structures identified in the Hoover et al. study (2000) is due to
the high peptide concentration required for crystallisation of the peptide
(Bauer et al., 2001; Schibli et al., 2002). Interestingly, it has also been shown
that DEFB103 can generate ion channel activity the membrane of Xenopus
oocytes, suggesting that DEFB103 may function by the pore-forming
mechanism (Garcia et al., 2001a).
41
1.3.4.10 Additional Functions of P-defensins
As with the a-defensins, it has been suggested that the p-defensins possess
additional cellular functions other than their direct antimicrobial activity.
Several studies have suggested that p-defensins may have a growth
inhibitory or eradicative role at epithelial surfaces. Incubation of DEFB1 with
the mouse tumour cell line NIH 3T3 demonstrated that the p-defensin was
cytotoxic and the authors propose that DEFB1 may play a role in eradicating
cells from epithelia in inflammatory processes (Zucht et al., 1998). However,
it remains unclear whether the observed cytotoxicity was via necrotic or
apoptotic mechanisms. Moreover, an analysis of gene expression in renal cell
carcinomas found that the expression of DEFB1 showed a seven-fold cancer-
specific down-regulation compared to benign tissue. This suggests that This
suggests that down-regulation of DEFB1 expression may be advantageous to
cell growth (Young et al., 2001). Furthermore, it has also been proposed that
p-defensins may play a role in cell differentiation (Frye et al., 2001). When
the expression of DEFB1 was monitored in relation to the differentiation and
proliferation of human HaCaT cells, it was found that DEFB1 expression was
low during proliferation but induced upon differentiation. Moreover, DEFB1
was overexpressed in keratinocytes and analysis of the marker keratin 10
found its expression to be greatly up-regulated in the presence of high levels
of DEFB1. These data suggest that DEFB1 may promote differentiation
processes in keratinocytes. In another recent study DEFB4, but not DEFB1,
was shown to induce prostaglandin D2 synthesis and degranulation in rat
peritoneal mast cells, this activity was also sensitive to pertussis toxin which
suggests that the effects are mediated via a G protein coupled receptor
(Niyonsaba et al., 2001).
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Perhaps the most studied area of (3-defensin function other than the spectra
of antibacterial activity is their ability to act as chemokines for immune
related cells. Previous studies have shown that DEFB4 can induce migration
of immature CD34+ progenitor derived dendritic cells and CD4+ T-cells in
vitro at nanomolar concentrations (Yang et al, 1999). However, in contrast to
HNP-1 and -2, which attract the CD4+/CDRA+ na'ive subset of T-cells, DEFB4
was chemotactic for the CD4+/CD45RO+ memory subset of T-cells. Mature
dendritic cells, naive T-cells and monocytes did not migrate in response to
DEFB4. This migration was found to be pertussis toxin-sensitive, again
suggesting the role of a G protein-coupled seven-transmembrane domain
receptor. Moreover, migration of HEK-293 cells transfected with the
chemokine receptor CCR6 was induced by DEFB1 and DEFB2 at similar
concentrations as dendritic cells and CD4 T-cells. In contrast, cells
transfected with CXCR4, CCR1 and CCR5 (the only other chemokine
receptors expressed on CD34+ dendritic cells) did not migrate suggesting that
(3-defensins act solely through CCR6. A recent study has demonstrated that
DEFB4 is also chemotactic for mast cells, and it is thought that activation is
mediated via a different receptor (Niyonsaba et al., 2002). DEFB103 has been
shown Lo be chemotactic for monocytes but not for neutrophils (Garcia et al.,
2001a), this suggests that different |3-defensins do not exhibit the same
pattern of chemotactic activity and that as with antibacterial activity p~
defensins may have developed a certain degree of specialisation. DEFB104
also possesses chemotactic activity for monocytes, but not for eosinophils or
for neutrophils (Garcia et al., 2001b). Another study has shown that a murine
Defb2 or Defb3 peptide fused to the lymphoma sFv antigen was chemotactic
for immature dendritic cells, but not mature dendritic cells (Biragyn et al.,
2001); this study however did not analyse the chemotaxis of Defb2 or Defb3
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peptides alone. Although, the sFv antigen alone was not chemotactic,
suggesting that the cell migration was due to Defb2 and Defb3. This thesis
presents novel data of the chemoattractant activity of Defb2 and Defrl.
Chemotaxis and the different immune cell types pertinent to this thesis are
discussed in greater detail in section 1.7.
1.4 Other Antibacterial Peptides
1.4.1 Cathelicidins
Cathelicidins constitute another main family of antibacterial peptides of
mammals (Lehrer and Ganz, 2002a). Cathelicidins consist of a putative N-
terminal signal peptide, a highly conserved cathelin (cathepsin L znhibitor)-
like domain in the middle of the molecule and an less conserved antibacterial
C-terminus (Figure 1.8).
29-30 aa 12-100 aa
Signal Peptide Cathelin-Like Domain ^^HAntimicrobial C-terminus
Figure 1.8: The Conserved Structure of Cathelicidin Peptides. The signal peptide is cleaved
prior to further processing and the cathelicidin domain shows a highly level of conservation among
the different cathelicidin peptides; however, the antimicrobial C-terminus shows high-levels of
diversity sequence of secondary structure, aa represents amino acids. Diagram adapted from
Yang et al., (2001).
Cathelicidins have been identified in many mammalian species, including
cattle (e.g., indolicidin and bactenecins), mouse (e.g., mCRAMP) and pigs,
where they are particularly abundant (for example the proline rich peptide
of 39 residues, PR-39 and also the protegrins) reviewed in (Ganz and Weiss,
1997). To date, however, only one cathelicidin peptide has been identified in
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humans, called hCAP18/LL37 (Bals et al., 1998c) (Agerberth et al., 1995;
Cowland et al., 1995; Larrick et al., 1995). The cathelin-like prepropeptide,
hCAP18 is cleaved off by neutrophil elastase to release the antimicrobial C-
terminus peptide called LL37. Cathelicidins are primarily expressed in the
granules of neutrophils and released upon stimulation, however LL37 is also
expressed by epithelial cells such as in the lung and also by monocytes and
T-cells (Agerberth et al., 2000). The C-termini of cathelicidins vary
considerably across the animal species in both sequence and structure (Yang
et al., 2001). For example, LL37 and rabbit CAP18 have an a-helical structure,
whereas others such as PR39 and the bovine bactenecins are show a
polyprohelical structure, and porcine protegrins have p-sheet structures.
Cathelicidins also possess a wide range of functions, including salt-sensitive
antibacterial activity against both Gram-positive and Gram-negative bacteria
and Candida albicans (Zanetti et al., 1995; Cho et al., 1998; Turner et al., 1998).
They have also been shown to have LPS-neutralising activity (Hirata et al.,
1994a; Hirata et al., 1994b; Larrick et al., 1994), to be chemotactic for mast
cells, T-cells and phagocytes (Agerberth et al., 2000; Yang et al., 2000b ; Yang
et al., 2000c ; Niyonsaba et al., 2002).
1.4.2 Histatins
Histatins are small histidine-rich peptides that are present in human saliva
and display moderate activity again C. albicans particularly under acidic
conditions and low salt concentrations (Tsai and Bobeck, 1997). Interestingly,
it is thought that Histatins are not membranolytic and instead act by binding
to a specific 67 kDa C. albicans protein (Edgerton et al., 1998).
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1.4.3 Granulysins
Granulysin is a peptide that belongs to the saposin-like protein gene family
and is found in the granules of CD8+ T-cells and natural killer (NK) cells
(Stenger et al., 1998). Studies with recombinant human granulysin
demonstrated that the peptide had antimicrobial activity against a broad
range of microorganisms, including Mycobacterium tuberculosis.
1.4.4 Cathepsin G
Cathepsin G is a neutral serine proteinase that is primarily present in the
azurophilic granules of neutrophils and to a lesser extent in a membrane-
bound form (Chertov et al., 1997). Additional functions that are ascribed to
Cathepsin G includes the activities seen with other antimicrobial peptides
such as antibacterial activity, neutrophil and monocyte/macrophage
chemotactic activity, but Cathepsin G also stimulates T-cell proliferation and
production cytokines such as interleukin-1, tumour necrosis factor-a (TNFa)
and interferon-y (IFN-y) (Yang et al., 2001; Travis, 1997).
1.4.5 CAP37/Azurocidin
The human cationic antimicrobial peptide 37 (CAP37) was isolated from
neutrophil granules as a component of the oxygen-independent
antimicrobial activity of phagocytes (Shafer et al. 1984) and is also known as
azurocidin (Gabay et al., 1989). The peptide is synthesised as a 351 residues
precursor and processed to give a mature peptide of 222 amino acids. It has
strong homology to serine proteases such as neutrophil elastase and, whilst it
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is too large to fit Scott's and Hancock's (2000) definition of a cationic
antimicrobial peptide (12 to 50 amino acids), it warrants consideration here as
it possesses no enzymatic activity, but exhibits a range of activities similar to
other antibacterial peptides (Yang et al., 2001). Apart form its antibacterial
activity it is also chemotactic for monocytes/macrophages (Chertov et al.,
1997) and T-cells (Chertov et al., 1996) and also binds to and neutralises LPS
(Pereira et al., 1993).
1.5 Bacterial Resistance Mechanisms to Cationic Antibacterial
Peptides
As discussed above the initial target of the cationic antimicrobial peptides are
the LPS, lipoteichoic acids (LTA) and anionic membrane phospholipids, such
as phosphatidylglycerol. Despite these targets being of fundamental
importance, some species of bacteria have developed mechanisms to alter
these structures and thus reduce the attraction of cationic peptides for them
reviewed in (Lehrer and Ganz, 2002b; Peschel and Collins, 2001).
S. aureus and S. xylosus tolerate high concentrations of antimicrobial peptides.
Laboratory-generated mutants were identified that displayed increased
sensitivity. Subsequent analysis revealed that the LTA of these strains lacked
D-alanine, and therefore the cells display an increased negative surface
charge (Peschel et al., 1999). The mutated genes were found to be in the dlt
operon and this complex is responsible for the transportation of D-alanine
and incorporating it into the LTA. The LTA backbone is highly charged and
the incorporation of D-alanine reduces the net negative charge and
consequently the mutant S. aureus in which the LTA contains no detectable
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alanine has a higher net negative surface charge and therefore a greater
binding capacity for cationic peptides (Peschel et al., 1999).
The mprF gene of S. aureus also confers some degree of resistance to
antimicrobial peptide on S. aureus (Peschel et al., 2001). A mprF mutant strain
S. aureus was killed considerably faster by human neutrophils and also
exhibited reduced virulence in mice compared to the wildtype. This suggests
that S. aureus resistance to defensins may play a key in the pathogenicity of
this bacterial species. The MprF gene product covalently modifies the
membrane phosphatidylglycerols with L-lysine, which has the effect of
reducing the net negative charge of the membrane surface. Moreover,
similar genes have been identified in Mycobacterium tuberculosis, Enterococcus
faecalis and P. aeruginosa.
While modification of the cell membrane will reduce its negative charge and
therefore the attraction of cationic peptides bacteria such as Staphylococcus
epidermidis possess a membrane bound transporter that ejects the peptide
from the membrane once they have inserted into the lipid bilayer via ATP
hydrolysis. However, this gene complex is used to protect S. epidermidis from
self-encoded antibacterial peptides such as epidermin and may not generate
resistance to mammalian antibacterial peptides such as defensins.
Furthermore, the naturally occurring staphylococcal plasmid pSKl has been
shown to confer resistance to HNP-1 and also the protegrin-1; this plasmid
encodes the drug exporter QacA, a proton motive force-dependent efflux
pump which transports peptides from the cell (Kupferwasser et al., 1999).
Other members of this family of pumps are the Bmr proteins of E. coli and he
EmrB protein of B. subtilis (Peschel and Collins, 2001). Other bacterial
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species such as P. aeruginosa, Enterococcus faecalis and Mycobacterium
tuberculosis possess several extracellular proteases that attack matrix
proteoglycan and cause the release of dermatan sulfate an anionic molecule
that binds to and inhibits the activity of cationic antimicrobial peptides
(Schmidtchen et al, 2001). Resistance in Salmonella typhimurium to cationic
peptides is also provided by PhoP-PhoQ proteins, which are though to
mediate resistance via the effector genes pmbrA-pmbrB. This results in
alterations to the structure of the LPS, which renders S. typhimurium less
sensitive to the activities of cationic peptides (Fields et al., 1989). Moreover,
PhoP-PhoQ have also been implicated in the observed resistance of
P. aeruginosa to cationic antimicrobial peptides (Macfarlane et al., 2000).
1.6 A Role for (3-Defensins in Cystic Fibrosis
As was discussed earlier it has been proposed that the salt-sensitive activity
of |3-defensins may play a role in the pathogenesis of cystic fibrosis, although
this theory remains controversial and there is a paucity of supporting data.
1.6.1 Pathology and Aetiology of Cystic Fibrosis
Cystic fibrosis is caused by a dysfunction of ion transport across epithelial
due to a mutation in the cystic fibrosis transmembrane conductance regulator
(CFTR). The disease affects many different systems: the gastrointestinal tract,
pancreas, lung reproductive tract, liver and sweat ducts are all altered in CF
patients.
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1.6.2 Cystic Fibrosis Lung Disease
The most serious clinical manifestation of CF is lung disease, which causes
90% of morbidity in CF individuals. CF lung disease is characterised by
chronic bacterial colonisation with repeated acute infection by a distinct flora
of bacteria. These infections induce prolonged inflammatory responses that
produce permanent lung damage. This establishes a vicious cycle of
infection, inflammation and airway damage. Typically, this results in
progressive bronchiectasis (abnormal and irreversible dilation of
bronchioles), respiratory failure and death.
The progress of CF lung disease sees an age dependent 'evolution' of the
bacterial pathogens that colonise the lung. Infections are established in
infants by Staphylococcus aureus and Haemophilus influenzae, but in later years
Pseudomonas aeruginosa is the dominant microorganism. Moreover, in some
cases the opportunistic pathogen Burkholderia cepacia may also colonisation
the lung.
1.6.3 From CFTR Mutation to CF Lung Pathology
It is still unclear how a defect in CFTR leads to lung infection by organisms
that are not normally an issue in human health, or to the excessive
inflammatory response. Several hypotheses have been proposed to explain
this; CFTR mutation may permanently alter the lung environment making it
susceptible to colonisation and infection, or there may be a more direct effect
of CFTR mutation (e.g. preceding airway inflammation). The differing
theories need not be mutually exclusive and it is probable that CF lung
disease will be caused by a multiplicity of factors.
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1.6.3.1 The Airway Surface Liquid
Two theories, which attempt to explain why the CF airway is prone to
infection, are based on alterations in the fluid that the lines the airways, the
airway surface liquid (ASL). ASL is composed of two phases, gel and sol
(perciliary), and contains a wide range of macromolecular products,
including glycoproteins, proteoglycans, lipids, defence molecules, DNA and
actin (reviewed in Pilewski and Frizzell, 1999). ASL covers both the distal
and proximal airways, though the thickness is reported to be relatively
constant (5-10 pm) and move up the airways by cilia action at the rate of
between 1.0 to 10 mm/min; thereby the proximal airways may receive liquid
from distal surfaces. ASL can also be added by the submucosal glands,
although the actual contribution of submucosal glands to ASL is unknown
(Boucher, 1994).
1.6.3.2 The High Salt Theory
This theory proposes that the ASL has an increased NaCl concentration and
this serves to inhibit the action of part of the lungs innate defence system.
This theory is based on work by Zabner and colleagues (1998) who
demonstrated, using a primary culture system, that CFTR is required for
maximal absorption of salt and water; with large amounts of water on the
apical surface both water and salt are absorbed. With tiny amounts on the
surface, salt is absorbed in excess of water; thus according to this model
normal ASL is hypotonic to blood plasma. The reduction in CF absorption
would result in lower Na+ absorption and water, which would be absorbed
by osmosis, is prevented from falling below the level of the cilia by capillary
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forces generated by the cilia. Therefore, in this model, CFTR mutation leads
to lower Na+ and CF absorption and as water absorption is prevented,
consequently the ASL of CF patients would have an elevated NaCl
concentration (Figure 1.9A).
Zabner and colleagues (1998) found ASL to be hypotonic and ASL from
cultured CF cells to have an increased NaCl concentration; they
demonstrated that Na+ concentrations of 50 mM in normal cells with 100 mM
in CF cells and the CF concentration of normal cells to be 37 mM, elevated to
90 mM in CF cells. An earlier study demonstrated that elevated NaCl levels
disabled the lungs innate antibacterial activity (Smith et al., 1996).
P. aeruginosa placed on the epithelia of normal cells in primary culture were
killed, but bacteria placed on the CF cells multiplied; the antibacterial activity
could be restored to CF epithelia with the expression of CFTR. Furthermore,
this antibacterial activity was shown to be a property of ASL, and that it was
lost when the NaCl of normal cells was increased and could be restored to CF
ASL when the salt concentration was lowered (Smith et al., 1996). Work by
Goldman and colleagues suggested that this inactivated component of the
lungs defence system could be the P-defensin DEFB1. Using a human
bronchial xenograft model, the concentration of Na+ and CF was found to be
83 mM in ASL from xenografts, but in CF ASL Na+was found to be 178 mM
and CF was 172 mM. Furthermore, it was demonstrated that anti-sense
oligonucleotides designed to the sequence of hBD-1 ablated the ability of
normal xenografts to kill bacteria. Importantly it was also shown that DEFB1
has salt sensitive antibacterial killing and may therefore be disabled in the CF
lung, thereby predisposing it to infection (Goldman et al., 1997).
52
1.5.3.3 The Mucus Dehydration Theory
While the high salt theory remains an attractive hypothesis the majority of
studies fail to find evidence for elevated salt levels in the ASL of CF patients.
For example, an important and elegant study by Jayaraman et al. (2001)
found no significant difference between the NaCl concentrations of the ASL
of CF individuals compared to non-CF individuals, however they did report
an elevated viscosity of the ASL, supporting the classical or mucus
dehydration theory of CF pathogenesis. The classical view of the CF lung is
of excessive production of dehydrated mucus clogging up the airways and
impeding the mucociliary escalator that is designed to remove bacteria and
other particulate matter from the lungs to the mouth and nostrils where it
can be removed. Bacterial products and the inflammatory response would
stimulate mucus secretion further, thus exacerbating the situation leading to
obstruction of the airways; this would establish the vicious cycle described
earlier.
Crucial to this model is the large disparity between the surface area of the
distal and proximal airways (70m2 and 60cm2, respectively) and that the
depth of ASL remains constant between the two regions (Boucher, 1994).
This implies that there must be absorption of large amounts of liquid as the
ASL is moved up the airways, estimations put this volume at approximately
700ml (Pilewski and Frizzell, 1999). In normal airways this would be driven
by absorption of Na+ through ENaC, CF would follow via CFTR and
paracellular routes and water would be absorbed by osmosis. It has been
proposed that CFTR also serves to suppress the activity of the epithelial
sodium channel (ENaC) and thus in the absence of CFTR there would be
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Figure I.9A: The High Salt Theory. In the absence of CFTR there is greatly reduced CI" absorption
with minimal absorption occurring via the paracellular route. Consequently Na+ absorption is
reduced and thus the concentration of NaCl in the ASL is raised which disables the antibacterial

















Figure 1.9b: The Dehydrated Mucus Theory. Na+ absorption is greater in CF cells due to
misregulation of ENaC, CL absorption via the paracellular route and water absorption (via osmosis)
are increased leading to insipissation of the mucus, which disables mucociliary clearance. Adapted
from Guggino, 1999.
increased level of water absorption (Figure 1.9b) (Matsui et al., 1998). This
would result in dehydration of the mucus, and if the sol layer drops below
the level of the cilia - as it was observed to do in the Matsui model system,
the mucociliary clearance system would be impaired.
1.6.3.4 Other Models for CF Lung Pathogenesis
Many other theories have been proposed to account for the pathogenesis of
CF lung disease. It has been suggested that acts as a specific cellular receptor
for P. aeruginosa via the oligosaccharide core of its lipopolysaccharide (LPS)
and this leads to internalisation. In CF, this process would be impaired and
therefore bacterial clearance reduced (Pier, 2000). According to the bacterial
adherence theory CF pathogens adhere better to CF epithelia than to normal
epithelia. It has been suggested that this is due to a higher proportion of
asialylated glycolipids present on CF epithelia compared to normal epithelia
(Saiman and Prince, 1993). Furthermore, further studies have suggested that
the loss of CFTR leads to defective acidification of intracellular organelles,
which results in the altered levels of asialylated glycolipids (Barasch et al.,
1991).
1.7 Microbiology of the CF Lung
As discussed above chronic bacterial colonisations and repeated bacterial
acute infections are a major symptom of CF. Interestingly, these infections
are by a narrow spectrum of bacteria that are not normally a health threat.
Moreover, the progress of CF lung disease sees an age-dependent 'evolution'
of the bacterial pathogens that colonise the lung. Infants with CF frequently
suffer infection by Staphylococcus aureus, which dominates in the first two
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years of life (often before the onset of overt clinical symptoms), and this is
followed by H. infleunzae. The next stage is characterised by the
predominance of P. aeruginosa, with a third of CF individuals infected by the
age of 5 years (Grimwood, 1997), rising to 90% of CF adults (Hutchison and
Govan, 1999). To add to the difficulties in treating CF, multidrug-resistant
strains from Burkholderia cepacia complex have recently emerged as a new CF
pathogen (Gilligan, 1991). The surprising feature of CF lung disease is that
these bacteria do not normally colonise the lung, although they may
occasionally cause concern in immunosuppressed patients; for example, B.
cepacia is more commonly regarded as a plant pathogen. Colonisation of the
lung by mucoid strains of P. aeruginosa is highly problematic and as they are
rarely cleared from the lung and represent a poor prognosis.
1.7.1 Staphylococcus aureus
The organism first recognised as a serious CF pathogen in the lungs of young
children was S. aureus (Anderson, 1949), although the use of aggressive
antibiotic therapy had reduced the incidence of S. aureus infections coincident
with an increase in infections with P. aeruginosa. However, the development
of antibiotic resistant strains means that S. aureus remains a major human
pathogen. Reports have suggested that as many as 85% of community
acquired S. aureus infections are penicillin resistant, and of particular concern
was the emergence of methicillin-resistant S. aureus (MRSA) in the 1980s.
The resistance to methicillin is conferred by the mecA gene and resistance to
other antibiotics has also been linked to mecA (Cohen., 1986; Kreiswirth et al,
1993; reviewed in Hutchison and Govan, 1999). Moreover, S. aureus remains
a pathogen that predominates in the lungs of CF patients in the first few
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years of life. Indeed, S. aureus is distinguished by a particular capacity to
cause both community and hospital acquired infections and it remains one of
the most frequent human pathogens causing severe morbidity and life-
threatening diseases of various organ systems (Peschel and Collins, 2001).
S. aureus is a Gram-positive, non-motile, non-spore-forming coccus. It is a
human commensal, commonly isolated form the upper respiratory tract,
nasal passages and the skin of healthy individuals, but is also an important
pyogenic organism and produces a number of haemolysins and enterotoxins
(Coia et al., 1992; Hutchinson and Govan, 1999). Moreover, S. aureus
produces teichoic acid and exopolysaccharide that appear to play a role in
adherence to respiratory epithelium in CF patients (Aly et al., 1987). The
precise role of these and other virulence factors in pulmonary colonisation
and subsequent evasion of immune clearance remains unclear. Several
previous studies have shown that S. aureus is susceptible to the activity of (3-
defensins (Singh et al., 1998; Morrison et al., 1998). However, as discussed in
section 1.5, S. aureus has also developed resistance mechanisms to
mammalian and bacterial antimicrobial peptides, which can broadly protect
against a range of cationic peptides (Peschel et al., 1999; Peschel et al., 2001;
reviewed in Peschel and Collins, 2001).
Infections with the Gram-negative Haemophilus influenzae are also common in
young CF patients, however, the role of this bacterium in the evolving
pathogenesis of CF is controversial and its importance may be underrated as
many clinics do not routinely treat patients colonised with this organism
(Govan and Nelson, 1992).
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1.7.2 Pseudomonas aeruginosa
Early studies of the bacterial flora of the CF lungs suggested that P.
aeruginosa played only a minor role in the microenvironment. However, it
appears that the introduction of antibiotic therapy may have had the effect of
reducing the effect of S. aureus infections and increasing the incidence of the
more antibiotic resistant P. aeruginosa. Subsequently, this bacterium has been
recognised as the most important CF lung pathogen, responsible for chronic
bronchopulmonary infection and progressive lung disease (Govan and
Nelson, 1992). After the first two years of life, P. aeruginosa infections begin
to predominate in the CF lung. A third of CF individuals are infected by the
age of 5 years, and this rises to 90% of CF patients in adulthood (Grimwood
et al., 1997; Govan and Nelson, 1992).
P. aeruginosa is a Gram-negative, motile, non-spore-forming, non-capsulate
bacillus widely found in soil and water and is generally acknowledged as an
opportunistic pathogen that causes a wide range of infections in
immunocompromised patients. The most striking feature of this colonisation
is that the infection remains confined to the lungs and that the organism
undergoes considerable phenotypic change. Most notable is the emergence
of mucoid variants due to excessive production of the exopolysaccharide
alginate these strains are unique to CF and practically diagnostic of the
disease (Doggett et al., 1964; Govan and Deretic, 1996). In vivo, the mucoidy
P. aeruginosa grows within this alginate that is composed of the highly
charged exopolysaccharide, host DNA and host mucins, and which serves to
protect the bacteria from antibiotics and phagocytosis (Anwar et al., 1992;
Govan and Harris, 1986; Simpson et al., 1988). The P. aeruginosa infection is
58
established by non-mucoidy, planktonic strains and then due to
environmental pressure these organisms convert to the mucoidy phenotype,
which predominates during the chronic lung infection in CF patients and a
single strain appears comes to dominate. Moreover, once established,
growth by the mucoid P. aeruginosa is hardly ever cleared and represents a
poor prognosis (Gilligan, 1991).
P. aeruginosa is naturally resistant to many antibiotics due to the relatively
impermeable OprF porin in the outer membrane, and active efflux system
and a p-lactamase enzyme (reviewed in Hancock, 1998). However, several
studies have demonstrated that it is susceptible to the activity of p-defensins
(Goldman et al., 1997; Singh et al., 1998; Morrison et al, 1998).
1.7.3 Burkholderia cepacia complex
During the 1980s, another bacterial pathogen emerged as a significant CF
lung pathogen, the first reported isolation of Burkholderia cepacia from lungs
of a CF patient was in 1972 (Ederer and Matsen, 1972). The prevalence of B.
cepacia infection in CF has risen from 10% in the 1970s (Isles et al., 1984), to the
current level of approximately 20% (Hutchison and Govan, 1999). However,
there exists considerable clinic-to-clinic variation, with an incidence of 30-
40% in some clinics where there was significant contamination between
patients, and reaching as high as 70% in some large clinics (Govan et al.,
1996). Moreover, B. cepacia has also been found to cause macerated
hyperkeratonic foot lesions in otherwise healthy marines living in swampy
conditions (Taplin, 1971).
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B. cepacia is a Gram-negative, non-sporing, aerobic, motile bacillus that is
found in soil and water. It was initially described as a plant pathogen from a
study of the soft rot of onions (Burkholder, 1950) and not immediately
recognised as a human pathogen. B. cepacia has a large genome of at least 7
Mb composed of as many as three megabase-sized replicons (Rodley et al.,
1995). B. cepacia has been shown to produce several virulence factors
(reviewed in Hutchison and Govan, 1999). These include a haemolysin that
produces pores in the membrane of erythrocytes, at least two proteases,
which show similarity to P. aeruginosa elastase, lipases and a catalase.
However, only the endotoxin has been shown to have a definitive role in the
pathogenesis of B. cepacia (Hughes et al., 1997; Hutchison et al., 1998). B.
cepacia also possesses a giant cable pilus that has strong affinity for mucin
binding and may serve to anchor bacteria to host lung epithelium (Sajjan et
al, 1995).
B. cepacia is notoriously resistant to the action of antibiotics, antimicrobial
peptides (Hancock, 1997a; Baird et al., 1999) and no effective antibiotic
therapy is yet available. Indeed one study demonstrated that B. cepacia could
use penicillin G as the sole carbon source (Beckman and Lessie, 1979). Strains
of this multiresistant bacterium constitute a threat to both CF patients and
individuals with chronic granulomatous disease, and mouse models of CF
have been shown to have an increased susceptibility to B. cepacia (Sajjan et al.,
2001). This multiresistance of B. cepacia can be attributed to the development
of several different resistant mechanisms (reviewed in Hutchison and Govan,
1999). A (3-lactamase gene that encodes a 31-kDa protein that confers
resistance to several penicillins such as imipenem and carbenicillin has been
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identified (Trepanier et al., 1997); an efflux pump homologous to the oprM
efflux pump of P. aeruginosa has also been described (Burns et al., 1996).
Until 1992, B. cepacia was actually classified as a Pseudomonas and referred to
as P. cepacia; however at this time it, and six other species belonging to the
Pseudomonas rRNA group II, were reassigned to the new genus Burkholderia
(Yabuuchi et al., 1992). However, there was a marked heterogeneity among
several B. cepacia strains isolated from both clinical and environmental
sources and the different strains were subsequently subdivided into at least
five genomic species (genomovars) based on DNA-DNA and DNA-rRNA
hybridisations, fatty acid content and whole-cell protein extract analyses
(Vandamme et al., 1997; reviewed in Coenye et al., 2001a). Since B. cepacia
genomovar I contains the type-strain it retains the formal name B. cepacia;
however, B. cepacia genomovar V was recognised as the previously identified
B. vietnamensis and genomovar II was renamed B. multivorans (Vandamme et
al., 1997) and recently genomovar IV was reclassified as a new species named
B. stabilis (Vandamme et al., 2000). Subsequent analyses identified two
additional members of the B. cepacia complex. Firstly, B. cepacia genomovar
VI, it is possible to phenotypically distinguish this organism from all other B.
cepacia complex members except for B. multivorans (Coenye et al., 2001b), and
B. cepacia genomovar VII, which has been named B. ambifaria and include
isolates form clinical and environmental specimens, such as strains from CF
patients as well as several well-characterised biocontrol strains (Coenye et al.,
2001c). There have been further recent additions to the B. cepacia complex; B.
anthinia has been recognised as genomovar VIII and B. pyrrocinia as
genomovar IX (Vandamme et al., 2002). In the absence of clear-cut
biochemical tests to distinguish genomovars III and VI from B. cepacia
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genomovar I and B. multivorans (genomovar II), these genomovars have not
been formally named. However, it has have recently been proposed that B.
cepacia genomovar III should be renamed as B. cenocepacia (Vandamme et al.r
2002).
Studies of B. cepacia complex infections in CF patients suggested that most
infections are actually caused by B. multivorans (genomovar II) and B.
cenocepacia (genomovar III) strains (Agodi et al, 2001; LiPuma et al., 2002).
Indeed genomovar III colonised patients were at higher risk for
complications and mortality (Aris et al., 2001). Moreover, genomovar III
strains may replace other B. cepacia complex strains in the CF lung
(Mahenthiralingam et al., 2001) and most outbreak strains also belong to
genomovar III (Speert et al., 2002). Furthermore, other studies have indicated
that B. cepacia infection can be spread form patient to patient, and this has
lead to isolation of infected patients. As indicated above, the transmissibility
of B. cepacia is strain dependent and outbreaks result from epidemic strains,
such as the Edinburgh-Toronto (Electrophoresis type 12 (ET/12)) strain. This
bacterium was isolated from the sputum of 33 of the 60 cases of B. cepacia
colonisation in Edinburgh and Manchester CF clinics between 1986 and 1992
(Govan et al., 1993; Govan and Deretic, 1996). This strain often referred to as
B. cepacia J2315, is one of the most resistant of the B. cepacia strains to
conventional antibiotics (Nzula et al., 2002) and used in this thesis to assess
the activity of novel (3-defensins. In this thesis however the proposed new
name B. cenocepacia is used. Previous studies have shown that strains from
the B. cepacia complex are resistant to the activity of cationic peptides such as
P-defensins (Morrison et al., 1998; reviewed in Hancock, 1997a). However the
recently reported DEFB103 was shown to have antibacterial activity against
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B. cepacia with an MIC of 6.6 pg/ml, although this remains the only report of a
p-defensin active against B. cepacia (Garcia et al, 2001a).
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1.8 Aims of this Thesis
The aims of this thesis were to investigate the antibacterial and
chemoattractant activities of murine p-defensins.
The murine p-defensin Defb2 was isolated recently by Dr Gillian Morrison
working in this laboratory. However, its antibacterial activity has not been
assessed and therefore on of the aims of this project is to assess the
antibacterial activity against a range of Gram-negative and Gram-positive
bacteria. This project was established, at least in part, to investigate the
potential role of p-defensins in the pathogenesis of cystic fibrosis (CF), and
therefore many of the bacteria used in this thesis are CF pathogens. The
antibacterial activity of the novel murine p-defensin Defrl, which lacks the
first canonical cysteine present in all p-defensin identified to date, is also
assessed.
Several studies have suggested that human p-defensins possess chemotactic
activity in vitro; it has also been demonstrated that Defb2 fused to the
lymphoma antigen sFv also possesses chemoattractant activity for dendritic
cells. This thesis also analyses the chemoattractant activity of Defb2 and
Defrl for neutrophils, dendritic cells and CD4+ T-cells.
Synthetic Defb2 and Defrl peptides were used in the studies introduced
above. However, such peptides are expensive and doubts persist as to their
correct folding and N-terminal sequence. Therefore, this thesis also describes
an attempt to establish a cell culture-based system for the production of
recombinant p-defensin peptides.
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Finally, novel human P-defensins have been identified by bioinformatics
techniques and another aim of this thesis is to investigate the expression of
these genes by RT-PCR in a variety of human tissues.
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2. Materials and Methods
2.1 Materials
Restriction enzymes, Proteinase K, RNase A, DNase 1, Polynucleotide kinase,
T4 DNA ligase, T4 DNA polymerase, Shrimp alkaline phosphatase and first-
strand cDNA synthesis kits were obtained from Roche, Lewes, East Sussex.
Taq polymerase from Perkin Elmer Applied Biosystems, Roche Molecular
Systems Inc, New Jersey, USA. Gel isolation, PCR purification and
Nucleotide-removal kits were obtained from Qiagen, UK. DNA size markers
X/Hind III came from Roche and the 1 kb ladder was from GibcoBRL;
standard and low melting point (LMP) agarose was from Sigma, Sigma-
Aldrich company Ltd, Dorset; high grade NuSieve agarose was purchased
from Biowhitaker. The membrane used for DNA and RNA blotting was
from React Scientific, Ayrshire, UK. Dialysis tubing for size exclusion and
removal of salt from tissue culture media was purchased form Fisher
Scientific, UK. RNAzol used in isolation of RNA was purchased from
Biogensis Ltd, Poole, Dorset. Diethylpyrocarbonate (DEPC) for dLLO
treatment came from Sigma. Chloroform, phenol and isopropanol were
certified as DNAse- and RNase- free and were purchased from Sigma. Foetal
calf serum (FCS), media and supplements for cell culture were obtained from
GibcoBRL. Tissue culture flasks were supplied by Nunc Intermed, Roskilde,
Denmark and Corning Costar, High Wycombe, Buckinghamshire. The
control chemokines used in the cell migration studies were purchased from
R&D Systems, Abingdon, UK. The filters used in the chemotaxis studies
were from Osmonics. The 48-well microchemotaxis chamber was form
Neuroprobe. Harris haemotoxylin and xylene were purchased from Fisher
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Scientific UK Ltd, Loughborough, UK All mice used were C57B1/6J and
were supplied from Charles River UK Ltd. All mice were female and aged
between 6 to 12 weeks. All radioisotopes came from Amersham
International PLC, Amersham, Buckinghamshire. Oligonucleotide probes
hybridisation and DNA primers for PCR were purchased form MWG
Biotech.Bacto-agar and L-Broth for general bacterial culture were purchased
from DIFCO laboratories, Detroit, USA. Agar and broth for culture of
specific bacterial strains used in antibacterial experiments was purchased
from Oxoid. Plasmids pOPRSV/MCSI and pBluescript II SK, were obtained
from Stratagene Ltd, Cambridge. pGEN-II was from Promega. All other
chemicals and reagents were of molecular biology grade and were obtained
from Sigma, Sigma-Aldrich Company Ltd, Poole, BDH Laboratory supplies,
Poole or Pharmacia Biotech AB, Uppsala, Sweden.
2.2 Standard Molecular Biology Techniques
2.2.1 Restriction Enzyme Digestion of DNA
Plasmid DNA was digested with 5-10 units enzyme/pg DNA for 1 hr.
Genomic DNA was digested overnight with 10 units enzyme/pg DNA.
Digestions were then analysed by gel electrophoresis.
2.2.2 Agarose Gel Electrophoresis ofDNA
Agarose gel electrophoresis of DNA was performed using standard gel-
running apparatus with agarose concentrations between 0.8-2.0 % w/v
depending on the desired fragment resolution. Gels consisting of 3 %
NuSieve agarose gel were used for resolution of DNA fragments below 200
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base pairs (bp). For electrophoresis of DNA for use as a radioactive-labelled
probe the digested DNA was run on a 1.5% low melting point agarose gel.
Agarose was dissolved and cast in TBE buffer (0.09 M Tris-borate; 0.002 M
EDTA (pH 8.0), which was also used as the running buffer. Ethidium
bromide (10 pg/lOOml) was added directly to the molten agarose. Gels were
photographed under UV illumination.
2.2.3 Agarose Gel Electrophoresis ofRNA
10-20 pg of total RNA were resuspended in a total volume of 20 pi sample
buffer (50 % formamide, 2.2 M formaldehyde, 1 x MOPS (20 mM MOPS; 5
mM sodium acetate; 1 mM EDTA)) and incubated at 55°C for 10 min then
placed on ice. 5 pi of 6 x formaldehyde gel-loading buffer (50 % glycerol, 1
mM EDTA (pH 8.0), 0.25 % bromophenol blue, 0.25 % xylene cyanol FF)
were added to each sample and then loaded immediately onto the
formaldehyde gel (1 % agarose; 1 x MOPS; and 18 % formaldehyde). An
RNA sample containing 0.1 pi of ethidium bromide (10 mg/ml) was also
loaded. The gel was run in 1 x MOPS at 50-80 V for 4-8 hr with recirculating
buffer.
2.2.4 Purification of DNA Fragments from Agarose Gels
Using UV illumination the fragment of interest was excised with the
minimum amount of agarose. Purification was carried out using QIAquick
Gel Extraction Kit (Qiagen) following the manufacturer's instructions and
eluting the purified DNA in 30 pi dFUO. For isolation of DNA from LMP
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agarose the band was excised, incubated with 3 volumes of dEEO (v/w) and
heated at 65°C for 3 min or until the gel slice had completely dissolved.
2.2.5 Analysis of Protein Content of P-Defensin Transfected Cells
The protein content of p-defensin transfected C127 cell lines were analysed
by electrophoresis of culture media, cell lysates and purified media/lysates
on a tris-tricine gel according to the method of Schagger and von Jagow
(1987). This system uses a two-layer resolving gel and is appropriate for the
separation of low molecular weight peptides in the MiniProtean II system
(Biorad, herts, UK). The gel apparatus were set up according to the
manufacturer's instructions. The lower resolving gel, composed of 16.5%
acrylamide (30% stock solution of 29:1 acyrlamide:bisacrylamide (Severn
Biotech Ltd, Worcs, UK) and 10% glycerol in lx Gel Buffer (3M Tris, 0.3%
SDS, pH8.45), was polymerised by the addition of 100 pi of a 10% ammonium
persulfate (AMPS) solution and 10 pi TEMED. Simultaneous with this, the
upper resolving gel (or spacer gel)of 10% acrylamide in 0.5% gel buffer was
polymerised and immediately layered over the lower resolving gel. When
this had set, the stacking gel (4% acrylamide in 0.25% gel buffer) was,
polymerised by the addition of 50 pi AMPS and 10 pi TEMED and layered on
top of the resolving gel.
The gel was placed inside the electrophoresis tank and the lower (anode)
buffer (0.2 M Tris) and upper (cathode) buffer (0.1 M Tris, 0.1 M Tricine,
0.1% SDS) were added to the tank. 30 ml of culture media (cell lysates or
purified media/lysate) were added to an equal volume of loading buffer (4%
SDS, 12% glycerol, 50 mM Tris, 2 mM 2-mercaptoethanol, 0.01%
bromophenol blue, pH 6.8), bolied for 5 min and returned immediately to ice.
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The protein samples were loaded on the gel with low molecular weight
markers (Sigma) and the gel was run for 2 hrs at 110 V. Following
electrophoresis, the gel was washed three times in dThO, fixed in a solution
of 50% methanol, 10% acetic acid for 30 min and stained with Bio-safe
Coomassie G-250 (Biorad) according to the manufacturers instructions to
reveal protein content of the loaded samples.
2.3 Preparation of DNA
2.3.1 Preparation of Genomic DNA from Cell Lines
Cell pellets were incubated overnight at 50°C in 1 ml of Quick Lysis Buffer
(100 mM Tris HC1 pH 8.5, 5 mM EDTA, 200 mM NaCl, 0.2% SDS) containing
50 pg of Proteinase K. 1 ml of phenol (pH6.8) was added to the digest, mixed
and then spun at 3 000 rpm for 5 min. The top layer was transferred to a
fresh tube and an equal volume of 25:24:1 phenol:chloroform:isoamyl alcohol
was added. The tube was mixed and centrifuged as before. The top layer
was transferred to a new tube and equal volume of chloroform was added,
and again the contents mixed and centrifuged as before. The top layer was
transferred to a new tube, to which 2.5 volumes of 100% ethanol and 0.1
volumes of 3 M ammonium acetate was added. The tube was vortexed and
spun as before and the precipitated DNA spooled onto glass rods. The DNA
was washed with 70 % ethanol and then air-dried for 5 minutes, after which
it was resuspended in 50 - 100 pi of TE (10 mM Tris HC1, 0.1 mM EDTA, pH
4.0).
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2.3.2 Rapid Small-Scale Plasmid Preparation for Restriction
Enzyme Analysis
5 ml of L-Broth, containing 50 pg/ml ampicillin, was inoculated with a single
bacterial colony using a sterile pipette tip. The cultures were incubated
overnight at 37°C. 1.5 ml of the cell cultures was centrifuged and the
supernatant resuspended in 100 pi of STET buffer (8 % sucrose; 0.5 % Triton-
X100; 50 mM EDTA (pH 8.0); 10 mM Tris-Cl (pH 8.0)). 100 pi of lysozyme (2
mg/ml) in STET buffer were added to each tube, mixed and left at room
temperature for 5 min. The samples were then boiled for 1 min and
centrifuged at 15 000 rpm for 10 min. The resulting pellet was removed with
a toothpick and the DNA precipiated with 3 pi 3 M ammonium acetate and
250 pi isopropanol, mixed and centrifuged at 15000 rpm for 10 min. The
pellet was washed with 70 % ethanol, dried and resuspended in 50 pi TE (pH
8.0). RNase A (100 pg/ml) was included at the time of restriction enzyme
analysis.
2.3.3 Small-Scale Preparation of High Quality Plasmid DNA for
Sequencing
High quality DNA suitable for sequencing was prepared using the QIAprep
Spin Miniprep Kit (Qiagen) following the manufacturer's instructions. The
DNA was eluted in 30 pi of dH20 and the concentration assessed by
spectrophotometry.
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2.3.4 Large-Scale Preparation of High Quality DNA
A 5 ml starter culture was prepared overnight. This was then added to 500
ml of L-Broth containing ampicillin at 100 pg/ml and incubated for 16 hr at
37°C. The culture was then centrifuged in 2 x 250 ml Sorvall bottles at 8 000
rpm for 5 min at 4°C. Both pellets were resuspended in a total of 20 ml of
GET solution (0.05 M glucose; 0.025 M Tris, 0.01 M EDTA (pH 8.0)) and a
small amount of lysozyme added and left on ice for 5 min. 40 ml of freshly
prepared 0.2 M sodium hydroxide/1 % SDS was added, mixed by inversion
and incubated on ice for 10 min. Then 30 ml of potassium acetate buffer (60
ml 5M potassium acetate; 11.5 ml glacial acetic acid and 28.5 ml dlLO) were
added, mixed by inversion and incubated on ice for 10 min. The samples
were then centrifuged at 12000 rpm for 20 min and the resulting supernatant
decanted to a fresh bottle by straining through muslin. The DNA was then
precipitated by the addition of 0.6 volumes of isopropanol, mixed and
centrifuged at 12000 rpm for 10 min. The pellet was washed with 70 %
ethanol, dried and resuspended in 2.5 ml TE (pH 8.0) before being
transferred to a universal containing 2.75 g caesium chloride. 1 mg of
ethidium bromide was added and the solution transferred to an
ultracentrifuge tube. The tubes were heat sealed and centrifuged at 80000
rpm overnight. The DNA, which was present as an ethidium bromide
stained band, was removed using a 21 G needle, transferred to a universal
tube and the ethidium bromide washed out with HzO-saturated butanol. The
DNA was then precipitated by the addition of 10 ml ethanol and centrifuged
at 5000 rpm for 15 min. The pellet was washed in 70 % ethanol, dried and
then resuspended in the desired volume of TE.
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2.4 Preparation of RNA
2.4.1 Preparation ofRNA from Cells and Tissues
3 ml RNAzol B was added to confluent cells in a 75 cm2 tissue culture flask,
and the flask incubated at room temperature for 3 minutes. When the cells
were completely lysed they were transferred to a fresh tube containing 300 pi
chloroform and vortexed for 15 sec followed by a 5 min incubation on ice.
The samples were then centrifuged at 15000 rpm for 15 min at 4°C and the
top layer transferred to a fresh tube on ice. The RNA was precipitated by the
addition of 4 pi glycogen and 500 pi of isopropanol and incubation at 4°C for
at least 15 min. The sample was then centrifuged at 15000 rpm for 15 min
and the resulting RNA pellet washed with 70 % ethanol and dried. The RNA
was resuspended in 35 pi DEPC treated H2O and the quantity and quality of
the preparation assessed by spectrophotometry. RNA was isolated from
whole tissues following the same method except the sample was
homogenized using an Omni portable homogeniser (Camlab limited).
2.4.2 DNase Treatment of RNA
RNA samples were treated with DNasel to remove any DNA present. The
RNA samples were treated in a total volume of 50 pi containing 5 pi of 10 x
DNasel buffer, 10 units of DNase 1 (RNase free) and 40 units of RNase
inhibitor. The samples were incubated at 37°C for 60 min and then extracted
using an equal volume of phenol:chloroform:isoamyl alcohol (25:24:1) by
vortex and then centrifugation for 15 min at 15000 rpm. The top layer was
transferred to a fresh tube and an equal volume of chloroform was added.
The samples were then vortexed and centrifuged for 15 min at 15000 rpm.
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The top layer was then transferred to a fresh tube on ice and the sample
precipitated with 0.1 volumes of 3 M sodium acetate (pH 5.6) and 2 volumes
of ethanol and incubated at -70°C for 30 min. The sample was then
centrifuged at 15 000 rpm for 15 min and the resulting pellet washed with 70
% ethanol. The pellet was dried and resuspended in the desired volume of
DEPC treated H2O and stored at -70°C.
2.5 General Cloning Techniques
2.5.1 Removal of 5' Phosphate Groups from Plasmid DNA
DNA was dephosphorylated with shrimp intestinal alkaline-phosphatase
(SIP) to minimise the recircularisation of plasmid during ligation reactions.
10-20 pg of plasmid DNA were digested as described earlier, the reaction
was then heated at 65°C for 10 mins to inactivate the restriction enzyme(s).
The tube was placed on ice and 1/10 volume of SIP buffer and 1 ml of SIP
enzyme was added, and the tube was incubated at room temperature for 15
mins. The DNA extracted with an equal volume phenol:chloroform:isoamyl
alcohol. The DNA was then precipitated with 2.5 volumes of ethanol for 20
min at 4°C and recovered by centrifugation at 12 000 rpm for 30 min. The
DNA was then resuspended in 90 pi TE buffer (pH 8.0).
2.5.2 Ligation of Fragments
Fragments with sticky complementary ends were ligated overnight at 15°C,
using 1 unit of T4 DNA ligase (Roche). A molar ratio of 3:1 between insert
and linearised vector was used with the concentration of vector at
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approximately 50 ng. Commercially supplied 10 x ligation buffer was used
and the volume of the reaction kept to a minimum, usually 10 pi.
2.6 Bacterial Transformations
2.6.1 Bacterial Transformation - Electroporation
Electrocomp™ TOPIOF cells (Invitrogen), were used for electroporation and
a Bio-Rad Gene Pulser™ and Bio-Rad Pulse Controller were used for the
electroporation procedure with capacitance set at 25 mFD, volts at 2.5 kV and
resistance at 200 Ohms. 2 pi of ligation reaction were added to 40 pi of cells
and incubated on ice for 1 min. The sample was then transferred to an
electroporation cuvette, placed in the electroporation chamber and the
electric charge discharged. 450 pi of room temperature L-Broth were added
immediately after electroporation and the sample transferred to a 15 ml
polypropylene tube. Samples were incubated with shaking at 37°C for 60
min. 10-100 pi of sample were spread onto LB plates (1.5 % w/v bacto-agar
in L-broth) supplemented with the appropriate antibiotic. The plates were
incubated overnight at 37°C.
2.6.2 Bacterial Transformation - Heat Shock Transformation
TOPIOF' One Shot™ Competent Cells (Invitrogen) or DH5a library
effeciency cells (Invitogen) were used for heat shock transformation. 3 pi of
ligation reaction were added to 40 pi of cells and incubated on ice for 30 min.
The sample was heat shocked at 42°C for 30 sec, placed on ice for 2 min and
then 250 pi of L-Broth added. The tubes were shaken at 37°C for 1 hr and
then spread onto plates as above.
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2.7 Direct Cloning of PCR Products
PCR products were cloned into vectors in one of two ways. PCR products
generated by Taq polymerase have 3' deoxyadenosine overhangs and use of
vectors containing single 3' deoxythymidine residues allows PCR inserts to
ligate efficiently with the vector. Direct PCR cloning was achieved using the
pTOPO-2.1 vector. Briefly, 1 pi of fresh PCR product (less then 24 hr old)
was incubated with 1 pi of TOPO vector and 1 pi of buffer and incubated for
30 minutes at room temperature. The reaction mix was then placed on ice
and bacteria transformed as described in section 2.6.
Alternatively, the pGEM-T® vector was used. 3 pi of PCR product was
mixed with 1 pi of pGEM-T vector, 5pl of rapid ligation buffer and 1 pi of T4
DNA ligase. The reaction was mixed and incubated for 1 hr at room
temperature; this was followed immediately by transformation as in section
2.6.2.
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2.8 Amplification of DNA and RNA by the Polymerase Chain
Reaction (PCR).
All PCR reactions were performed using plugged RNase- and DNase-free
tips.
2.8.1 Amplification from DNA
DNA was amplified according to Saiki et al. (1988). A 50 pi reaction
containing up to 1 pg of genomic DNA or 1 ng of plasmid DNA, 5 pi 10 x
PCR buffer (P), 5 pi of 25 mM MgCb, 1 pi of 50 x dNTP mix (10 mM of each
nucleotide) and 100 nm of each primer was prepared in a 0.5 ml thin-walled
PCR tube (Advanced Biotechnologies) or 96-well thermoplate. 2.5 units of
thermostable DNA polymerase from Thermus aquaticus (Taq polymerase)
were added to the mixture. Thermal cycling was controlled by a
programmable heating block (OmniGene, Hybaid). As the defensin genes
are all of a similar size a highly similar PCR amplification conditions could be
used for all reactions, the annealing temperature (Ta) was adjusted,
depending on the melting point (Tm) of the amplimers used, but generally
the annealing temperature was at least 5°C below the melting temperature.
Step 1: 94°C for 3 mins,
35 cycles of:
Step 2: 94°C for 1 min,
Step 3: Ta°C for 30 sees,
Step 4: 72°C for 1 min,
Step 5: 72°C for 10 mins.
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Gene Amplimer Name Amplimer Sequence Ta(°C)
DEFB1 DEFB1 f1 (5') tccaaaggagccagcctctc 55
DEFB1 r1 (3') aaaaagttcatttcacttctgcgt
c
55
DEFB2 DEFB4 f1 (5') ccagccatcagccatgagggt 56
DEFB4 r1 (3') ggagccctttctgaatccgca 56
DEFB105 DEFB105 f1 (5') cgtgctcttctttctgaccc 56
DEFB105 r1 (3') gttcttcatttttcccgcaa 56
DEFB106 DEFB106 f1 (5') tctatttgctatgttcttcattttg
g
56
DEFB106 r1 (3') gcagcagagaaagttcagcc 56
DEFB107 DEFB107 f2(5') tgagactccatttgcttctcc 56
DEFB107 r2 (3') gcaggcaccaatttgatctt 56
DEFB108 DEFB108 f1 (5') tgctgtcctcttcttcacca 56
DEFB108 r1 (3') cggctatttaaacatctccca 56
DEFB109 DEFB109 f1 (5') ttttggctgctctcattcttc 56
DEFB109 r1 (3') tgcagcaaaatggtgctaat 56
hGAPDH hGAPDH f1 (5') gggagccaaaagggtcatc 55
hGAPDH r1 (3') caccgtcactaccgtacctg 55
Defbl Defbl f1 (5') cactctggaccctggctgcc 54
Defbl r1 (3') aatccatcgctcgtccttta 54
Defb2 Defb2 f1 (5') gccatgaggactctctgctc 54
Defb2 r1 (3') tgtcacttgacttccatggc 54
mp -Actin p-Actin f1 (5') ggcccagagcaagagaggtatcc 55








Table 2.1 Sequence of Amplimers used in PCR and RT-PCR
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2.8.2 Amplification from RNA
First-strand cDNA synthesis was accomplished using a First-strand cDNA
Synthesis Kit for RT-PCR (AMV) (Roche). Briefly, duplicate samples of 2 pg
of total RNA in a total volume of 7.8 pi in DEPC treated H2O were
denatured at 65°C for 15 min. To one set of samples were added 2 pi 10 x
PCR buffer, 4 pi MgCh, 2 pi 10 mM dNTPs, 0.4 pi gelatin, 2 pi of random
primer p(dN)6, 40 units RNase Inhibitor, 0.8 pi AMV reverse transcriptase.
The other was set up identically except that AMV reverse transcriptase was
omitted and replaced with DEPC-treated dFEO to verify for RNA
amplification. A minus RNA control was also included to assay for
contamination. The samples were incubated at room temperature for 10 min
to allow the primers to anneal and then placed at 42°C for 1 hr followed by
5min at 95°C to inactivate the enzyme. After the tubes had been cooled on
ice, 5 pi of each reaction were used in a standard PCR reaction as described
in section 2.8.1.
2.9 Transfer of RNA and DNA
2.9.1 Southern Blot Transfer of DNA
The DNA fragments were separated by agarose gel, and then the gel was
soaked in denature buffer (0.5 M sodium hydroxide; 1.5 M sodium chloride)
for 20 min before being briefly rinsed and then soaked in neutralisation
buffer (0.5 M Tris; 1.5 M sodium chloride) for 20 min. The gel was then
transferred onto a nitrocellulose membrane by capillary transfer overnight in
20 x SSC (3 M sodium chloride; 0.3 M sodium citrate). The membrane was
fixed by baking at 80°C for 20 min and then UV stratalinked (Stratalinker
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1800, Stratagene). The membrane was then hybridised as described in
section 2.10.1 or 2.10.2.
2.9.2 Northern Blot Transfer ofRNA
RNA was separated by electrophoresis and the lane containing the RNA-
ethidium bromide was excised and photographed under UV light to visualise
separation. The gel washed 3 x 20 min in dThO and then blotted onto a
nitrocellulose membrane as described in section 2.9.1 but using DEPC-treated
reagents. Hybridisation was performed as described in section 2.10.1.
2.9.3 Construction of Bacterial Colony Hybridisation Filters
A nitrocellulose filter (0.45 pm pore) was placed on a LB agar plate and
marked for orientation. Individual bacterial colonies were then streaked
within a gridded box on the filter and the plate was incubated overnight at
37°C. The filters were removed from the plate and floated in 10 % SDS
(colony side up) for 1 min to lyse the cells and left to dry on filter paper for 1
min. The filters were submerged in denaturing solution (0.5 M sodium
hydroxide; 1.5 M sodium chloride) for 5 min and then neutralisation buffer
(0.5 M Tris; 1.5 M sodium chloride) for 5 min followed by 2 x SSC for 30 sec
and left to dry on filter paper for 30 min. The DNA was fixed onto the
membrane by baking at 80°C.
80
2.10 Radioactive Hybridisation
2.10.1 Preparation of Radioactively-Labelled DNA Probes
Approximately 60 ng of purified DNA in a total volume of 12 pi were boiled
for 10 min to ensure denaturation and then labelled using 4 pi of High Prime
(Roche) and 30 pCi [a-32P] dCTP and the reaction was incubated at 37°C for
30 min. Incorporation was assessed by purifying the probe through a NIK
column (Amersham International PLC, UK). The probe was stripped by
boiling for 10 min with 1 mg sonicated salmon sperm and then added to the
prehybridised filters.
2.10.2 Preparation of Radioactively-Labelled Oligonucleotide
Probes
Labelled probes from oligonucleotides 15-25 bp in length were made by end-
labelling. Approximately 50 ng of oligonucleotide probe were labelled in a
total volume of 20 pi containing 2 pi of 10 x polynucleotide kinase (PNK)
buffer, 10 units of PNK and 30 pCi [y-32P] dATP. The reaction was
incubated at 37°C for 1 hr and then added directly to the prehybridised
filters.
2.10.3 Hybridisation of Radioactive DNA Probes.
Filters were pre-hybridised at 68°C for 2 hr in rotating hybridisation bottles
with 20-30 ml hybridisation solution (6 M sodium chloride, 0.6 M trisodium
citrate, 0.4% sodium dodecyl sulfate, 0.2% sodium pyrophosphate, 2x
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Denhardts (50x Denhardts, 1% polyvinyl pyrrolidine, 1% bovine serum
albumin, 1% Ficoll 400) and 1% of 10 mg/ml of sonicated salmon sperm).
After pre-hybridisation, the radiolabeled probe was added directly to the
solution and the blots hybridised overnight at 68°C. Filters were then
washed with hybridisation wash (3 M sodium chloride, 0.3 M trisodium
citrate, 0.1% sodium dodecyl sulfate) for 2 x 20 min. The background
radiation was monitored with a Geiger counter and if a high-level of
background radiation persisted the washes were repeated but with the SSC
concentration reduced to 1 x and, if required, 0.1 x SSC. The filters were
exposed to Kodak X-OMAT AR film at -70°C in cassettes containing
intensifying screens phosphor-imager intensifying screen at room
temperature.
2.10.4 Hybridisation of Radioactive Oligonucleotide Probes
Filters were pre-hybridised at 48°C for a minimum of 4 hr in rotating
hybridisation bottles with 20-30 ml oligonucleotide hybridisation buffer (3 M
sodium chloride, 0.3 M trisodium citrate, 0.4% sodium dodecyl sulfate and
0.2% sodium pyrophosphate) and 1 mg sonicated salmon sperm. After pre-
hybridisation, radiolabeled oligonucleotide probe (Table 2.2) was added
directly to the solution and the blots hybridised for 4 hr at a temperature of
4-6°C lower than the oligo Tm. Filters were then washed with 6 M sodium
chloride, 0.6 M trisodium citrate and 0.1% sodium dodecyl sulfate. The filters
were then exposed to Kodak X-OMAT AR film at -70°C in cassettes




Sequencing of double strand DNA was performed using the ABI Prism™
dRhodamine Terminator Cycle Sequencing Ready Reaction Kit (PE Applied
Biosystems). 500 ng of double stranded DNA were amplified in a total
volume of 20 pi containing 18 ng or 3.2 pmol of amplimer (Table 2.1)
Terminator Ready Reaction Mix in 0.2 ml Micro-Tubes (Advanced
Biotechnologies Ltd) with the following cycling conditions: 25 cycles of 96°C
for 30 sec; 50°C for 15 sec; 60°C for 4 min. The resulting products were then
precipitated by the addition of 2 pi 3 M sodium acetate and 50 pi 95 %
ethanol and centrifuged at 15000 rpm for 30 min. The resulting pellet was
washed with 70 % ethanol and dried in a speedivac. Samples were
electrophoresed on a ABI 377 sequencing machine (Perkin Elmer Applied
Biosystems) and the results analysed using Sequencing analysis software
ImageQuant™ (Molecular Dynamics).











Table 2.2: Sequence of Oligonucleotide Probes.
Sequence reads 5' to 3'.
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2.12 Cell Isolation and Culture
2.12.1 Culture of C127 and HBE cell lines
The CI27 mouse mammary epithelial cell line and human bronchial
epithelial (HBE) cell line were cultured in Dulbecco's Modified Eagle
Medium (DMEM) with 5-10% foetal calf serum (FCS) L-glutamine, 500 Units
penicillin and 50 mg/ml streptomycin, and the cells incubated at 37°C in
humidified incubator with 5% CO2. When approximately 90% confluent, the
cells were subcultured into a fresh culture flask. The monolayer was washed
once with versene (0.48% EDTA in Dulbeccos's PBS)) and then incubated at
37°C with 3 ml of trypsin solution (0.075% in Hanks Buffered Saline
Solution, Sigma), preheated to 37°C for 5 min or until all the cells had
detached from the surface. 12 ml of culture media was added to stop the
reaction and 1-5 ml of the cell suspension was transferred to a new culture
vessel.
2.12.2 Transfection of C127 and HBE Cell Lines
The C127 and HBE cell lines were transfected by the calcium phosphate
method. One day prior to the transfection cells were trypsinised from the
culture vessel and resuspended in a 6 mm-diameter culture dish at a density
of 5x 106 cells/dish, giving approximately 50-70% confluence after 24 hrs. 10
pg of linearised defensin-pOPRSVII/MCS or empty vector was resuspended
in 218.75 pi of 0.1% TE buffer (1 mM Tris, 0.1 mM EDTA, pH8.0), and
transferred to a sterile 5 ml Falcon tube. To this 31.25 pi of 2 M Calcium
Phosphate, with gentle agitation (generated by gently blowing air bubbles
through the mixture) 250 pi of 2 x HEPES-buffered saline (HBS, 5 M sodium
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chloride and 1 m HEPES) was added over a 30 second period. The complex
of calcium phosphate precipitation was allowed to form over 20 minutes
with constant agitation. Media was removed from the cells to be transfected
and the monolayer washed twice with phosphate buffered saline (PBS)
(Sigma, UK). The calcium-phosphate suspension was added directly to the
monolayer and the cells were incubated at 37°C for 15 min. After this period,
4 ml of complete media was added and the cells incubated for a further 4
hours. The media-precipitate mixture was removed and the monolayer
washed once in media.
The monolayer was then treated with a solution of 24% DMSO in HBS for 3
min at room temperature; the monolayer were then washed three-times with
serum-free media, complete media was added and the cells incubated for 24
hrs as normal. After this time the cells were subcultured, as described above,
1:3 into 6-well plates and G418-selection was added to the culture media at a
concentration of 500 mg/ml and the cells were incubated as normal.
2.12.3 Selection of C127 Defensin-Transfected Clones
Transfected cells were grown in presence of the selection for approximately
14-21 days, after this time most cells had died and single G418-resistant
colonies could be seen. When sufficiently large the clones were trypsinised
from the culture flask as described earlier and cultured in a 48-well culture
dish with continued selection. The procedure was repeated to allow the
selected clones to be cultured in successively larger vessels up to a 75 cm2
culture flask.
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2.12.4 Harvesting of Cell Lysates and Culture Media
Following approximately 48 hr of a confluent cell monolayer maintained in
25 ml of media (as described above with 5% FCS), the media was harvested
into a 50 ml Falcon tube and frozen at -70°C. The cell monolayer was
harvested by trypsinisation, as described earlier. The cell pellets were
resuspended in dFbO and lysed with a few strokes of a homogenizer and the
lysate was then stored at -70°C.
2.12.5 Dialysis of Cell Lysates and Culture Media
Dialysis was performed in dialysis tubing with a molecular weight cut-off of
500 Da (10 mm diameter). A 15-20 cm length of tubing was cut and rinsed
briefly in PBS and one end was closed with a clamp, 10ml of media was
pipetted into the tubing, which was then sealed at the open-end with another
clamp. The tubing was the submerged completely into a minimum of 5 litres
of dFTO and left to dialyse overnight. The clamp at one end was removed
and the dialysed media was drained into a sterile vessel and frozen at -70°C
until required.
2.12.6 Purification of cell lysates and culture media
Media and cell pellets were purified using a SepPak Cis carboxymethyl
cartridge (Waters) according to the method of Diamond et al. (1991). 40 ml of
media or 5 cell pellets (from T75cm2 culture flasks) were retrieved from -70°C
storage and cells were resuspended in 40 ml PBS and homogenised with a
few strokes of a Omni portable homogeniser. Trifluoroacetic acid (TFA) was
added to the media to a final volume of 0.1%. The cartridges were
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conditioned with 10 ml of a 60:40 solution of acetic acid:0.1% TFA and then
washed with 10 ml of 0.1% TFA. The sample was then loaded onto the
column at a flow rate of 5-10 ml/min. The column was washed with 10 ml of
0.1% TFA and then eluted with 4 ml of 60:40 acetic acid:0.1% TFA. The
elutant was then freeze-dried for 24 overnight and resuspended in 1 ml of
phosphate buffer (see section 2.14.2).
2.12.7 Isolation of Neutrophils
Mice were injected intraperitoneally with 0.5 ml 9% casein solution. 24 hr
later the mice were injected with a second dose of casein and 3 hr later killed
by cervical dislocation. The peritoneal cavity was lavaged with 5 ml
DMEM/0.5mM EDTA and the collected fluid placed on ice. 16 ml ice cold
0.83 % ammonium chloride (pH 7.4) were added to the lavage fluid tolyse
contaminating red blood cells. The suspension was incubated at room
temperature for 15 min then 30 ml 1 x Hanks Buffered Salt Solution (HBSS)
were added and the sample centrifuged for 10 min at 1450 rpm. The
supernatant was discarded and 10 ml HBSS added to the cells and
centrifuged at 775 rpm for 10 min after which the supernatant was discarded
and the cells resuspended in 5 ml HBSS and centrifuged at 775 rpm for 5 min.
The resulting pellet was resuspended in 500 pi PBS. The total cell count was
performed using a Neubauer haemocytometer chamber and the percentage
of neutrophils estimated from a differentially stained cytospin (Cytospin,
Shandon Scientific). Samples of at least 90 % neutrophils were used for the
chemotaxis assay and the cells were resuspended in DMEM/0.5 mM EDTA at
a concentration of 5 x 106 cells/ml.
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2.12.8 Isolation of CD4+ T-lymphocytes
CD4+ T-cells were isolated from mouse spleens using positive selection
protocol in an autoMACS magnetic cell-sorter (Miltenyi Biotec). The mice
were killed by cervical dislocation and the spleen removed and placed into
RPMI media supplemented with 10% FCS, L-glutamine, 500 units penicillin
and 50 mg/ml streptomycin. The spleen was disassociated by passage
through a 100 pm cell filter with the rubber end of the plunger from a 1 ml
syringe into 30 ml of media as above to give a single-cell suspension. The
cells were spun at 300 x g at 4°C for 7 min. The pellet was resuspended in 1
ml of PBS Dulbecco's PBS without calcium and magnesium (Sigma, UK) and
4 ml of red blood cell (RBC) lysis buffer (1 mM ammonium carbonate and 114
mM ammonium chloride) and incubated on ice for 5 mins. Immediately this
time was up 10 ml of Dulbecco's PBS was added to stop any further lysis and
the cells spun as before. The pellet was resuspended in 10 ml of PBS and the
cells counted in a haemocytometer. The cells were resuspended in MACs
buffer (PBS + 0.5% BSA) at a concentration of lxlO7 cells/90 pi (»1.11 x 108
cells/ml), this was supplemented with 10 pi of MACS CD4+ (L3T4)
MicroBeads (Miltenyi Biotec) per 1 x 107 cells. The celkMicroBead suspension
was incubated at 4°C for 15 mins; 30 ml of MACS buffer was added to stop
further reaction and the cells were spun as before for 10 mins. The cells were
resuspended at a concentration of 2 x 108 cells/ml and run on the positive
selection programme POSSEL1 on the autoMACS. The positive fraction was
eluted in 2 ml of MACS buffer, the volume was adjusted to 10 ml and the
cells counted. The cells were centrifuged as before and resuspended in
chemotactic media (RPMI 1640 +10% foetal calf serum) at 5 x 106 cells/ml. The
cells were incubated at 37°C prior to the chemotaxis experiment. The purity
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of the cell population was assessed the analysing the proportion of cells
positive for CD3 and CD4 by fluorescence-activated cell sorting (FACS).
2.12.9 Culture of Bone Marrow-Derived Dendritic Cells.
2.12.9.1 Isolation of Bone Marrow Cells and Basic Culturing
Bone marrow-derived dendritic cells were cultured from bone marrow cells
isolated from mouse tibia and femur bones following the method of Inaba et
al (1992). The mice were killed by cervical dislocation and the long bones of
the hind legs were removed. The bones were cleaned of muscle and place
into complete media (as detailed in section 2.12.8). The bones were broken
at the knee and cleaned further, both ends of the bones were cut with a
scalpel to create an open tube. The 2 ml syringe was filled with media and
using a 23G needle the marrow was washed out of the bones into fresh
media. Clumps of marrow were broken up into single cells by passage
through the 25G needle. The cells were centrifuged at 300 x g for 7 min at
4°C. The resultant pellet was resuspended in 1 ml PBS, 4 ml of RBC lysis
buffer was added and the suspension incubated on ice for 5 min. At the end
of this period the suspension was centrifuged as before, the cells washed 3
times with 10 ml of complete media and resuspended in 20 ml of complete
media. The cells were counted in a haemocytometer and the volume
adjusted to give 3.75 x 105 cells/ml in complete media supplemented with 5%
(500 U/ml) of supernatant from the granulocyte-macrophage colony
stimulating factor (GM-CSF) -expressing cell line (Stoiber et al., 1995) and the
cells cultured in a 24-well plate with 1 ml per well.
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2.12.9.2 Preparation of Day 6 Immature Dendritic Cells
The GM-CSF supplemented culture media was replenished on day 3 of the
experiment (with day 0 being the start). The plate was swirled gently but
firmly 20 times to aid the removal of non-adherent cells, (mainly
contaminating granulocytes). The media was removed from half the wells
using a 1 ml pastette, fresh medium was gently added and the process
repeated with the remaining wells. The cells are sufficiently developed for
use on day 6. The "loosely-adherent" day 6 immature dendritic cells (d6iDC)
are harvested by swirling the plate as described above and then vigorously
pipetting around the well with a 1 ml pastette 6-10 times. The cells are
centrifuged as above and washed twice in chemotactic media. The cells were
counted in a haemocytometer and the concentration adjusted to 5 x 106
cells/ml. The cells were the incubated at 37°C for at about 1 hr prior to usage
in the chemotaxis experiments.
2.12.9.3 Preparation of Day 7 Immature Dendritic Cells
7 day-old immature dendritic cells (d7iDC) were cultured as in section
2.12.9.2, except that on day 6 the media was replenished as on day 3 and the
cells harvested on day 7.
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2.12.9.4 Preparation ofMature Dendritic Cells
For the preparation of mature dendritic cells the above protocol (2.12.9.3)
was followed but 100 ng/ml of Escherichia coli LPS was added to the culture
media on day 7 to mature the dendritic cells.
2.12.10 Fluorescence Associated Cell Sorting (FACS) Analysis
Identification of the cell population under investigation was conducted by
fluorescent analysis for expression cell surface markers using a FACS can
flow cytometer (Coulter Corporation, USA). All antibodies used were
purchased form Pharmingen/Becton Dickinson (USA). The labelling
antibodies used, and the corresponding isotype, used as specificity control
are detailed in Table 2.3.
MACs-isolated splenic CD4+T-lymphocytes were double stained for the CD4
and CD3 cell surface markers. Dendritic cell populations were analysed by
double staining for CDllc and MHC-II expression, and single-stained for
CD54 and CD86 expression. The level of contamination was assessed by
single staining for the granulocyte marker Grl and the B-cell marker CD45.
Marker Labelling Antibody Isotypic Antibody
CD4 FITC anti-mouse CD4 (L3T4) FITC rat IgG2b k
CD3 PE anti-mouse CD3e PE Hamster IgG|A. (anti-TNP)
CDllc PE anti-mouse CD1 lc (HL3) PE Hamster IgGi^. (anti-TNP)
MHC-II FITC anti-mouse I-Ab (ABb) FITC Mouse IgG2a k (anti-TNP)
CD54 PE anti-mouse CD54 (ICAM-1) PE Hamster IgG|k (anti-TNP)
CD86 PE anti-mouse CD86 (B7-2) PE Rat IgG2b k
Grl PE anti-mouse Ly-6G (Grl) PE rat lgG2b k
CD45 FITC anti-mouse CD45/B220 PE rat IgG2a k
Table 2.3: Cell surface markers used to identify the population of cell under study. Antibodies
were conjugated either to phycoerythrin (PE) or fluorescein isothiocyanate (FITC).
91
For direct antibody labelling 5 x 105 cells/sample were added to a flexible 96
round-bottom well plate and centrifuged at 300 x g for 3 min at room
temperature. The antibodies were diluted to a final concentration of 5 pg/ml
in 100 pi of FACS buffer (PBS + 0.5% BSA, 10% mouse serum, 0.1% sodium
azide). The appropriate antibody or antibodies were added to the
corresponding well and the cells incubated in the dark on ice for 30 min. The
cells were washed twice in FACS buffer, and finally resuspended in 400 pi of
1:1 FACs buffer/FACS fix (Dulbecco's PBS + 4% paraformaldehyde). Cell
sorting by flow cytometry was carried out within 5 days after staining.
2.13 Culture of Bacteria for Analysis of Defensin Antibacterial
Function
Bacteria were provided by Professor John Govan and prepared by Wendy
Hannant, Dr Cathy Doherty, or Wendy Hannant, Department of Medical
Microbiology, University of Edinburgh. The bacterial strains used were;
Staphylococcus aureus CF clinical isolate C1705, Pseudomonas aeruginosa CF
clinical isolate J1385 and J1532 and strain PAOl, Escherichia coli clinical
isolates J2408 and J3201, and Burkholderia cenocepacia CF clinical isolate J2315.
Pseudomonas aeruginosa CF clinical isolate J1385 has been documented to have
preferentially infected several CF individuals, despite exposure to other
strains simultaneously in a jacuzzi, and its mucinophilic strain is called J1532
(Nelson et al 1990). Burkholderia cenocepacia CF clinical isolate J2315, is the
virulent Edinburgh-Toronto epidemic strain ET/12 (Govan and Deretic 1996).
An aliquot of the appropriate strain was recovered from storage, in 10% w/v
skimmed milk at -70 °C, thawed and streaked on the appropriate media.
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This was incubated at 37 °C overnight (for 48 hr for B. cenocepacia). Nutrient
broth (25 g/L, 0.5% w/v Yeast extract; Oxoid Ltd., Hampshire, UK) was
inoculated with a few colonies and incubated at 37 °C overnight in an orbital
incubator. The bacterial suspension was centrifuged at 3000x g for 10
minutes and the supernatant removed. The bacterial pellet was resuspended
in 0.85% saline and standardised using a spectrophotometer at OD590, to a
density previously determined to correspond to ~ 1 x 109 CFU/ml.
The following media were used: S. aureus was grown on Blood agar (39 g/L
Columbia base agar (Oxoid Ltd., Basingstoke, Hampshire, UK), 5%
defibrinated horse blood (E & O Laboratories Ltd., Burnhouse, Bonnybridge,
Scotland) added after autoclaving and cooling), P. aeruginosa was grown on
Pseudomonas isolation agar (45 g/L, 2% glycerol; Difco Laboratories Ltd.,
West Molesey, Surrey, UK), Escherichia coli was grown on MacConkey agar
(44.5 g/L; Mast Diagnostics, Mast Group Ltd., Bootle, Merseyside, UK), B.
cenocepacia was grown on Cepacia medium (32.5 g/L, Ticarcillin lOOmg/L,
Polymixin B 300,000 u/L; Mast Diagnostics, Mast Group Ltd., Merseyside,
UK).
2.14 Analysis of Defensin function
2.14.1 Synthesis of peptides
Synthetic defensin peptides (DEFB2, Defb2 and Defrl) were designed to
represent the mature portion of the prepropeptides of DEFB2, Defb2 and
Defrl respectively. The peptides were purchased from and synthesised by
Albachem Ltd., King's Buildings, Edinburgh, UK, as described below.
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2.14.2 Antibacterial Assays
The optimisation of this method was performed by Drs Donald Davidson
and Duncan Borthwick, MRC Human Genetics Unit, Edinburgh, UK.
Fresh, overnight cultures of bacteria were prepared as described in section
2.3 and supplied in 0.85% saline at ~ 1 x 109 colony framing units per ml.
Immediately prior to use, 1 ml aliquots of bacterial suspension were
centrifuged at lOOOx g for 10 minutes at room temperature and resuspended
in 10 ml of 10 mM Phosphate buffer (8 mM K2HPO4, 2 mM KH2PO4, 5.6 mM
D-Glucose) containing either 0 mM, 30 mM, 60 mM, 90 mM, 120 mM or 150
mM NaCl (buffer pH 7.60 at OmM NaCl, pH 7.40 at 30 mM NaCl, pH 7.33 at
60 mM NaCl, pH 7.27 at 90 mM NaCl, pH 7.23 at 120 mM NaCl and pH 7.20
at 150 mM NaCl).
A 1 in 50 dilution of the bacterial suspension was performed in the same
buffer providing a suspension of ~ 2 x 106 CFU per ml. Two sets of duplicate
500 pi reactions were prepared containing 50 pi of either 10 mM Phosphate
buffer alone or lOx stock of synthetic peptide (0.5 mg/ml to give a final
concentration of 0.05 mg/ml unless otherwise stated) rehydrated in 10 mM
Phosphate buffer, 47.5 pi of 10 x stock of NaCl in lOmM Phosphate buffer (0
mM, 300 mM, 600 mM, 900 mM, 1.2 M or 1.5 M NaCl) and 377.5 pi of lOmM
Phosphate buffer, to which 25 pi of bacterial suspension (~ 5 x 104 CFU) in the
appropriate salt concentration was added.
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These reactions were incubated for 30 minutes at 37 °C, after which duplicate
sets of serial, enfold dilutions were prepared from each sample, in 10 mM
Phosphate buffer with the appropriate concentration of NaCl. 100 pi
samples were plated out on the appropriate agar, incubated at 37 °C for 24
hours (48 hours for B. cenocepacia), colony counts were performed and
extrapolated to provide the CFU count for the neat sample. The anti¬
microbial activity of the peptide was compared against buffer alone, to
control for the effects on the bacteria of varying the NaCl environment.
These studies were repeated to ensure the validity of results, reproducing the
salt-sensitive antibacterial profile on a minimum of two separate occasions
for each set of conditions.
The assessment of the antibacterial activity of defensin-transfected cells lines
were conducted by following the same method except that phosphate buffer,
salt and peptide solution, to which the bacteria were added was replaced by
475 pi of media, lysate or purified lysate and media solution resuspended in
phosphate buffer.
2.14.3 Statistical Analysis
The data were classified by factors of Salt concentration; treated or untreated
with peptide and the number of 'replicate sources. It was found that a
Loge(l+x) transformation of the counts was best for stabilising the between-
group variances. The data were transformed and averaged over the repeated
counts. A three-factor balanced analysis of variance was done using the
three-factor interaction as the error term. When other two-factor terms were
found to be non significant, they were removed from the model and the
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fitted values recalculated. This increases the number of degrees of freedom
for error and reduces the confidence range.
The 'human and 'mouse' data were analysed separately. Tables of the
transformed data were produced with standard errors, and the data were
transformed back to the original scale to give estimates of counts and 95%
confidence limits classified by Salt concentration treatment and 'replicate' .
The response of the different 'replicates' was sufficiently different that they
could not be averaged.
The differences between the corresponding transformed values for Untreated
and Treated were calculated ( Peptide - Blank ) . The same form of analysis
of variance was done and fitted values calculated. By transforming the
means back to the linear scale it was possible to estimate the likely
proportion of cells reduced by peptide under the varying salt levels - or '%
Kill' and also give 95% confidence limits. Negative '% Kill' values reflect the
possibility of cell counts actually being higher under high salt concentrations.
2.14.4 Cell Migration Assays
30 pi of p-defensin at 0, 0.1, 1, 10, 100, 1000, 10000 ng/ml in chemotactic
media or the control chemoattractant, which had been preheated to 37°C and
vortexed, were added to the bottom chamber of a Neuroprobe Standard 48
Well Chemotaxis Chamber (Neuro Probe, Inc). All samples were assayed in
triplicate. A Nuclepore Polycarbonate membrane (Costar) was placed on top
of the bottom chamber followed by the silicon gasket and then the top
chamber to which 50 pi of the neutrophil suspension was added to each well.
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The chamber was incubated in a humid 5 % CO2 incubator at 37°C for 1 hr for
neutrophils, 1.5 hr for T-cells and 4.5 hr for dendritic cells after which the
chamber was inverted and the filter removed (migrated cells side up). The
side of the filter with non-migrating neutrophils was washed in PBS and
scraped across a blade to remove the cells.
2.14.5 Staining of Filters
For neutrophils the filter was then fixed and stained using Diff-Quik®
(Dade®), placed on a 76 mm x 52 mm microscope slide and the number of
neutrophils migrated in each well counted. For all other cell types, the
membrane was fixed in methanol and then stained in Harris' haematoxylin
(0.4%) for 4 min, then washed in water for 1 min. The filter was briefly dried
and then placed in Scotts' tap water (0.2 M sodium bicarbonate and 0.8 M
magnesium sulfate) for 2 min and again rinsed in water. The membrane was
dehydrated by incubation for 1 min in increasing concentrations of industrial
methylated spirits (64% > 74% > 100%), and then submerged in xylene for 1
min before being mounted on a slide. Membranes were viewed by
brightfield microscopy at 400 x magnification and three random of fields of
view (FOV) were counted per well.
2.14.6 Statistical Analysis
The counts in each well were classified by Experiment, Agent and
Concentration. Counts were made from three aspects A, B and C. The data
were transformed to log(x) (or log(x)+l if the data contained a zero) and
((x+3/8)) respectively. Means were taken of the transformed and
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untransformed data classified by the factors Experiment, Agent and
Concentration and tested for homogeneity of variance between each of the
treatment groups classified by the factors Agent and Concentration.
A preliminary analysis of variance was done with the model including all
main effects and two-factor interactions of the factors Experiment, Agent and
Concentration. When either of the two-factor interactions with Experiment
were not significant (p > 0.2) they were removed form the model. This
helped to increase the degrees of freedom available for estimating error.
Analysis of Variance was then repeated for each case with the (possibly)
modified model, and produced a table classified by the factors Agent x
Concentration, which contained means, standard errors of means and
Minimum Significant (at 5%) Difference (MSD).
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Chapter 3; The Antibacterial Activity of B-Defensins.
3.1 Introduction
Antimicrobial peptides comprise an important aspect of the innate immune
system; their main function is to kill invading microorganisms. There exists
many different families of antibacterial peptides; one of the largest, found in
plants, insects and vertebrates is the defensin family. In vertebrates,
defensins are classified into three subfamilies which are called a-, P- or 9-
defensins depending on the connectivity of the intramolecular disulfide
bridges. Whilst the activity of a-defensins has been fairly well documented,
the function of p-defensins has been less well characterised. However, these
peptides came to wider acknowledgement when their dysfunction was
implicated in the pathogenesis of cystic fibrosis (CF) lung disease (Goldman
et al., 1997).
A defect in the antibacterial activity of the airway surface liquid (ASL) of the
lungs was implicated in the lung pathogenesis of CF. The ASL of primary
cultures of human airway epithelial cells has been demonstrated to possess
salt-sensitive antibacterial activity that was inhibited by the addition of NaCl.
In contrast, cultures of airway epithelia from CF individuals showed
markedly reduced antibacterial activity, and this could be restored by
reducing the concentration of salt in the ASL (Smith et al., 1996). Further
work suggested that the expression of CFTR was required for maximal
absorption of NaCl across the epithelium, and thus, CF cultures show
reduced absorption of salt, and elevated levels of NaCl in the ASL (Zabner et
al., 1998). Together, these data suggest that the loss of functional CFTR in CF
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elevates NaCl concentrations, which reduces the antibacterial activity of the
ASL and that this may predispose CF airways to bacterial infections.
However, other theories explaining CF pathogenesis have been proposed
(see section 1.6) and due to the difficulty in measuring the salt concentration
of ASL the 'defensin/elevated-salt' theory and the role of defensins in CF
pathogenesis remain controversial. Indeed, a recent study found evidence
for the existence of a salt-independent defect in the antibacterial activity of
CF ASL and suggested that absence or dysfunction of an as yet unidentified
antimicrobial factor(s) may explain the reduced antimicrobial activity (Bals et
al., 2001).
The ASL contains a multiplicity of antimicrobial factors such as defensins,
cathelicidins, secretory leukocyte protease inhibitor (SLPI), lysozyme and
lactoferrin. Studies carried out using a human bronchial xenograft model
system suggested that DEFB1 (hBDl) may play a central role in the
antibacterial activity that is compromised in CF (Goldman et al., 1997).
Ablation of the expression of DEFB1 using anti-sense RNA directed against
the 5' region of DEFB1 cDNA was shown to abrogate almost completely the
antibacterial activity of the ASL, and furthermore synthetic DEFB1 peptide
was shown to possess salt-sensitive antibacterial activity.
These experiments broadened the interest in the activity of p-defensins.
Investigation of the salt-sensitive nature of the antibacterial activity of DEFB1
and a murine homologue Defbl was conducted by Dr Donald Davidson,
working in this lab (Morrison et al., 1998; Morrison et al., 2002b). These
experiments revealed that synthetic both DEFB1 and Defbl possessed
significant salt-sensitive antimicrobial activity at a concentration of 50 gg/ml.
This activity was broad range, killing P. aeruginosa CF isolate J1385, S. aureus
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CF isolate C1705 and E. coli clinical isolate J2408. However, the spectrum of
activities differed between the two peptides; DEFB1 showed the highest
activity against P. aeruginosa J1385, and lowest against E. coli J2408, whereas
Defbl killed S. aureus CI705 most efficiently and showed least activity
against P. aeruginosa J1385. These results may indicate the evolution of
species differences in the specific activities of the different p-defensins against
different bacteria. Further studies have been conducted mouse mutant
models deficient in expression of a p-defensin. In one study Defbl
expression was disrupted by gene targeting (Morrison et al.r 2002a) however
S. aureus were still efficiently cleared from the lungs these mice after
nebuliseation. Although no overt deleterious pathogen was evident in these
Defbl-'-, there were significantly greater numbers of S. aureus bacteria in the
urine of mutant mice compared to wildtype control. However, another
mouse model with ablation of Defbl expression has been reported (Moser et
al., 2002). Interestingly, this mouse model demonstrated delayed clearance of
the CF pathogen Haemophilus influenzae compared to wildtype mice.
Moreover, this study also reported that the cellular and cytokine responses in
the mutant mice were normal, suggesting that the defective clearance was
due to the loss of Defbl antibacterial activity. Furthermore, a role for
defensins in host defence is further suggested by an earlier study that
prevented production of functional a-defensins (cryptidins) in the mouse
intestine by ablating expression of matrilysin, an enzyme that processes the
a-defensins to the function form (Wilson et al., 1999). Bacteria administered
to these MaW mice survived in greater numbers and showed greater
virulence than in wildtype mice. Thus, these data suggest that the cryptidins
serve to protect the mouse intestinal surfaces from bacterial colonisation.
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Since these initial studies were conducted many more p-defensins have been
identified in both human and mice, but the precise function of P-defensins in
the ASL of the lung and other tissues remains unknown. DEFB4 (originally
termed hBD2 or DEFB2) was the second human p-defensin to be identified; it
is expressed in the skin, lungs, uterus and trachea, but expression is induced
in foreskin-derived fibroblasts in response to bacterial stimulus (Harder et al.,
1997). Further studies have shown that synthetic a DEFB4 peptide possessed
potent antimicrobial activity against Gram-negative bacteria, such as E. coli
and P. aeruginosa, and it also demonstrated synergistic activity with lysozyme
and lactoferrin (Bals et al., 1998b). An inducible p-defensin, Defb2, has also
been identified in the mouse (Morrison et al., 1999). Defb2 shows 36%
similarity at the amino acid level to DEFB4 and 50% similarity to Defbl; it is
expressed constitutively in the kidney and uterus, also expression can be
stimulated in the trachea by bacterial LPS. The discovery of Defb2 raises
interesting questions about its activity and salt-sensitivity as well as the
degree of functional homology between murine and human p-defensins.
All of the defensins discussed above possess the characteristic six cysteines
and have the typical pattern and spacing in their arrangement. Recently,
however, a novel murine P-defensin has been identified that lacks the first
canonical cysteine (Morrison et al., 2002a). Defensin-related 1 (Defrl) is
expressed in the testis, uterus and heart, but expression was not induced in
the trachea in response to LPS-treatment. At the amino acid level Defrl
shows low (less than 50%) similarity to Defbl and 2 and has greater greatest
similarity (73%) to Defb3.
The discovery of novel p-defensins also raises many important and
interesting questions about the function of these antibacterial peptides and
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their interaction with other defensins and also with the different
components of the innate and adaptive immune systems. One of the
most remarkable features of the different peptides is the pronounced
sequence divergence in the mature peptide (Figure 3.1). This
suggests that the evolution of (3-defensins may have been driven by
positive selection for amino acid substitutions (Hughes, 1999;
Morrison et ah, 2002c). This would have lead to the rapid evolution
of a large number of peptides with greatly divergent primary
structures, and may have had the effect of increasing the spectrum of
activity of fl-defensins against potentially pathogenic microorganisms.
The effect of this pronounced sequence divergence on the activity of
the various (3-defensins remains a largely unexplored area, and may




Defrl MRIHYLLFT FLLVLLSPLAAFSQKIN DPVTYIRNGGICQYRCIGLRHK-IGTCG
DEFB4 MRVLYLLFS FLFIFLMPLPGVFGGIG DPVTCLKSGAICHPVFCPRRYKQIGTCG







Figure 3.1: Alignment of Synthetic (3-Defensin Peptides. Multiple sequence
alignment of (3-defensins whose functions have been analysed as synthetic peptides.
Amino acids in red represent the sequence of the mature synthetic peptides tested,
* indicates a direct match. Note that Defrl lacks the first canonical cysteine (t).
Analysis was performed using the Clustal W program at www.hgmp.mrc.ac.uk with
default settings.
To assess the antibacterial profile DEFB4, Defb2 and Defrl
these peptides were synthesised by Albachem Ltd
(Edinburgh, UK) to the amino acid sequence of the proposed
mature peptide (Figure 3.1). 5 x 104 colony-forming units
(CFU) of bacteria were incubated for 30 min at 37°C with or
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without the peptide in the presence of 0, 30, 90 or 150 mM NaCl. Duplicate
reactions were performed and at the end of the incubation period, each
reaction was itself plated out in duplicate on the appropriate agar (Figure
3.2). In order to assess the effect of salt alone on bacterial survival, control
reactions were set up without peptide. The number of CFU in the control
sample was compared to those from the peptide-treated samples at each
NaCl concentration, and the quantity of bacteria surviving in the peptide
sample was expressed as a percentage of the counts from the control sample
(percent-kill). These studies will help to address several of the outstanding
questions regarding the antibacterial activity and salt-sensitivity of these (3-
defensins. These experiments are designed to assess the activity of the
synthetic peptides against a variety of CF and non-CF pathogens. They may
also facilitate the understanding of the effect of different peptide sequences
on the spectrum of antibacterial activity and the species differences between





















Figure 3.2: Schematic Diagram of Antibacterial Assays. Bacteria were incubated in phosphate buffer
with or without the peptide at various salt concentrations. Following incubation at 37°C for 30 min, 1:10
and 1:100 serial dilutions of the bacterial suspension were made. These were plated out, incubated
overnight and the numbers of surviving colony forming units (CFU) were counted. The reactions indicated
above were set up in duplicate, and the whole experiment was repeated a minimum of three time (i.e. n=3).
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3.2 Antibacterial Activity of DEFB4 and Defb2
The antibacterial activity of DEFB4 and Defb2 and their salt-sensitivity was
assessed against a range of bacteria. These were the Gram-positive
Staphylococcus aureus CF clinical isolate CI705, and the Gram-negatives
Pseudomonas aeruginosa CF clinical isolates J1385 and J1532, and laboratory
strain PAOl, Burkholderia cenocepacia CF clinical strain, epidemic strain J2315
and Escherichia coli (clinical isolates J2408 and J3201). The activity of DEFB4
against a range of pathogens has already been demonstrated (Harder et al.,
1997; Bals et al., 1998b; Singh et al., 1998), however its salt-sensitivity has not
been fully characterised.
A previous study assessing the activity of DEFB1 against P. aeruginosa
obtained similar bacterial killing with synthetic DEFB1 with a concentration
ranging from 60 - 500 gg/ml (Goldman et al., 1997). Moreover, work carried
out in this laboratory on the activity of DEFB1 and Defbl found significant
antibacterial activity at a concentration of 50 gg/ml (Morrison et al., 2002b)
(Morrison et al., 1998). For these reasons and to allow for easier comparison
between the different studies a concentration of 50 pg/ml has also been used
in the following experiments. Studies were tested for reproducibility in a
minimum of three experiments (n=3) and representative experiments are
illustrated below in Figures 3.3 -3.9.
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3.2.1 Antibacterial activity of DEFB4 and Defb2 against S. aureus
C1705.
At a concentration of 50 pg/ml and in the absence of NaCl, DEFB4 displayed
high levels of activity and killed approximately 80% of bacteria. This fell to
«40% in 30 and 90 mM NaCl, but killing was only 10% in 150 mM of NaCl
(Figure 3.3 A and C). This antibacterial activity was statistically significant (p
< 0.01) between 0 and 90 mM, but the low level of activity observed at 150
mM was not statistically significant. Defb2 was observed to exhibit lower
levels of activity compared to DEFB4 at each NaCl concentration tested
(Figure 3.3 B and D). Defb2 killed just over 40% of bacteria in the absence of
NaCl, and this activity fell rapidly in the presence of NaCl. The percent-kill
in 30 mM NaCl was 12% and the level of activity fell further in the 90 and 150
mM NaCl to just 5%. The activities seen in 0 mM and 30 mM NaCl were
statistically significant (p < 0.01), however the very low levels observed in 90
and 150 mM NaCl were not significant. The activity of DEFB4 was
significantly greater than that of Defb2 in the presence of 0 or 30 mM NaCl (p
< 0.01) and also in 90 mM (p <0.05).
The concentration of NaCl in the absence of peptide had no statistically
significant affect on bacterial survival, with the level of survival in control
sample remaining fairly constant across all NaCl concentrations tested. This
suggests that the observed effects were due to the action of the peptides and
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FIGURE 3.3: Antibacterial activity of DEFB4 and Defb2 against Staphylococcus aureus
C1705.
Bacteria were incubated with the peptide at 50 pg/hi over a rarge of salt concentrations.
Graphs A and B show the rrurrber of colory forming units (CFU) ± standard error from the
blank-control and peptide-treated samples. Graphs C and D show the mean percentage kill ±
standard error; this is assessed by calculating the nurrber of CFU surviving in the peptide-treated
sample as a percentage of the counts from the blank-control sample. * * = p < 0.01, * = p < 0.05.
Experimentswere repeated three times and the above is a representative experiment (n=3).
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FIGURE 3.4; Antibacterial activity ofDEFB4 and Defb2 against PsrtKlornonas aerutpnosa
J1385.
Bacteria were incubated with the peptide at 50 pg/hi over a range of salt concentrations.
Graphs A and B show the nurrfcer of colony formirg units (CFU) ± standard error from the
blank-control and peptide-tneated samples Graphs C and D show the mean percentage kill ±
standard error this is assessed by calculating the rrurrber of CFU surviving in the peptide-trealed
sample as a percentage of the counts from the blank-control sample. * * = p < 0.01, * = p < 0.05.
Experimentswere repeated three times and the above is a representative experiment (n=3).
3.2.2 Antibacterial activity of DEFB4 and Defb2 against P.
aeruginosa J1385.
DEFB4 also displayed statistically significant activity against P. aeruginosa
J1385 (Figure 3.4 A and C). In the absence of salt and in 30 mM NaCl DEFB4
killed 100% of bacteria; this fell to 80% in the presence of 90 mM NaCl and
killing was reduced again by 150 mM NaCl, with activity at approximately
20%. The activities seen in 0, 30 and 90 mM of NaCl were found to be
statistically significant (p < 0.01) however, the activity in 150 mM NaCl was
not significant. Again, Defb2 demonstrated considerably lower levels of
activity compared to DEFB4 at each NaCl concentration examined (Figure 3.4
B and D). Killing by Defb2 was significantly lower at all concentrations (p <
0.01), except 150 mM, where no significant difference was observed. Killing
of P. aeruginosa J1385 by Defb2 was 60% in the absence of NaCl,
approximately 30% in the presence of 30 mM of NaCl. Both of these
activities were significant, p < 0.01 in the absence of NaCl and p < 0.05 at 30
mM NaCl, however the reduced levels of activity observed at 90 and 150 mM
were not statistically significant.
The level of NaCl alone did have a significant effect on the survival of P.
aeruginosa J1385 in the control samples. This effect was greatest at the
extremes of NaCl concentrations tested (0 and 150 mM) with significantly
fewer bacteria surviving at these concentrations compared to the survival at
30 and 90 mM NaCl (p < 0.01). This pattern was also seen in the previous
studies on the activity of DEFB1 and Defbl against P. aeruginoisa J1385
(Donald Davidson, PhD Thesis, Edinburgh University, 2000). However, as
these NaCl concentrations also represent the conditions under which the
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greatest and least activities of DEFB4 and Defb2 are observed, this suggests
that the effects of the peptides are independent from the effects of NaCl
alone, although the low number of bacteria surviving in 150 mM did lead to
quite variable results at this concentration of NaCl.
3.2.3 Antibacterial activity of DEFB4 and Defb2 against P.
aeruginosa PAOl.
The activity of DEFB4 and Defb2 were also tested against the PAOl
laboratory strain of P. aeruginosa. DEFB4 demonstrated statistically
significant killing (p < 0.01) at all NaCl concentrations tested (Figure 3.5 A-
D). DEFB4 showed greater activity across all NaCl concentrations against P.
aeruginosa PAOl compared to P. aeruginosa J1385 (Figure 3.5 A and C).
DEFB4 killed 100% of bacteria in 0 and 30 mM NaCl, this is the same level of
activity observed against the P. aeruginosa J1385. However, the activity was
greater against P. aeruginosa PAOl than against P. aeruginosa J1385 at the
higher salt concentrations, 95% and 80% killing compared to 85% and 25% in
90 mM and 150 mM NaCl respectively. These differences suggest that as
with conventional antibiotics, the spectrum of antibacterial activities may be
specific to different strains of bacteria.
Defb2 also killed P. aeruginosa PAOl more efficiently at each NaCl
concentration tested compared to P. aeruginosa J1385, and again, Defb2 was
less effective than DEFB4 (Figure 3.5 B and D). The greatest activity of Defb2
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FIGURE 3l5: Antibacterial activity ofDEFB4 and Defb2 against Pseudomonas aeruginosa
PAOL
Bacteria were incubated with the peptide at 50 ug/ii over a range of salt concentrations.
Graphs A and B show the number of colony forming units (CFU) ± standard error from the
blank-control and peptide-treated samples Graphs C and D show the mean percentage kill ±
standard error; this is assessedby calculating the number of CFU surviving in the peptide-treated
sample as a percentage of the counts from the blank-control sample. * * = p < 0.01, * = p < 0.05.
Experimentswere repeated three times and the above is a representative experiment (n=3).
bacteria were killed, this fell to 60% when the NaCl was elevated to 30 mM,
and to »35% and «25% in 90 mM and 150 mM respectively. The effect of
Defb2 was statistically significant compared to blank control at 0 mM (p <
0.01), and 30 and 90 mM NaCl (p <0.05). However, the antibacterial activity
of Defb2 was significantly lower than that of DEFB4 at all NaCl
concentrations (p < 0.01 at 0-90 mM and p < 0.05 at 150 mM).
3.2.4 Antibacterial activity of DEFB4 and Defb2 against P.
aeruginosa J1532.
The activity of DEFB4 and Defb2 was also examined against the P. aeruginosa
J1532 (Figure 3.6 A to D). This is the mucoidy version of the CF isolate P.
aeruginosa J1385. DEFB4 demonstrated very high, and statistically significant
(p < 0.01), levels of antimicrobial activity against P. aeruginosa J1532 at all
NaCl concentrations tested (Figure 3.6 A and C). At 0 mM and 30 mM
DEFB4 killed 100% of bacteria; at higher concentrations of NaCl the activity
was reduced to 95% (90 mM) and 85% (150mM). Defb2 also killed P.
aeruginosa J1532 significantly more efficiently than it killed P. aeruginosa J1385
(p < 0.01). In the absence of NaCl Defb2 killed 75% of bacteria, the level of
activity in the reduced compared to 0 mM but static between 30 mM and 150
mM NaCl, with 60% to 55% of bacteria killed and at 150 mM NaCl (Figure
3.6 B and D). The activities for both DEFB4 and Defb2 against P. aeruginosa
J1532 were statistically significantly higher than their activities against the
non-mucoid P. aeruginosa J1385
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FIGURE &G Antibacterial activity of DEFB4 and Defb2 against Mucoid Pseudomonas
aeruginosaJ1332.
Bacteria were incubated with the peptide at 50 pg/hi over a rarge of salt concentrations.
GraphsA and B diow the nurrber of colony formirg units (CFU) ± standard error of S aureus
C1705 from the blank-control and peptide-tnsated samples. Graphs C and D show the mean
percentage kill ± standard error; this is assessed by calculatirg the nurrber of CFU surviving in
the peptide-treated sample as a percentage of the counts from the blank-control sample. * * = p <
0.01, * = p < 0.05. Experiments were repeated three times and the above is a representative
experiment (rt=3).
3.2.5 Antibacterial activity of DEFB4 and Defb2 against E.coli J2408
and J3201.
The antibacterial activities of DEFB4 and Defb2 against E. coli clinical isolate
J2408 were also examined (Figure 3.7 A-D). Neither DEFB4 nor Defb2
demonstrated killing at any of the NaCl concentrations examined. However,
weak activity was observed against another clinical strain, E. coli J3201. This
level of activity was very similar for DEFB4 and Defb2, both killing at
approximately 25% in the absence of NaCl and 15% at 30 mM NaCl (p <0.01).
Antibacterial activity was ablated by the presence of 90 or 150 mM NaCl
(Figure 3.8 A to D).
3.2.6 Antibacterial activity of DEFB4 and Defb2 against B.
cenocepacia J2315.
In agreement with previous p-defensin killing data, neither DEFB4 nor Defb2
had any effect on the survival of B. cenocepacia J2315, and no significant
differences were observed between peptide and control sample at the 50
pg/ml at any of the NaCl concentrations tested (Figure 3.9 A to D). Previous
work has found this bacterial strain to be resistant to the effects of defensins
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F1GURE3L7: Antibacterial activity ofDEFB4and Defb2againstEscheridvaco/iJ240&
Bacteria were incubated with the peptide at 50 ug/nl over a rarge of salt concentrations.
Graphs A and B show the rrurrber of colony forming units (CFU) ± standard enor from the
blank-control and peptide-treated samples. Graphs C and D show the mean percentage kill ±
standard error; this is assessedby ealculatirg the nurrber of CFU surviving in the peptide-trealed
sample as a percentage of the counts fromthe blank-control sample. * * = p < 0.01, * = p < 0.05.
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F1GURE3.8: Antibacterial activity ofDEFB4 and Defb2against EsdysricMaooliJ320L
Bacteria were incubated with the peptide at 50 ug/tnl over a rarge of salt concentrations.
Graphs A and B show the number of colony forming units (CFU) ± standard error from the
blank-control and peptide-treated samples. Graphs C and D show the mean percentage kill ±
standard error; this is assessed by calculatirg the number of CFU surviving in the peptrde-treated
sample as a percentage of the counts from the blank-control sample. * * = p < 0.01, * = p < 0.05.
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FIGURE 3.9t Antibacterial activity ofDEFB4 and Defb2 againstBurktokteriacenocepaaa
J2315.
Bacteria were incubated with the peptide at 50 pg/frJ over a range of salt concentrations.
Graphs A and B show the nurrber of colony formirg units (CFU) ± standard enor from the
blank-control and peptide-tneated samples. Graphs C and D show the mean percentage kill ±
standard error; this is assessedby calciiatirg the nurrber of CFU survivirg in the peptide-treated
sample as apercentage of the counts from the blank-control sample. * * = p < 0.01, * = p < 0.05.
Experimentswere repeated three times and the above is a representative experiment (n=3).
3.3 Antibacterial Activity of Defrl
The identification of defensin-related 1 (Defrl), a P-defensin that lacks the
first canonical cysteine raises interesting questions about the function of a
peptide that diverts so dramatically from the typical p-defensin structure.
Defrl was synthesised and its antibacterial activity was assessed as for
DEFB4 and Defb2. The activity of Defrl was tested in comparison with a
newly synthesised batch of Defb2 (and for the sake of comparison only
termed Defb22nd) as a control this peptide was made using the same amino
acid sequence that was used for the original batch Defb2. These peptides
were tested against Staphylococcus aureus CF clinical isolate C1705,
Pseudomonas aeruginosa CF clinical isolates J1385 and laboratory strain PAOl,
Burkholderia cenocepacia CF clinical strain, epidemic strain J2315 and
Escherichia coli clinical isolates J2408. Again, 50 pg/ml of peptide was used as
standard. Studies were tested for reproducibility in a minimum of three
experiment (i.e. n-3) and representative experiments are illustrated below in
Figures 3.10-3.17.
3.3.1. Antibacterial activity of Defrl against A. aureus C1705
Defrl was observed to have statistically significant (p < 0.01) salt-sensitive
activity against S. aureus C1705 at 0, 30 and 90 mM NaCl (Figure 3.10 B and
D). The activity was maximal in the absence of NaCl, where 100% of bacteria
were killed; this was reduced to 80% in the presence of 30 mM NaCl and
further reduced by incubation with higher concentrations of NaCl. Thus,
antibacterial activity was 50% in 90 mM NaCl and almost ablated at 150 mM.
The activity of the second batch of Defb2 (Defb22nd), used as a control
peptide, showed almost identical activity to the first batch of Defb2 (Figure
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FIGURE 3wl0c Antibacterial activity ofDefb2fild and Defr 1 against Sbaphykxxxxus aureus
C1705.
Bacteria were incubated with the peptide at 50 pg/tnl over a rarge of salt concentrations.
Graphs A and B show the nurrber of colony formirg units (CFU) ± standard error from the
blank-control and peptide-treated samples. Graphs C and D show the mean percentage kill ±
standard error; this is assessed by calculatirg the nurrberof CFU survivirg in the peptide-treated
sample as a percentage of the counts from the blank-control sample. ** = p< 0.01, * = p< 0.05.
Experimentswere repeated three times and the above is a representative experiment (rt=3).
3.10 A and C), with no statistically significant differences between the two
sets of data. A comparison of the activities of Defrl and Defb22nd shows that
the antimicrobial activity of Defrl against S. aureus CI705 was significantly
greater than that shown by Defb2 at 0, 30 and 90 mM NaCl (p < 0.01). Indeed
the activity of Defrl against S. aureus was the highest level of activity of any
of the peptides previously analysed (DEFB2, Defb2, DEFB1 and Defbl) using
this method.
3.3.2 Antibacterial activity of Defrl against P. aeruginosa J1385
Defrl demonstrated highly potent and virtually salt-insensitive antibacterial
activity against P. aeruginosa J1385 at 50 pg/ml over the full range of NaCl
concentrations tested (Figure 3.11 B and D). Defrl killed 100% at, 0, 30 and
90 mM the activity was slightly reduced only in the presence of 150mM with
»95% of bacteria killed. This is the first peptide to show such high levels of
activity. Defb22nd also showed statistically significant levels of salt-sensitive
antibacterial activity (p < 0.01). This activity was maximal in 0 mM NaCl
with 100% of bacteria being killed, this was reduced slightly to 90 % in the
presence of 30 mM NaCl and further reduced to 75% and 20% in 90 and 150
mM NaCl respectively.
In comparison with the first-batch of Defb2, Defb22nd showed significantly (p
< 0.01) greater levels of antibacterial activity at 0, 30 and 90 mM NaCl (Figure
3.10 A and C). The first batch of Defb2 demonstrated a maximum
antibacterial activity of 60% in the absence of salt and this fell to 30% in 30
mM, 20 % in 90 mM and activity was almost ablated by the presence of 150
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FIGURE 3.11: Antibacterial activity of Defb2Pad and Defrl against Pseudomonas
aeruginosaJ138S.
Bacteria were incubated with the peptide at 50 pg/hi over a range of salt concentrations.
Graphs A and B show the nurrber of colony formirg units (CFU) ± standard error from the
blank-control and peptide-treated samples. Graphs C and D show the mean percentage kill ±
standard error; this is assessedby calculating the nurrber of CFU surviving in the peptide-treated
sample as a percentage of the counts from the blank-control sample. * * = p < 0.01, * = p < 0.05.
Experimentswere repeated three times and the above is a representative experiment (n=3).
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FIGURE &12: Antibacterial activity of Defb2PMl and Defrl against Pseudomomas
cerugmosaPAOh
Bacteria were incubated with the peptide at 50 pg/hi over a rarge of salt concentrations.
Graphs A and B show the number of colorg forrrirg units (CFU) ± standard error from the
blank-control and peptide-treated samples. Graphs C and D show the mean percentage kill ±
standard error; this is assessed by calculaiirg the number of CFU survivirg in the peptide-treated
sample as apercentage of the counts from the blank-control sample. * * = p < 0.01, * = p < 0.05.
Experimentswere repeated three times and the above is a representative experiment (n=3).
amino acid composition, and therefore may represent differences in the
folding of the two peptides.
3.3.3 Antibacterial activity of Defrl against P. aeruginosa PAOl
Defrl also showed very potent and statistically significant (p < 0.01) levels of
activity against P. aeruginosa PAOl (Figure 3.12 B and D). The levels of
activity displayed were very similar to those against P. aeruginosa J1385
described above. Defrl killed 100% of bacteria across the full NaCl
concentration tested. Defb22nd also showed statistically significant levels of
salt-sensitive antibacterial activity against P. aeruginosa PAOl (Figure 3.12A
and C). This activity of was greatest in the absence of NaCl and lowest at the
150 mM NaCl. Defb22nd killed 100% of bacteria at 0 mM and this was
reduced to 85 % at 30 mM, the activity in 90 and 150 mM was fairly static
with approximately 75% of bacteria killed. This activity was also greater
than the activity shown against P. aeruginosa J1385. This is similar the
relationship seen with the first-batch of Defb2 against P. aeruginosa PAOl and
J1385. However, the levels of activity of Defb22nd were again significantly
higher than those observed with the first-batch of Defb2 at each NaCl
concentration tested (p < 0.01).
3.3.4 Antibacterial Activity of Defrl against P. aeruginosa PAOl:
Effect of reduced peptide concentrations in high levels of salt.
At 50 gg/ml Defrl demonstrates highly potent and salt-insensitive activity
against P. aeruginosa PAOl and J1385. The activity of Defrl was assessed in
150 mM NaCl at peptide concentrations of 0, 5,10, 25 and 50 pg/ml (Figure
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FIGURE a 13- Antibacterial activity of Defr 1 against Pseudomonas aeruginosaPAO1 at
different peptide concentrations.
Bacteria were incubated with a rarge of peptide concentrations in 150 mM NaCl. Graph A
shows the nurrber of colony formirg units (CFU) ± standand error from the blank-control and
peptide-treated samples. Graph B show the mean percentage kill ± standard error; this is
assessed by calculating the nurrher of CFU surviving in the peptide-treated sanple as a
percentage of the counts from the blank-control sample. ** = p < 0.01, * = p < 0.05.
Experimentswere repeated three times and the above is a representative experiment (n=3).
3.13A + B). Defrl showed marginally greater activity against P. aeruginosa
PAOl compared to P. aeruginosa J1385 and consequently P. aeruginosa PAOl
was used in these experiments. Defrl showed statistically significant activity
at all peptide concentrations tested compared to the blank-control (p <0.01).
Maximal killing was observed at 50, and 25 pg/ml, where 100% of bacteria
were killed, and at 10 pg/ml killing was reduced to «90%. When the Defrl
concentration was reduced to 5 pg/ml, killing was also reduced to
approximately 50%. This result supports the previous data suggesting that
Defrl is a highly potent antimicrobial peptide against P. aeruginosa PAOl.
3.3.5 Antibacterial Activity of Defrl against P. aeruginosa PAOl at
5 pg/ml.
In 150 mM NaCl, at a concentration as low as 10 pg/ml Defrl displays highly
potent and apparently salt-insensitive activity, killing approximately 90% of
bacteria. However, at a concentration of 5 gg/ml the activity is significantly
reduced with only »50% of bacteria killed. The antimicrobial activity of 5
pg/ml of Defrl was therefore examined over the normal range of salt
concentrations to investigate the effect of the lower concentrations of NaCl
on Defrl activity (Figure 3.14 B and D). At NaCl concentrations of 0, 30 and
90 mM Defrl demonstrated statistically significant (p < 0.01), highly potent
and salt-insensitive antimicrobial activity, killing 100% of bacteria (p < 0.01).
In 150 mM, killing was reduced to approximately 50% (p < 0.05) in agreement
with the previous findings. The antimicrobial activity of Defb22nd was also
assessed at 5 pg/ml. However, no significant antibacterial activity was
observed at this concentration (Figure 3.14 A and C).
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3.3.6 Antibacterial Activity of Defrl against E. coli J2408
Defrl demonstrated a statistically significant antibacterial effect against E. coli
J2408 (Figure 3.15B and D). The activity of Defrl was maximal in the absence
of NaCl; killing 100% of bacteria and the activity was reduced by increasing
the concentration of NaCl. In the presence of 30 mM NaCl, activity was
reduced to «50%. A NaCl concentration of 90 mM reduced activity further
still, killing approximately 30% of bacteria. The lowest level of activity was
observed at 150 mM, at this concentration of NaCl activity was significantly
reduced with «10% of a bacteria killed. The antimicrobial activity of Defrl
was statistically significant at 0 and 30 mM NaCl (p < 0.01) and 90 mM NaCl
(p <0.05). Defb22nd did not display antimicrobial activity against E. coli J2408.
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FIGURE 3.14: Antibacterial activity of Defb2Pxl and Defrl against Pseudomonas
aeruginosaPAO 1 at 5 gg/hd.
Bacteria were incubated with the peptide at 50 pg/M over a rarge of salt concentrations.
Graphs A and B show the rioter of colony foimirg units (CFU) ± standard error from the
blank-control and peptide-treated samples. Graphs C and D ?how the mean percentage kill ±
standard error; this is assessed by calcilatiig the nurrber of CFU surviving in the peptide-treated
sample as a percentage of the counts fromthe blank-control sample. * * = p < 0.01, * = p < 0.05.
Experimentswere repeated three times and the above is a representative experiment (n=3).
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FIGURE 3.15c Antibacterial activity ofDefb2PKl and Defr I against Escheric/ixacoliJ2408.
Bacteria were incubated with the peptide at 50 pg/hi over a rarge of salt concentrations.
Graphs A and B show the number of colony forrrdrg units (CFU) ± standard error from the
blank-control and peptide-treated samples. Graphs C and D drow the mean percentage kill ±
standard error; this is assessed by calculatirg the number of CFU surviving in the peptide-treated
sample as a percentage of the counts from the blank-control sample. Experimentswere repeated
three times and the above is a representative experiment (n=3).
3.3.7 Antibacterial Activity of Defb22nd against E. coli J3201
The activity of Defb22nd against P. aeruginosa J1385 and PAOl has varied in
comparison to the response observed with the first-batch. To assess if the
activity of the two Defb2 batches varied further, the activity of Defb22nd was
also tested against E. coli J3201 (Figure 3.15 A and B). The first-batch of Defb2
demonstrated a low level of antibacterial activity against this strain, killing
«25% of bacteria in the absence of NaCl. Defb22nd showed very similar levels
of activity; in 0 and 30 mM NaCl Defb22nd demonstrated statistically
significant levels of activity, killing approximately 25% and 15% of bacteria
respectively and at 90 and 150 mM NaCl concentrations activity was ablated.
This follows the same pattern as the activity displayed by the first-batch of
Defb2.
3.3.8 Antimicrobial Activity ofDefrl against B. cenocepacia J2315
- Culture on B. cepacia-Selective Agar
Surprisingly, Defrl also demonstrated statistically significant antibacterial
activity against B. cenocepacia J2315, a bacterium previously found to be
resistant to the activity of antimicrobial peptides (Morrison et al. 1998 and
Hancock, 1997) (Figure 3.16 B and D). This is one of the first reports of a p-
defensin active against B. cenocepacia J2315. Killing was maximal in the
absence of NaCl, with «45% killing (p < 0.01), this was reduced to
approximately 20% in 30 mM NaCl (p < 0.05), but killing was ablated by
NaCl concentrations of 90 and 150 mM. No killing was observed with
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Defb22nd against B. cenocepacia (Figure 3.16A and C), matching the response
seen with the original batch of Defb2.
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FIGURE a 16c Antibacterial activity ofDefbt?**1 againstEscherichiacoliJ32DL
Bacteriawere imitated with the peptide at 50 pg/hi over a rarge of salt concentrations. Graph
A shows the nurrter of colony forming units (CFU) ± standard error from the blank-control and
peptide-treated samples. Graph B taws the mean percentage kill ± standard error; this is
assessed by calculating the nurrter of CFU surviving in the peptide-treated sample as a
percentage of the counts from the blank-control sample. Experimentswere repeated three times
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FIGURE 3l17: Antibacterial activity of Defb2PMi and Defrl against Burkholderia
cenxepaciaJ2315. Culture onB. cepaciasdective agar.
Bacteria were incubated with the peptide at 50 pg/hi over a rarge of salt concentrations.
Following incibation the bacteriawere plated out onB. cepacia selective agar as detailed in the
materials and methods. Graphs A and B show the nunber of colony forming units (CFU) ±
standard error from the blank-control and peptide-treated samples. Graphs C and D show the
mean percentage kill ± standard error; this is assessed by calcriatirg the number of CFU
surviving in the peptide-treated sample as a percentage of the counts from the blank-control
sample. * * = p < 0.01, * = p < 0.05. Experimentswere repeated three times and the above is a
representative experiment (n=3).
3.3.9 Antimicrobial Activity of Defrl against B. cenocepacia J2315
- Culture on Nutrient Agar
The experiments described in section 3.3.8 were performed using selective
agar to support the growth of B. cenocepacia J2315. This agar contains two
antibiotics (polymyxin B and ticarcillin) to select for the growth of all
bacterial strains of B. cepacia complex, which are resistant to these antibiotics.
To confirm that the antimicrobial activity against B. cenocepacia J2315 was due
to Defrl alone and not due to an interaction of the antibiotics with Defrl, the
experiments were repeated using nutrient agar with no selection. In the
absence of the selective antibiotics, however, Defrl killed in the same pattern
as was previously seen with the selective agar (Figure 3.17 A and C).
Moreover, 50 pg/ml (7790 Units/mg) of Polymyxin B, another antimicrobial
peptide, failed to kill B. cenocepacia, this agrees with previous studies that
have found B. cenocepacia to be resistant to this antibiotic (Figure 3.17 B and
D). This result suggests that the experimental procedure does not render B.
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FIGURE 3,18; Antibacterial activity of Defrl and polymyxin B against Buridwlderia.
cenocepaciaJ2315. Culture ofnutrient agar.
Bacteria were incubated with the peptide at 50 pg/fri over a range of salt concentrations.
Following incrbation the bacteriawere plated out onB. cepacia selective agar as detailed in the
materials and methods. Graphs A and B sfiow the nurrber of colory formirg units (CFU) ±
standard error from the blank-control and peptide-tneated samples. Graphs C and D daow the
mean percentage kill ± standard error; this is assessed by calculatirg the nunber of CFU
survivirg in the peptide-treated sample as a percentage of the counts from the blank-control




Many epithelial tissues such as the epidermis of the eye, the surfaces of the
airways, and the digestive, reproductive and urinary tracts are exposed to
the environmental microbes and are therefore potentially prone to
colonisation. However, these epithelial surfaces are protected, in part, by the
production of a variety of cationic antimicrobial peptides reviewed in
(Zasloff, 2002). These peptides typically contain between 15 and 50 amino
acids, are amphipathic in structure and have a net positive charge due to the
presence of a high number of lysine and arginine residues. The a-defensins
are expressed mainly in the granules of neutrophils but are also in the crypts
of the small intestine. The p-defensins are produced by epithelial tissues
such as the skin, salivary glands and urogenital and respiratory tracts (Bals,
2000). However, whilst the function and activity of a-defensins has been well
studied, the activity of the p-defensins is less well characterised. They came
to wider interest when the salt-sensitive nature of their activity was
implicated in the pathogenesis of CF lung disease (Goldman et al., 1997). It
has been shown that primary cultures of CF airway epithelial have elevated
NaCl concentrations in the airway surface liquid (ASL) and this results in a
reduced ability to kill bacteria (Smith et al., 1996; Zabner et al., 1998).
Moreover, it has also been demonstrated that synthetic human p-defensin 1
(DEFB1) has salt-sensitive antibacterial activity and is an important
constituent of innate defence in the ASL (Goldman et al., 1997). These results
suggest that the loss of CFTR elevates NaCl concentrations and reduces the
antibacterial activity and that this may leave the lungs of CF individuals
prone to bacterial infection and colonisation, however evidence in support of
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this theory remains largely absent. Furthermore, the p-defensins are viewed
as 'natural antibiotics' and in the view of the increasing bacterial resistance to
standard antibiotics, the study of antibacterial activity and role in the innate
immune system of defensins is of great interest (Diamond, 2001).




Peptide %Kill° NaCIMax %Kill° NaCIMax %Kill° NaCIMax
DEFB4 80 90 100 90 100 150
Defb2 40 90 60 30 85 30
Defb22nd 45 90 100 150 100 150





Peptide %Kill° NaCIMaa %Kill° NaCIMax
DEFB4 0 0 0 0
Defb2 0 0 0 0
Defb22nd 0 0 0 0
Defrl 100 150 45 30
Table 3.1: Table showing the spectrum of antimicrobial displayed by synthetic P-defensins at 50
pg/ml. The %Kill° represents the maximum percent-kill displayed by each peptide at 0 mM NaCl.
NaciMax indicates the maximum NaCl concentration at which that peptide displayed statistically
significant antimicrobial killing (p < 0.05 or 0.01).
3.4.2 Antibacterial Activity of Synthetic DEFB4
The data presented in this chapter (Summarised in Table 3.1) are consistent
with previous observations that p-defensins possess salt-sensitive
antimicrobial activity against Gram-negative and Gram-positive bacteria.
DEFB4, Defb2 and Defrl all showed - to varying degrees -reduced activity in
the presence of NaCl (Table 3.1). These studies found the greatest activity for
DEFB4 against P. aeruginosa compared to all other bacteria tested. DEFB4
killed 100% of P. aeruginosa J1385 and PAOl in salt-free and 30 mM NaCl
buffer, however activity was reduced by incubation with 90 mM and 150 mM
NaCl. DEFB4-mediated killing of laboratory strain P. aeruginosa PAOl was
more resistant to the effects of elevated salt than killing of the CF isolate P.
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aeruginosa J1385. For example, in the presence of 150 mM NaCl killing of P.
aeruginosa J1385 was almost completely ablated, whereas significant activity
was still observed against P. aeruginosa PAOl. DEFB4 also showed
significantly elevated antibacterial activity against the mucoid-convertant P.
aeruginosa J1532 compared to the non-mucoid P. aeruginosa J1385. These two
bacteria are the same strain (confirmed by pulsed field gel electrophoresis; C.
Doherty, personal communication). Therefore, this may suggest that the
conversion to the mucoidy phenotype results in reduced resistance to DEFB4.
This finding contrasts with a recent study that found that conversion to the
mucoid form of growth in P. aeruginosa PAOl is associated with activation of
genes for resistance to antibiotics such as the cationic antibiotic tobramycin
(Whiteley et al, 2002). However, mucoidy P. aeruginosa are normally
protected from the environment by production of a biofilm. However, in the
experiments presented in this is thesis the bacteria were resuspended in a
solution, which may have prevented production of an effective biofilm.
DEFB4 was also found to have significant antibacterial activity against S.
aureus CF isolate CI705 in low salt, however, this activity was ablated by salt
at a concentration of 150 mM, and in a NaCl concentration of 90 mM only
«40% of bacteria were killed. No significant activity was observed for DEFB4
against E. coli clinical isolate J2408 and only a low level of activity was
recorded against E. coli J3201, where 25% of bacteria were killed in the
absence of salt. DEFB4 also failed to kill B. cenocepacia J2315, this result is
consistent with previous findings that this bacteria, indeed the B. cepacia
complex, is highly resistant to the activity of antimicrobial peptides
(Hancock, 1997a).
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These results generated using synthetic DEFB4 are in broad agreement with
those from previously reported findings. The peptide used in one of these
studies (Bals et al., 1998b) was generated by a baculovirus system, which
produced peptides of two different lengths due to variations in cellular
processing. The most predominant form was a peptide of 41-amino acids,
which corresponded to the sequence of the mature peptide initially isolated
from skin (Harder et al., 1997), and this also appears to be the predominant
form in the ASL. A 38-amino acid peptide, missing 3 amino acids at the NH2-
terminal, was also isolated; however, no significant difference was observed
between the activity of the two peptides (Bals et al., 1998b), and the 38 amino
acid peptide is used in the studies described in this chapter. The Bals et al.
study found activity against P. aeruginosa and S. aureus using recombinant-
derived DEFB4 with a minimum inhibitory concentration (MIC) of 62 jig/ml,
however their study also reporter an inhibitory effect of DEFB4 on E. coli D31,
whereas the current work found no activity against E. coli J2408. Another study
observed much greater levels of activity of DEFB4 against P. aeruginosa with
a LD90 (concentration required to reduce bacterial survival by 90%) of near
lOpg/ml and it is interesting to note that this study used the 41-amino acid
peptide (Harder et al., 1997). Against the Gram-positive S. aureus, however,
DEFB4 showed only bacteriostatic activity at relatively high concentrations
(100 pg/ml). It is not stated how the peptide used in the Harder et al. (1997)
study was generated, nor how the antibacterial activity was assessed, so it is
possible that the recorded differences are due to experimental-design
differences or variations in the production and folding of the peptide.
Moreover, it is difficult to compare the results between these different studies
as the methods of data presentation (% kill, MIC and LDw) differ markedly.
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A further study also assessed the antibacterial activity of DEFB4 and
reported salt-sensitive antibacterial activity (Singh et al., 1998). This work
assessed bacterial viability using an E. coli expressing a luminescence protein.
Interestingly, they found the recombinant DEFB4 used in their study to be far
more active than in the studies reported here, although it is possible that the
strains of bacteria used are more sensitive. In their assay, recombinant
DEFB4 was able to kill approximately 100% of bacteria in the presence of 75
mM NaCl at a concentration of only 0.5 gg/ml. In the studies described in
this chapter, synthetic DEFB4 showed no activity against E. coli J2408 and
only weak activity against E. coli J3201 in low salt and at a concentration of 50
gg/ml. A similar trend was also found with recombinant DEFB1 compared to
the results obtained by Dr Donald Davidson from this laboratory using
synthetic DEFB1 (Morrison et al., 1998; Morrison et al., 2002b). Moreover,
Singh et al also reported that DEFB4 was more active than DEFB1 against E.
coli and P. aeruginosa PAOl in 10 mM NaCl; these findings were not repeated
with synthetic DEFB4 or DEFB1 in this study. Furthermore, DEFB4 showed
no activity against E. coli J2408, whereas DEFB1 was found to kill -50% of E.
coli J2408 in the absence of salt. However, whilst both DEFB4 and DEFB1
showed potent activity against P. aeruginosa PAOl in low levels of NaCl
(both killed 100% of P. aeruginosa PAOl in the absence of salt); DEFB4
maintained highly potent killing activity in 30 mM, whereas DEFB1 activity
was greatly reduced by high levels of salt.
The failure of the DEFB4 used in these studies to show activity against £. coli
J2408 and only weak activity (25% killing in salt-free phosphate buffer)
against £. coli J3201 may be due to strain differences such as their origins, or
experimental differences. However, it is unusual as antibacterial activity was
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reported for DEFB4 by two earlier studies (Bals et al., 1998b; Singh et al.,
1998). As mentioned earlier, the MIC of recombinant DEFB4 against E. coli
D31 was reported to be 62 pg/ml (Bals et al., 1998b). Singh and colleagues,
however, found strong activity at 0.1 gg/ml DEFB4 in low concentrations of
NaCl against E. coli DH5a. Another study by Tomita et al. (2000) also using
synthetic DEFB4 found activity against five different E. coli strains at 20
gg/ml or less (Lehrer and Ganz, 1996). The high levels of activity found in the
Singh et al. system and the activity reported by Bals et al. and Tomita et al.
against E. coli suggests that DEFB4 does indeed possess antimicrobial activity
against E. coli. The discrepancy between these findings and the current study
may be due to the different bacterial strains, peptide production methods or
the assays used. For example, the incubation time used in the other studies
discussed was considerably longer than the 30 min used in the studies
presented in this chapter. Moreover, the other studies on DEFB4 used a 41-
amino acid peptide that was three residues longer at the NHb-terminus than
the synthetic peptide used in this study, and this may have affect its activity.
Although, Singh et al. report no difference in the activities of the peptide
variants, another study on natural variants of DEFB1 found in urine did find
significant differences in the activity of peptides of different lengths. The 36
amino acid variant of DEFB1 was shown to have greater antimicrobial
activity against E. coli compared to the longer peptide varieties (37 and 42
residues) (Valore et al., 1998). The murine orthologue of DEFB4 is Defb4, it
would be predicted that these two peptides would show similar levels and
spectra of activity, however, no functional data has yet been published for
Defb4 and therefore comparison is impossible.
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3.4.3 Antibacterial Activity of Defb2
This chapter includes novel data on the antimicrobial activity of synthetic
murine p-defensin 2, Defb2 (Table 3.1). Defb2 demonstrated lower levels of
activity compared to DEFB4 against S. aureus CF isolate C1705, and P.
aeruginosa CF isolate J1385 and laboratory strain PAOl. The finding that
DEFB4 and Defb2 show greater activity against P. aeruginosa PAOl than P.
aeruginosa J1385 is in agreement with previous findings with both DEFB1 and
Defbl, which also found P. aeruginosa J1385 to be more resistant to p-
defensins compared to P. aeruginosa PAOl (Morrison et al., 1998). P.
aeruginosa J1385 is a virulent CF pathogen, whereas the PAOl strain is a
highly passaged laboratory strain. This may explain, at least in part, the
different susceptibilities to defensins. As with DEFB4, Defb2 showed no
activity against B. cenocepacia J2315, nor E. coli J2408, and only a low level of
antimicrobial activity against E. coli J3201. Defb2 only showed significant
antibacterial activity against the bacteria tested in the presence of NaCl
concentrations of 30mM or less, this contrasts with DEFB4, which was
observed to maintain statistically significant antibacterial activity (P < 0.05) in
up to 90 mM NaCl against P. aeruginosa J1385 and PAOl and S. aureus C1705.
A similar pattern was also observed in the work using DEFB1 and Defbl at
50 pg/ml against P. aeruginosa J1385 (Morrison et al., 1998; Morrison et al.,
2002b). The findings in two different studies that mouse p-defensins 1 and 2
are less active than human p-defensins 1 and 2 against P. aeruginosa J1385,
suggests that differences in the success of peptide folding are unlikely to be a
factor, and may represent the existence of species-specific differences in the
activities of p-defensins. It is possible that Defbl and Defb2 have greater
activity against a different range of bacteria than DEFB1 and DEFB4. The
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pathogens used in this study, such as P. aeruginosa J1385, are human
pathogens and rarely colonise mice; indeed established P. aeruginosa
infections in CF mouse models suggest that mice are not particularly
susceptible to colonisation with P. aeruginosa (McCray et al, 1999; Larbig et
al, 2002). Therefore, murine antimicrobial peptides, such as the p-defensins,
may not have evolved activity against these bacteria, but rather against
bacteria that are pathogenic in mice and relevant to their ecological niche. It
would be of great interest to investigate the relative activity of human and
murine p-defensins against pathogens known to cause infections in mice.
3.4.4 Antibacterial Activity of Defb22nd
A second batch of Defb2 (solely for comparison purposes referred to as
Defb22nd) was also synthesised to use as a control in the analysis of Defrl
function (see later). This peptide gave the same spectrum of activity as the
first batch of Defb2 against S. aureus C1705 and E. coli J3201, and like the first
batch of Defb2 also showed no activity against B. cenocepacia J2315 and £. coli
J2408 (Table 3.1). Surprisingly, however, Defb22nd demonstrated significantly
different spectra of activity against the two previously tested strains of P.
aeruginosa (Table 3.1). Defb22nd had much higher antimicrobial activity
against P. aeruginosa PAOl and J1385 than was originally observed for Defb2;
in both cases the activity was more similar to the spectrum of activity seen for
DEFB4 against the same bacteria. Against P. aeruginosa J1385 in the absence
of NaCl, Defb22nd killed 100% of the bacteria, this contrasts with 40% of
bacteria killed in experiments using the first batch of Defb2. Furthermore,
whereas the original Defb2 peptide showed no significant killing in the
presence of 90 or 150 mM NaCl, Defb22nd killed approximately 75% of
bacteria in 90 mM NaCl and «25% of bacteria in 150 mM NaCl. A different
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set of results was also obtained for Defb22nd against P. aeruginosa PAOl
compared those originally recorded with Defb2. The first batch of Defb2
showed the greatest activity in the absence of NaCl, killing =80% of bacteria,
whereas Defb22nd killed 100% of bacteria at the same NaCl concentration. In
the presence of 90 or 150 mM NaCl, Defb22nd maintained significant activity,
killing approximately 75% of bacteria, whereas the original Defb2 show no
reproducible significant activity at 90 or 150 mM NaCl. The bacteria used in
the two studies were cultured and handled in an identical fashion and were
certified as the appropriate strain and were confirmed to be identical to the
isolate used in the initial experiments by restriction endonuclease digestion
(personal communication, C. Doherty, University of Edinburgh). Therefore,
it is unlikely that the different activities were due to differences in the
bacterial strains used. The differences may however be due to differences in
the production of the two peptides. Albachem Ltd. (Edinburgh, UK)
analysed the structure of the two peptides by MALDI TOF mass
spectrometry. Analysis of the HPLC spectra produced for the two peptides
reveals that whereas Defb22nd produced a single main peak suggesting the
existence of only one form of the peptide, the analysis for the original batch
of Defb2 shows the presence of two large peaks (See Appendix). Whilst one
peak corresponds to the peptide also seen in Defb22nd analysis. A second peak
indicates the presence of a substantial quantity of Defb2 in which the
methionine at position 38 has become oxidised (Figure 3.1). The effects of
this on the structure of Defb2 are unknown. However, the reduced
antimicrobial activity of this batch of Defb2 compared to Defb22nd may
suggest that the result is a less active form of the peptide against P.
aeruginosa, although the activity of Defb2 against the other strains of bacteria
tested was not affected by this change. However, with the exception of P.
aeruginosa, the results obtained with Defb22nd are in agreement with the
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activities observed with the original batch of Defb2, suggesting that these
results are reproducible. Nevertheless, the differences observed against P.
aeruginosa may suggest that alterations in the peptide folding can lead to
large changes in the activity of the peptide and thus stresses the importance
of peptide folding and composition. It is noteworthy that even after taking
into account the increased anti-pseudomonal activity of Defb22nd, the results
still indicate that murine Defb2 is less effective against the tested pathogens
than human DEFB4. Although it is important to note when comparing the
results of these two peptides that DEFB4 and Defb2 are not functional
orthologues, and may therefore have evolved quite separately with
specificity against different pathogens.
The results presented here are in broad agreement with previous studies on
the activity of murine p-defensins. In comparison with synthetic Defbl,
Defb2 shows similar levels of activity against S. aureus CI705, both peptides
killed 75-80% of bacteria in the absence of salt and the activity of both p-
defensins was ablated by high levels of salt. However, Defbl showed weak
antimicrobial activity against E. coli J2408, whereas Defb2 failed to kill this
organism and showed only weak activity against a second E. coli strain,
J3201. Moreover, both batches of Defb2 showed greater activity against P.
aeruginosa J1385 than did Defbl, which killed approximately only 40% of
bacteria in the absence of salt (Morrison et al, 1998), suggesting that Defb2
has antimicrobial activity against a different range of bacteria than Defbl. A
separate study on the antimicrobial activity of cell lysates from cell lines
transfected with Defbl cDNA showed that Defbl possessed potent and salt-
sensitive antimicrobial activity against E. coli, S. aureus and P. aeruginosa
compared to untransfected cell lines (Bals et al., 1998a). However, this study
did not quantify or purify Defbl, so the level of Defbl used in this study is
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not known, and furthermore, the possibility that Defbl interacted with other
factors present in the cell lysates to increase its activity can not be ruled out.
Mouse (3-defensin 3 (Defb3) has been shown to possess highly potent
antibacterial activity against P. aeruginosa PAOl with an MIC of 8 gg/ml and
also displays activity against E. coli D31 with an MIC of 16 pg/ml (Bals et ai,
1999). This suggests that Defb3 has potent activity against Gram-negative
bacteria, whereas Defb2 activity does not appear to be potent against Gram-
negative bacteria as it failed to kill E. coli and showed variable activity
against P. aeruginosa.
3.4.5 Antibacterial Activity of Defrl
Defensin-related 1 (Defrl) is a novel p-defensin gene in which the first of the
canonical cysteines that are present in all p-defensins previously isolated has
been substituted for a tyrosine. As the loss of this residue would prevent the
formation of a disulfide bond and therefore likely lead to large structural
changes the antimicrobial activity of Defrl was also assessed using a
synthetic peptide (Morrison et al, 2002a). Defrl demonstrated salt-sensitive
antimicrobial activity against S. aureus C1705 and E. coli J2408 (Table 3.1). In
the absence of salt 100% of bacteria were killed, this is greater activity than
was seen against either S. aureus C1705 or E. coli J2408 with any of the other
peptides analysed in this chapter, however antimicrobial activity was
reduced in 30 and 90 mM NaCl and ablated by 150 mM salt. Defrl also
demonstrated highly potent activity against P. aeruginosa J1385 and PAOl;
these results suggest that the loss of the first canonical cysteine does not
result in loss of antimicrobial activity (Table 3.1). This is also demonstrated
in a previous study in which analogues of the a-defensin, HNP-1 engineered
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to have one or two disulfide bridges maintain activity seen with the native
peptide (Mandal and Nagaraj, 2002).
Defrl exhibited its greatest activity against both P. aeruginosa strains
compared to all other bacteria tested. The antimicrobial effect of Defrl
against P. aeruginosa J1385 was virtually salt-insensitive at 50 pg/ml and the
activity was completely resistant to the effects of salt against P. aeruginosa
PAOl at the same concentration. In the presence of 150 mM NaCl the
antimicrobial activity of Defrl against P. aeruginosa J1385 was only marginally
reduced to «95%, at all other NaCl concentrations, and in the case of P.
aeruginosa J1385 across the full salt concentration range, killing was 100%.
Previous studies have indicated that salt-sensitivity can be overcome by
increasing the peptide concentration (Singh et al, 1998). In this study, the
concentration of DEFB1 and DEFB4 was increased to abrogate the effect of
elevated NaCl. To further investigate the potency of Defrl against P.
aeruginosa the effect of lower concentrations of Defrl on the survival of P.
aeruginosa PAOl was assessed at 150 mM NaCl. Defrl maintained a high
level of potency in concentrations as low as 25 pg/ml, with 100% of bacteria
killed and even at a concentration of 10 pg/ml -90% of bacteria were killed.
However, at a concentration of 5 pg/ml antibacterial activity was reduced to
50% killing. This suggests that Defrl possesses significant antimicrobial
killing at comparatively low concentrations, even in the presence of 150 mM
NaCl. The full salt-sensitivity of Defrl at 5 pg/ml was also assessed to
investigate whether Defrl possessed salt-insensitive activity at this
concentration. At this concentration however, Defrl still possessed highly
potent antimicrobial activity in salt concentrations as high as 90 mM, killing
100% of bacteria in 0, 30 and 90 mM NaCl, but in 150 mM NaCl antibacterial
activity was reduced to 50% in agreement with the previous study. By
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comparison, Defb22nd showed no significant activity against P. aeruginosa at 5
gg/ml. These results suggest that Defrl possesses highly potent anti-
pseudomonal activity; the LD90 of Defrl against P. aeruginosa PAOl of 10
pg/ml and LD50 of 5 gg/ml compares highly favourably with the LD90 of 'near'
10 pg/ml for DEFB4 against P. aeruginosa (Harder et al.r 1997). Moreover, the
LD90 of Defrl is only slightly higher than the MIC of 4.1 pg/ml for DEFB104
also against P. aeruginosa PAOl, which is the lowest MIC observed to date for
a (3-defensin (Garcia et al., 2001b) and is lower than the MIC (8 pg/ml) of
Defb3 against P. aeruginosa PAOl (Bals et al., 1999). Interestingly, however,
while the activity of Defrl against P. aeruginosa is significantly lower than the
MIC recorded for DEFB103 of 26.5 pg/ml, this peptide does demonstrate salt-
insensitive killing of the Gram-positive S. aureus (Garcia et al., 2001a).
Greater analysis of the structure of these two peptides may help to elucidate
the structural differences responsible for their P. aeruginosa (Defrl) and S.
aureus (DEFB103) specificities. Furthermore, these results may further
suggest the evolution of some P-defensins with specific, rather than broad
antimicrobial activities (Schroder, 1999). It must be noted, however, many of
these antimicrobial studies were performed under different experimental
conditions, which make comparison difficult. Consequently, the MIC of
Defrl should be calculated using a standard Microbroth dilution method to
make a more accurate comparison.
Defrl expression has been detected in the heart, uterus and testis. This
pattern of expression is quite limited and unique compared to that of the
other p-defensins. However, a recently identified murine P-defensin, Defb6,
was found to be expressed in skeletal muscle (Yamaguchi et al., 2001) and a
defensin-like molecule, Binbl, which possesses antimicrobial activity has
been identified in rats and its expression appears to be confined to the caput
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region of the epididymis (Li et al., 2001). These findings demonstrate
widespread distribution of the (3-defensin (and P-defensin-like) gene
expression. Many tissues express a multiplicity of p-defensins and their
functions in these tissues may be, to some extent, overlapping. However, in
other tissues specific p-defensins may form an important aspect of the
immune system.
Perhaps the most startling result obtained with the Defrl peptide was the
finding that it has antimicrobial activity against B. cenocepacia J2315. This
bacterium was previously thought to be resistant to the action of cationic
peptides due to a nonreactive outer surface (Hancock, 1997b). However,
synthetic DEFB103 was shown to have antimicrobial activity against B.
cenocepacia ATCC17770 and also against an unspecified clinical isolate at a
low concentration of the peptide (6.6 pg/ml) (Garcia et al., 2001a). Synthetic
Defrl killed =45% of bacteria in the absence of salt, this was reduced by
incubation in 30 mM, but 90 or 150 mM salt ablated antimicrobial activity. It
is interesting to note that the B. cenocepacia CF isolate J2315 is the Edinburgh-
Toronto epidemic strain, and is one of the most resistant to the action of
conventional antibiotics (Nzula et al., 2002). In comparison with Defrl,
neither DEFB4 nor either batch of Defb2 demonstrated the ability to kill B.
cenocepacia. In the above experiments, following incubation with Defrl the
surviving bacteria were plated out on B. cepacia-selective agar, which
contains high levels of antibiotics (32.5 mg/ml polymyxin B and 100 pg/ml
tircarcillin). Therefore, the experiments were repeated using nutrient agar
without antibiotic-selection to investigate the possibility that the observed
antibacterial activity was due the interaction of Defrl and the antibiotics.
These studies gave the same spectrum of results as was seen previously,
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suggesting that the antimicrobial activity was due to the action of Defrl
alone; moreover in this set of experiments 500 gg/ml Polymyxin B, to which
B. cenocepacia is resistant, was also included as a control and this failed to kill
B. cenocepacia. This suggests that the observed activity is not an artefact of
the experimental procedure.
It is unclear why Defrl possesses activity against B. cenocepacia when other
cationic peptides do not display such potent anti-pseudomonal activity. One
possible explanation is that while many p-defensins show broad-range
antibacterial activity, others have evolved more specific and defined activity
against a narrow spectrum of bacteria (Schibli et al, 2002; Schroder, 1999).
Defrl may have evolved highly potent anti-pseudomonal activity, as it has
been argued that DEFB103 evolved highly specific activity against S. aureus
(Garcia et al., 2001a). The manner in which Defrl is folded may also have
lead to greater clustering of its positive residues compared to other |3-
defensins, and this may result in its increased potency as this clustering may
increase the electrostatic interaction between peptide and target membrane
(Yu et al., 2000). Yu et al. (2000) have shown that a-defensins engineered to
have a head-to-tail cyclic structure are more potent and less salt-sensitive
than the native compound and proposed that this was due to clustering of
positively charged residues. However, the activity seen by Defrl may also be
due to the loss of the cysteine and subsequent alterations in the (3-defensin
structure. However, the precise effect of the amino acid substitutions on the
structure of the peptide remains unknown. The structure of p-defensins and
its effect on antibacterial activity is discussed in detail below.
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3.4.6 {3-Defensin Structure
To date the structures of several different murine and human p-defensins
have been analysed. A crystal structure of DEFB4 has been determined for
two different forms that differed in the quaternary arrangement of the
DEFB4 monomer (Hoover et al., 2000). In both forms, however, the three-
dimensional structure of the monomer was highly similar and were shown to
include an N-terminus a-helix and three antiparallel P-sheets. In one form, a
dimer was observed to be formed by interaction between the first p-sheets of
each monomer. The second crystal structure was an octomer formed from
four dimers. The authors proposed that it was likely that the dimer was the
native form and the octomeric form of DEFB4 represents the form bound to
bacterial membranes (Hoover et al., 2000). This oligomerisation of DEFB4
contrasts with the structure of DEFB1, which showed no evidence of higher-
order structures similar to the octomeric DEFB4 although dimers were
identified (Hoover et al., 2001). Despite this difference in the quaternary
arrangements, the tertiary structure of DEFB1 was very similar to that for the
DEFB4 monomer. Another study has determined the solution structure of
DEFB1 and DEB2 using nuclear magnetic resonance (NMR) analysis and
observed a highly similar secondary structure as compared to the crystal
structure of DEFB1 and 2 but found only monomeric forms(Bauer et al.,
2001). Furthermore, the authors argue that the oligomerisation of DEFB4
observed in the crystal structure was an effect of the conditions used for
crystallisation such as high local concentration. It is possible, therefore, that
P-defensins exert their antimicrobial effects as oligomers. Interestingly,
however, the recently determined solution structure of DEFB103 suggests
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that it does exist as a dimer in solution, moreover this study saw DEFB1 and
DEFB4 to exist in only monomeric form (Schibli et al., 2002).
In order to elucidate the structure of Defb22nd and Defrl Studies of the
synthetic peptides have been conducted by Dr Perditta Barran at the
Chemistry Department, University of Edinburgh. Analyses of Defb22nd
reveal the presence of one monomeric form, which possesses three disulfide
bonds. The analyses the Defrl structure, however, reveal that it exists both
in monomeric and dimeric forms. Further study confirmed that the
monomer contained two disulfide bonds as would be expected for a
molecule with five cysteines. However, the dimer was composed of two
forms. One form possessed three disulfide bonds, whereas the alternate form
had four, although the arrangements of the disulfide bonds are not known.
Interestingly, a very recent study has identified a polymorphism in the
DEFB1 gene that substitutes a serine for one of the conserved cysteines. The
peptide, however, retained levels of antibacterial activity similar to the
originally identified DEFB1 even though the cysteine-pairing is altered (Circo
et al., 2002).
Bauer et al., (2001) have recently reported the structure for Defb8, a (3-
defensin that differs form Defrl by only three amino acids, one of which
gives the Defb8 peptide the six cysteine pattern conserved in other p-
defensins. Moreover, Defb8 is 98% identical to Defrl across the entire length
of the gene, which suggest that these are different forms of the same gene.
However, Defb8 was not detected by Dr Gillian Morrison working in this
laboratory, and moreover the public database in the mouse genome at
ENSMBL reports the peptide sequence for Defrl and not Defb8. The solution
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structure of Defb8 was elucidated in the Bauer et al. (2001) study and was
found to exist only as a monomer with a similar structure to DEFB1 and
DEFB4. This may suggest that the two three amino acid differences between
Defrl and Defb8 are responsible for the structural differences, although the
variations in peptide synthesis may also have had an effect. Further analysis
of the antimicrobial activities of all the different peptide forms (i.e. both
monomeric Defrl and dimeric Defrl) is required to identify any variations in
their function, as the activities observed might be due to different forms of
the peptide. For example, the activity seen against B. cenocepacia could be
due to one specific form, or an interaction between several of the different
forms of Defrl. DEFB103 and Defrl have been shown to exhibit
antimicrobial activity against B. cenocepacia and also to have salt-insensitive
activity at 50 gg/ml (DEFB103 against S. aureus and Defrl P. aeruginosa). It is
interesting to note that these two p-defensins have also both been shown to
exist in solution as dimers, in contrast some reports suggest that DEFB1 and
DEFB4 exist as dimers only at high concentration or in crystal form (Bauer et
al., 2001; Schibli et al., 2002). If the hypothesis suggested by Bauer et al. and
Hoover et al. is correct (Hoover et al., 2000; Bauer et al., 2001) and p-defensins
do exert their antimicrobial activity as oligomers, then the suggested ability
of DEFB103 and Defrl to oligomerise at low concentrations may explain their
particularly potent activities. However, this would require further
investigation to confirm if DEFB103 and Defrl do possess the ability to
dimerise at low concentrations and to investigate whether the effects of Defrl
are mediated by the monomeric or dimeric forms of the peptide. As the basis
for the activity of cationic peptides is thought to be the net positive charge, it
is interesting to note that DEFB103 has a very high net positive charge of +11.
The net positive charge of Defrl (+5) is higher that that of some other p-
defensins, for example Defb2 (+3), DEFB1 (+4) and Defbl (+4). It has been
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suggested that the very high positive charge of DEFB103 may explain its
unusual patterns of activity (Harder et al., 2001; Lehrer and Ganz, 2002b).
However, whilst the charge of Defrl may be higher that some other
defensins it may not be high enough to explain the observed activities.
Moreover, the net positive charge of DEFB4 is +6, even though it less potent
than Defrl against the bacteria tested. Therefore, the activity is probably
dependent on more than the net positive charge. It should be noted that as
the (3-defensin family shows a very high rate of amino acid substitution
(Hughes, 1999; Morrison et al., 2002c), the observed activities could, of
course, be due to any of the other amino acid changes. Further analysis of
the antibacterial activities of P-defensins and in particular, the monomeric
and oligomeric forms are necessary.
The importance of different individual amino acid residues in the activity of
antimicrobial peptides is demonstrated by the human neutrophil peptides-
(HNP-) 1, 2 and 3. HNP 1 and 2 have demonstrated potent antimicrobial
activity against Candida albicans. However, HNP3, which differs only by an
additional amino acid at the, N-terminus showed no significant activity
against C. albicans (Lehrer et al., 1988). Furthermore, in a separate study Raj
et al., showed that the addition of two arginine residues at both the N- and C-
termini of HNP-2 significantly enhanced its antifungal and antibacterial
activities (Raj et al., 2000). Moreover, these modified peptides showed
activity against Actinobacillus actinomycetemcomitas and Porphyromonas
gingivalis whereas the native HNP-2 peptide did not. Other mutational
studies have also been conducted on the a-defensins to assess the importance
of structure on antimicrobial activity. A recent study synthesised various
structural analogues of HNP-1, and demonstrated that cyclisation of HNP-1
lead to an increase in its potency to various Gram-negative and Gram-
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positive bacteria and a reduction in its salt-sensitivity. Interestingly, it also
showed that a covalent dimer formed between two cyclic HNP-1 molecules
was the most potent in high salt and the only peptide to show activity against
Klebsiella pneumoniae (Yu et al, 2000). Furthermore, the recently identified 0-
defensin RTD-1 shows salt-insensitivity and a 3-fold greater antimicrobial
activity against S. aureus than the open chain analogue, which possesses an
additional charge at both termini, and it is proposed that this reduces the
ability of the peptide to interact with the membrane (Tang et al., 1999).
3.4.7 Physiological Roles of P-Defensins
It is notable from the salt-sensitivity of the P-defensins analysed that, with a
few exceptions, they do not show significant antimicrobial activity in NaCl
concentrations of 150 mM, and their activity in 90 mM is greatly reduced.
Elucidation of the physiological salt concentration at the sites of antimicrobial
action will provide insights as to the likely endogenous relevance of these
antibacterial peptides. In addition to this, the concentration of p-defensins at
their site of action (e.g. the ASL of the lungs, or the surfaces of other
epithelial tissues) is also of relevance here, however, there is a paucity of data
regarding the concentration of the various P-defensins. One study failed to
detect DEFB1 at all in broncheoalveolar lavage fluid (BALF) although the a-
defensins human neutrophil peptides 1-3 (HNP1-3) were detected (Schnapp
and Harris, 1998). The Singh et al. study previously discussed also analysed
the concentration of DEFB1 and DEFB4 in the airways (Singh et al., 1998).
They found that DEFB1 was present in broncheoalveolar lavage fluid (BALF)
at a concentration of less than 2 ng/ml, and DEFB4 was detected 0.1 -100
ng/ml. A separate study found DEFB1 and DEFB4 at low (0.05 -0.1 ng/ml) in
the lungs of healthy patients and at 0.2-2 ng/ml in patients with
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inflammatory lung disease (Ganz, 1998). It is thought that this is within the
range of antimicrobial activity for DEFB4, but not for DEFB1 and these
concentrations are well below those used in the studies reported here and
much of the previously published data. The concentrations of p-defensins
reported by Singh et al. may represent the average or overall level, whereas
BALF may in reality be composed of a mosaic of high and low local
concentrations. It must also be considered that the BAFF is fluid from the
lower airways and there may exist higher concentrations of p-defensins in
the upper airways, indeed Ganz suggests as much as a 1:100 dilution of ASF
in BAFF (Ganz, 1998). A study of the antimicrobial peptides present in nasal
secretions detected DEFB4 at concentrations ranging from 0.3 to 4 pg/ml
(Cole et al., 1999). Also, it could be argued that as the upper airways, such as
the trachea and nasal turbinates, are likely to be where bacteria first colonise
following inhalation that the level of p-defensins in this section of the airways
may be of more functional importance than the lower airways such as the
alveoli. Furthermore, a study analysing the concentration of a-defensins in
the sputum of five different CF patients detected HNP 1-4 at concentrations
of 300 to 1600 gg/ml, this concentration is well above bactericidal
concentration and was sufficient to be cytotoxic to a CF tracheal epithelial cell
line (Soong et al., 1997). In a separate study human neutrophil peptides were
detected at a concentration of up to 170 gg/ml in the plasma of patients with
septicaemia (Panyutich et al., 1993). In addition, the effective antimicrobial
concentration has been shown to be dictated by the NaCl concentration,
which as will be discussed below, remains unknown in the airways.
The complete absence of, or at least severe reduction in, the antibacterial
activity of p-defensins in high levels of salt and the relatively high
concentration of peptide required for the antibacterial activity observed in
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the studies described in this chapter remains a confusing yet interesting
finding. These observations may suggest that p-defensins are incapable of
functioning as antimicrobial peptides at physiological levels of salt, indeed if
their main function is as antimicrobial peptides, then why do they show least
activity at physiological levels of NaCl? One explanation for this may be that
their main function is not as antimicrobials, but as signalling molecules, and
in fact p-defensins have been shown to act as chemotaxins reviewed in (Yang
et al., 2001) and to induce mast cell degranulation and regulate prostaglandin
production (Niyonsaba et al., 2001). It is also possible that the large number
of bacteria used in this assay or the short incubation time compared to many
of the other studies may artificially conceal antibacterial activity as cationic
peptides are intended to kill a small number of invading bacteria not to kill a
large number of bacteria. Also, as the p-defensins function at epithelial
surfaces they will likely interact with other aspect of the immune system.
This raises the possibility that the activity of p-defensins to act synergistically
with other antimicrobial proteins, and this may serve to raise the activity of
otherwise salt-inhibited p-defensins to functional levels. It has previously
been shown that the HNP 1-3 can act synergistically with hydrogen peroxide
to lyse tumour cells (Lichtenstein et al., 1988), and DEFB4 is synergistic with
either lactoferrin or lysozyme (Bals et al., 1998b). Moreover, a further study
showed that synergy between HNP1 and the human cathelicidin LL-37 was
able to overcome the ablation of HNP1 antimicrobial activity by high levels
of NaCl (Nagaoka et al., 2000). It should also be borne in mind that the
studies presented in this chapter used synthetic peptides and due to effects of
cellular processing peptides produced in vitro may be more effective than
those chemically synthesised. For example, Singh et al., reported
antimicrobial activity by DEFB4 with concentrations as low as 100 ng/ml
157
using recombinant peptides that had undergone cellular processing (Singh et
al., 1998).
3.4.8 Putative Role of (5-Defensins in Cystic Fibrosis
As was discussed earlier the salt-sensitive activity of (3-defensins has been
implicated in the pathogenesis of CF lung disease. This theory necessarily
predicts a hypotonic ASL in non-CF individuals and that loss of CFTR
function leads to an isotonic ASL. This contrasts with the theory proposed
by Matsui et al. (1998), which predicts an isotonic ASL in non-CF individuals.
This theory suggests that the primary defect in CF is excessive absorption of
fluid leading to dehydrated mucous and reduced mucociliary clearance
(Matsui et al., 1998). Consequently the concentration of NaCl in the ASL as
well as the nature of p-defensin activity have become of great interest.
Several studies have attempted to measure the ionic composition of ASL,
however, this issue remains unresolved. In humans, the ASL is
approximately 10-20 pm thick (reviewed in Pilewski and Frizzell, 1999) and
consequently sampling fluid from it has proved to be technically difficult.
The main technique employed has been to absorb liquid using small pieces of
filter paper, however as this method generates relatively large quantities of
fluid there is speculation that the collected samples do not represent normal
ASL but instead secreted fluid. Studies by Joris et al. using the filter paper
technique and Gilljam et al. using a dry aspiration technique found ASL to be
in non-CF individuals and elevated in CF individuals (Gilljam et al., 1989;
Joris et al., 1993). However, other studies by Zhang and Englehardt., and Hull
et al., using different techniques found no significant difference in ASL
between CF and non-CF individuals, with Na and CI levels between 80 and
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125 mM (Hull et al., 1998; Zhang and Engelhardt, 1999). Furthermore,
Jayaraman et al. (2001) used a novel in situ fluorescence technique to measure
the properties of the freshly secreted fluid form the submucosal glands of CF
and non-CF lungs. This technique revealed the ASL pH was approximately 7
and the Na+ and CF were 92 and 94 mM respectively. Significantly, they
found no differences between the salt concentration of the ASL from CF and
non-CF lungs, but the fluid from CF lungs displayed great viscosity than the
fluid from non-CF lungs. This important study provided evidence that
rejected the hypotonic ASL/defensin theory and supported the classical view
of CF pathogenesis as suggested by Matsui et al. (1998). Studies have also
been conducted on ASL from murine airways. A capillary electrophoresis
fluid collection technique was used to show that the ASL of wild-type mice is
hypotonic with a Na concentration of 87-112 mM, but this was not found to
be elevated in the Cftr'mlUnc/CftrtmlUnc CF mouse model (Cowley et al., 1998).
Another study using the CftrtmlKth/CftrlmlKth CF mouse model has found
evidence of hypotonic ASL with CI levels of 18 mM, but again found no
evidence for significantly elevated NaCl levels in the CF mutant mice
compared to non-CF littermates (McCray, Jr. et al., 1999). However, one
study using a cryoprobe has found evidence for significantly elevated NaCl
concentrations in the CftrtmlHxu/CftrtmlHxu CF mouse model compared to non-
CF littermates (Zahm et al., 1999). This study found very low levels of Na (12
mM) and CI (8.5 mM) in non-CF mice; and the concentrations were elevated
to 52.9 and 37.2 mM respectively in CftrtmlHsu/CftrtmlHsu mice. Interestingly,
these mice have been demonstrated to develop lung disease following
exposure to CF pathogens S. aureus and B. cepacia (Davidson et al., 1995). The
studies on the NaCl concentration of ASL in mice or humans have given
varied results. It is interesting to note, however, that while few studies have
found evidence for elevated NaCl concentrations in CF compared to non-CF
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individuals (or non-CF littermates) several have reported hypotonic ASL,
and consequently this is an environment in which p-defensins may be able to
function as antimicrobial peptides. Clearly, further analysis of this issue is
required as the concentration of NaCl is crucial to resolving the validity of
the hypotonic ASL/defensin theory of CF pathogenesis. It may also be
possible that the salt-sensitivity of p-defensins is not of relevance in CF
pathogenesis, but dysfunction of p-defensins may still be of relevance. One
further theory may be that reduced fluid movement across epithelia due to
thickened mucous of CF patients may reduce the concentration of
antimicrobial peptides such as the p-defensins in the ASL and thus render the
airways susceptible to bacterial colonisation (Cole et al., 1999).
The current studies support the salt-sensitive nature of p-defensins, and
synthetic DEFB4 has potent activity against P. aeruginosa, which is severely
reduced by 150 mM NaCl. Thus, dysfunction of DEFB4 in a high-salt
environment may result in increased susceptibility to P. aeruginosa, and a
similar trend was observed for DEFB1 against P. aeruginosa (Morrison et al.,
1998). Interpretation of the antibacterial activity for the mouse p-defensins is
somewhat problematic as the bacteria analysed in this chapter are human
pathogens, although both batches of Defb2 did show a significant reduction
in the antibacterial activity against P. aeruginosa in the presence of salt. Defrl
has highly potent, and to some extent salt-insensitive, activity against
P. aeruginosa, however, Defrl expression was not detected in the airways
(Morrison et al., 2002a). It is possible therefore, that alternative antimicrobial
peptides or cellular components of the immune system may mediate
resistance to P. aeruginosa in the airways and these may not be impaired by
high salt concentrations. The evolution of species-specific spectrums of
activity within the p-defensins suggests that the dysfunction of p-defensins
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such as Defb2 in high levels of salt may increase the susceptibility of mice to
different, mouse-specific spectra of bacteria. This might suggest that whilst
the underlying defect remains the same in mice and humans, the effect of
that defect is to make the organism susceptible to different spectra of
bacteria. Further, analysis of the spectrum of mouse pathogens needs to be
examined.
3.4.9 Summary
In conclusion, this chapter has presented data that demonstrates that
synthetic [3-defensins DEFB4, Defb2 and Defrl are salt-sensitive antibacterial
peptides. In the absence of salt human DEFB4 kills P. aeruginosa J1385 and
PAOl very efficiently, S. aureus CI705 was also killed quite efficiently, but
less so than P. aeruginosa. The mouse p-defensin, Defb2, also killed S. aureus,
but there were conflicting results regarding the activity of Defb2 against P.
aeruginosa. The first batch showed only mild activity, but the second batch
demonstrated significantly greater activity, giving a profile more similar to
that seen with DEFB4. Neither DEFB4 nor Defb2 killed E. coli J2408 or B.
cenocepacia J2315, but weak antimicrobial activity was seen against E. coli
J3201. The antimicrobial activities, however, were ablated by high levels of
NaCl, and this may contribute to species-specific susceptibility to bacterial
infection secondary to CFTR dysfunction. Studies with synthetic Defrl
showed that this peptide is a highly potent antimicrobial peptide, which kills
S. aureus CI705 and E. coli J2408 highly efficiently in the absence of salt, but
this activity was also ablated by high levels of salt. However, its activity
against P. aeruginosa was salt insensitive and it maintained a high degree of
potency even at comparatively low concentrations. Surprisingly, Defrl also
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showed antimicrobial activity against B. cenocepacia, the first p-defensins to
demonstrate such activity.
These studies provide highly interesting results regarding the activity of
human and mouse p-defensins. However, more studies of the activity of
other members of the P-defensin family as well as mutational studies are
required to further elucidate the structure-function relationships of this
family of antimicrobial peptides. Greater analysis of the role of P-defensins
in the ASL of the airways and at other epithelial surfaces is also desirable to
allow better understanding of the role of p-defensins in the innate immune
system.
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Chapter 4: Chemoattractant activities of murine B-defensins
4.1.1 Introduction
Chemotaxis is defined as a process of directed migration of cells along a
chemical gradient. This process is recognised as an important cellular
process and has been shown to be important in cancer metastasis,
embryogenesis and the inflammatory response. One of the main areas of
study of chemotaxis has been its role in the immune system where large
number of chemoattractant substances have been identified of which one of
the main families is the chemokines. Chemokines are low molecular weight
chemoattractant cytokines, they induce extravasation, chemotaxis and
activation of a wide variety of leukocytes and other immune cells for review
see (McFadden and Kelvin, 1997). However, both human a- and (3-defensins,
and other cationic antimicrobial peptides such as the cathelicidin LL-37, have
also been shown to possess chemoattractant properties towards neutrophils,
monocytes, T-lymphocytes, dendritic cells and mast cells reviewed in (Yang
et al., 2001). The defensin-induced migration of T-lymphocytes is particularly
interesting as they were first recognised as antibacterial peptides, and such a
mechanism provides a link between the innate and adaptive immune
systems. However, chemoattractive ability is not a universal property of
defensins as Guinea pig neutrophil defensins GNCP1 and 2 do not induce
migration in neutrophils, whereas human neutrophils peptides HNP 1 and 2
induced migration in neutrophils (Chertov et al., 1996). Moreover, whilst
studies have shown HNP1 and 2 to be chemoattractants for monocytes, CD4+
and CD8+ T-lymphocytes and immature dendritic cells, HNP3 has not been
found to induce migration of these cells (Territo et al., 1989; Yang et al.,
2000a). To date induction of cellular migration has not been reported for
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murine p-defensins, with the exception of a study by Biragyn et al., which
showed that murine p-defensins fused to the lymphoma antigen sFv can
induce migration of dendritic cells (Biragyn et al., 2001). This study
demonstrated that Defb2 or Defb3 peptides fused to the sFv antigen induced
migration of immature, but not mature, dendritic cells, whereas the sFv
antigen alone did not induce migration. Flowever, the authors did not
analyse the migration induced by the p-defensins alone.
This chapter presents data analysing the chemoattractant activity of the
synthetic murine p-defensins, Defrl and the second batch of Defb2 that were
shown in the previous chapter to possess antimicrobial activity. The studies
were performed using a 48-well microchemotaxis chamber (Falk et al., 1980)
and the ability of different concentrations of p-defensins to induce migration
in neutrophils, CD4+ T-lymphocytes and dendritic cells was analysed.
Neutrophils were isolated from mouse peritoneum following the method of
Rot (1991). CD4+ T-lymphocytes were isolated form mouse spleens and
purified by selecting for CD4-expressing cells using the autoMACS system
(Miltenyi Biotec). Dendritic cells (DCs) were derived from bone marrow cells
cultured in the presence of granulocyte-macrophage colony stimulating
factor (GM-CSF) (Inaba et al., 1992). Previous reports have shown that a- and
P-defensins attract immature but not mature dendritic cells (Yang et al., 1999;
Yang et al., 2000a). Therefore, the chemoattractant abilities of Defb2 and
Defrl were analysed against immature DCs that had been cultured for 6 days
(d6iDC), immature dendritic cells cultured for 7-days (d7iDC) and mature
dendritic cells (mDC).
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4.1.2 Chemotaxis of Immune-Related Cells
Many immune factors have chemotactic activity such as the group of
chemotactic cytokines (called chemokines), some complement factors (e.g.
C5a) and, as discussed above, some antimicrobial peptides (e.g. a- and (3-
defensins and LL37) (reviewed in Yang et al., 2001 and in Mackay, 2001).
Most types of immune-related cells possess the ability for chemotaxis
(reviewed in Luster, 2002). In chapter 4 of this thesis, the migration of
neutrophils, T-cells and dendritic cells in response to murine (3-defensins is
analysed and what follows is a brief introduction to these cell types.
4.1.3 Migration towards sites of Infection
Many immune cells will migrate or 'patrol' to some degree throughout the
body and upon stimulation with inflammatory cytokines will migrate more
specifically to the site of infection by following chemotactic gradients
(reviewed in Delves and Roitt, 2000a; Delves and Roitt, 2000b).
Inflammatory signals, such as LPS, induce the up-regulation of adhesion
molecules such as the E-selectins on the surface on the vascular endothelium.
The E-selectins on the endothelium bind sialylated carbohydrate ligands,
often displayed mucin-like molecules (Springer, 1994). These interactions are
weak and cause the patrolling cell to 'roll' along the endothelium (Figure
4.1A). This is followed by rapid activation of integrins on the leukocytes.
These interact with immunoglobulin superfamily (IgSF) members, such as
ICAM1 and 2, expressed on the endothelial surface (Figure 4.IB). The main
function of this interaction is to arrest the rolling process and to bring about
firm adhesion to the endothelial surface (Figure 4.1C). The activated
neutrophil then passes through the endothelial wall (Figure 4.1D), moving
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up the chemotactic gradient to accumulate at the site of infection where it can
function as an effector cell (Figure 4.1E, F).
The immune cell is attracted through the endothelium by interaction with
various chemokines that are immobilised on the endothelial surface by
presentation molecules such as proteoglycan and possibly also due to direct
production of chemokines by endothelial cells (reviewed by Witko-Sarsat et
al., 2000). It has been suggested that the cell migrates through the
endothelium via interaction between immune cell expressed integrins and P-
selectins, which have been shown to be concentrated on endothelial cell
borders (Burns et al., 2000). Homophilic interactions between the cell
adhesion molecule CD31, which is expressed on the surface of both
leukocytes and endothelial cells, are also important for transendothelial
migration, and a zipper model has been proposed to account for maintenance
of endothelial permeability (Muller et al., 1993). It has been suggested that
leukocytes navigate through complex gradients of chemoattractants in a
stepwise fashion by responding to one agonist source after another. The
direction of leukocytes movement is directed by first the steepest local
chemoattractant gradient and is then regulated by successive receptor
desensitisation and attraction by distant agonists and finally, end-target
attractants (e.g. formyl peptides, C5a) are dominant over regulatory cell
derived agonists (e.g. interleukin-8, leukotriene B4) (Witko-Sarsat et al., 2000
and Foxmann et al., 1999). Chemotactic cells are typically elongated and
more sensitive to an attractant at one end. Chemoattractants are detected by
G-protein-coupled receptors (Iijima and Devreotes, 2002). However,
previous studies have shown that the chemotactic receptors are uniformly
distributed on the cell surface and therefore it is proposed that the signalling
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al., 2000). The mechanism by which the cell senses the direction of the
gradient remains unknown, however one theory proposed to explain this is
the local excitation/global inhibition theory (Parent and Devreotes, 1999).
This theory is based upon a balance between rapid excitatory and slower
inhibitory processes, which are each controlled by receptor binding,
regulating the response. When the receptor is bound by a chemoattractant,
the excitation signals rapidly increase and a response is generated until
inhibition signals reach the same levels. In a chemical gradient the excitation
signals at the front of the cell exceeds the inhibitory signals at the back, which
generates a persistent excitatory signal, and moreover at the back of the cell
the inhibitory signal predominates and therefore there is no response. Thus,
according to this model, the duration of the response is related to the cells
localisation within a chemical gradient. The signal results in localised
polymerisation of F actin at the site of the cell cortex closest to the
chemotactic source, leading to the formation of a new pseudopod, cell
polarisation and the forward protrusion of the leading edge. This is followed
by assembly of conventional nonmuscle myosin and retraction of the
posterior of the cell (Parent and Devreotes, 1999).
4.1.4 Neutrophils
Neutrophils are among the first immune cells to arrive at the site of infection
and are important contributors to the acute inflammatory response
(reviewed in Witko-Sarsat et al., 2000). Neutrophils are activated by
cytokines produced primarily by macrophages and endothelial cells and
their main role is to migrate to sites of infection (as described above) and into
the infected site, where they phagocytose foreign particles and release the
contents of the different granules that they contain. Neutrophils also possess
168











Tertiary Vesicles | Infecting Bacteria
Gelatinase
Figure 4.2: Neutrophil Effector Functions. The complement opsonins C3b and and C4b are
recognised by CRl and CR3, whereas IgG opsonised particles are recognised via the immunoglobulin
receptors (Fcy-R). This leads to activation of the neutrophil. The first microbicidal pathway is the
oxidative response, which consists of the production of radical oxygen species following NADPH-
oxidase complex activation, including superoxide anion (02~), hydrogen peroxide (H202), and via
myeloperoxidase, hypochlorous acid (HOC1) and chloramines. The second microbicidal pathway is
non-oxygen-dependent and consists of the release in the phagolysosome or in the extracellular medium
of performed proteins stored in granules. Serine proteases, antimicrobial proteins, as well as
myeloperoxidase are contained in the in azurophilic granules. Metalloproteinases such as collagenase
and gelatinase, and antimicrobial peptides such as lactoferrin and cathelicidin are contained in specific
granules. Gelatinase is also contained in tertiary granules. Figure taken from Witko-Sarsat et al.
(2000).
receptors for the antibody IgG (Fcg-R) and complement proteins (CR) and
they migrate to and accumulate at sites of complement activation; therefore,
they actively phagocytose opsonised particles and function as effector cells of
humoral immunity. The various effector functions of neutrophils are
summarised in Figure 4.2.
The azurophilic granules of neutrophils contain a-defensins, which have
been shown to be chemotactic for immature dendritic cells, and T-cells, but
not neutrophils (Yang et al., 2000a), moreover studies using p-defensins have
shown that they do not induce migration of neutrophils. However,
cathelicidins, which are contained within the specific granules of neutrophils,
do show chemotactic activity for neutrophils, suggesting the existence of a
peptide-mediated positive feedback mechanism for neutrophil recruitment at
the site of infection (Yang et al., 2000b). Data analysing the migration of
neutrophils in response to the murine P-defensins Defb2 and Defrl are
presented in chapter 4 of this thesis.
4.1.5 CD4+T-Lymphocytes
CD4+ helper T-cells are lymphocytes that secrete various cytokines required
for the functional activity of other cells in the immune system. At least two
types of helper T-cells are recognised. Type 1 helper (Thl) T-cells secrete the
cytokine interferon-y, but not IL-4, -5, or -6 and are mainly involved in
activation of macrophages and cytotoxic CD8+ T-cells. In contrast, type 2
helper (Th2) T-cells produce IL-4, -5 and -6 (but not IFN-y), their main
function is in humoral immunity, each CD4+ T-cell subtype inhibits the
activity of the alternate type (Delves and Roitt, 2000a; Delves and Roitt,
2000b). Most T-cell responses are initiated by antigen presenting cells (APCs)
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in the T-cell dependent areas of the lymphoid tissues, through local release of
IL-12. These APCs skew the nai've T-cells towards production of either the
Thl or Th2 subset of cytokines (reviewed in Sprent and Surh, 2001).
Cytotoxic (CD8-expressing) T-cells kill cells infected with intracellular
pathogens and thus interact with MHC I molecules that are expressed on the
surfaces of most cells. CD4+ T-cells, however, are mainly cytokine secreting
cells and respond primarily to extracellular pathogens. Antigens generated
form such pathogens are presented on MHC II molecules by APCs; three cell
types are recognised as APCs: dendritic cells (see below), B-lymphocytes and
macrophages (reviewed in Thery and Amigorena, 2001). Interaction between
an antigen-primed APC and a CD4+ T-cell can lead to its activation and the
subsequent production of cytokines and activation of appropriate immune
responses.
As indicated above, Thl CD4 T-cells activate cytotoxic CD8+ T-cells and
macrophages (Figure 4.3A). Upon interaction with an antigen/MHC II
complex expressed on the surfaces of macrophages they produce IFN-y by
the Th 2 cells activates CD8 T-cells and macrophages to kill intracellular
pathogens and IFN-y also sets up a state of cellular resistance to viral
infection (reviewed in von Andrian and MacKay, 2000).
Antigens are taken up by B-cells functioning in their APC role, processed and
then presented at the cell surface on MHC II molecules. Neighbouring Th2
CD4+ T-cells that recognise these peptide-MHC II complexes become
activated and express costimulatory molecules such as CD154 (also known as
CD40 ligand) on their surface; interaction of CD154 with the CD40 expressed
on B-cells prompts the B-cells to begin the process of somatic hypermutation
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Figure 4.3: T-Cell Responses and Generation of Memory Cells. CD4+ T-cells can stimulate
cytotoxic T-cell responses (A), as well as humoral responses. Most of these reactions occur in the T-
cell areas of the lymphoid organs following interaction with dendritic cells (B). Bacterial products
are taken up and presented to T-helper cells by dendritic cells or B-cells acting in their antigen-
presenting role. This leads to activation of the T-helper cells. Following activation T-cells undergo
clonal expansion and differentiation into effector cells and memory cells (C). Figure adapted from
Delves and Roitt (2000b) and von Adrian and Mackay (2000).
and immunoglobulin class switching (Figure 4.3B). Moreover, this process is
aided by the production of IL-4, -5 and -6, which are also secreted by the
CD4+ T-cell.
A hallmark of the immune system is that the responses to a second infection
by a pathogen are generally manifested more quickly and are more
vigorously than the initial response. This immunological memory is present
at the level of the T-cell and the B-cell. T-cell activation is followed by clonal
expansion and differentiation, and a proportion of naive (i.e. T-cells that have
not yet been exposed to antigen and subsequently activated) T-cells
differentiate into short-lived effector cells and long-lived memory T-cells
following this initial antigenic challenge (Figure 4.3C) (Sprent and Surh,
2001). Thus, memory T-cells are distinguished from naive T-cells in that they
are hyper-responsive to antigen and in synthesizing cytokines in large
quantities, and in particular whether they secrete the Thl or Th2 subset of
cytokines. However, the mechanisms behind the generation of immunity (i.e.
why do some T-cells cells survive?) are unknown, although it has been
proposed that the capacity of some T-cells to evade death is based on the
CD40 ligand on the surface of the T-cell with CD40 on the surface of the APC.
In the absence of the CD40L-CD40 interaction, there is only a limited
generation of memory cells, however, other costimulatory molecules on
APCs, such as B7, have all been shown to play a role in generation of
memory cells (Sprent and Surh, 2001).
Interestingly, it has been shown that a- and [3-defensins elicit migratory
responses from different T-cell subsets, a-defensins such as HNP1 and 2
induce migration of naive CD4+ T-cells, whereas DEFB2 induces migration
of the memory subset of CD4+ T-cells (Yang et al., 1999; Yang et al., 2000a).
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CD8+ T-cells have been shown to migrate in response to a-defensins, it is not
known if they respond to (3-defensins or if a similar subset-specific activity
exists (Yang et al, 2000a). The reason for this difference in response is
unclear, but may be associated with the different sites of expression of a- and
P-defensins and different expression of chemokine receptors. Data on the
migration of murine CD4+ T-cells in response to murine p-defensins is
presented in chapter 4 of this thesis.
4.1.6 Dendritic Cells
Dendritic cells (DCs) are the main professional antigen-presenting cells in the
immune system and data analysing the migration of DCs in response to
murine p-defensins is presented in chapter 4 of this thesis. Like T-cells,
generally exist in a 'resting' phase in the absence of challenge, but are rapidly
activated upon contact with an inflammatory stimulus (Delves and Roitt,
2000a; Delves and Roitt, 2000b). DCs are distributed throughout the tissues
of the body where they act as 'sentinels' and constantly sample the
surrounding environment. Upon detection of an antigen, DCs become
activated and migrate to the lymphoid organs, which is the main site for T-
cell activation. DCs generate three signals in the activation process. Signal 1
is the delivery of antigen to T-cells on MHC II molecules, signal 2 is the up-
regulation of costimulatory molecules, with a consequent increase in
immunogenicity to T-cells and signal 3 is the production of cytokines such as
IL-10, 12 or 18 which can direct subsequent T-cell differentiation (reviewed in
Reis e Sousa, 2001).
DCs are directly activated by contact with pathogen-associated molecular
patterns (PAMPs) with a pattern recognition receptor (PRRs). PAMPs are
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evolutionarily conserved molecules, essential to pathogen function, which
are absent from the host such as lipopolysaccharide or CpG motifs of bacteria
or (3-glucans in yeast and other fungi. These molecules have been exploited
by the host in the development of PRRs such as toll-like receptors (TLR) to
detect their presence and thus mount appropriate immune responses.
DCs also exist in two different states - immature and mature, the two types
are distinguished by the organisation of antigen-presenting capacity and
their function (reviewed in Watts, 1997). Immature DCs show high rates of
endocytosis and antigen processing, however they do not efficiently present
antigen on the cell surface. In contrast, mature DCs show reduced levels of
endocytosis, but elevated rates of antigen presentation. Thus, in an
immature state - prior to exposure to inflammatory stimuli - DCs act as
'sentinels', readily sample, and process the local milieu. In this state the DC
MHC II biosynthesis, endocytosis and subsequent processing of the ingested
products to MHC II-peptide complexes occurs, however these are largely
maintained in the lysosomes or reach the cell surface and are then rapidly
recycled (Figure 4.4A). The maturation process is initiated upon stimulation
with inflammatory stimuli such as TNFa or LPS and the DC then changes
function from sentinel to antigen presenter; there is increased biosynthesis of
MHC II, which maximises loading of antigen onto the MHC II molecules
(Figure 4.4B). The DC then migrates from the non-lymphoid tissue, where the
stimulation occurred to the T-cell rich areas of the lymphoid organs.
Following migration, the MHC-II/peptide complexes are efficiently
expressed on the surface of the cell, where they persist for longer periods
than in the immature DCs, due to the reduction in endocytosis (Figure 4.4C).
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Figure 4.4: Dendritic Cells act as Sentinels in the Non-Lymphoid Tissues and, Following
Stimulation by Inflammatory Stimuli, Migrate to the Lymphoid Organs where they act as
Antigen Presenting Cells.
A) Endocytosis (purple squares) and MHC biosynthesis occurs but the assembled complexes (purple
circles and black sticks) accumulate in the lysosomes of mouse DCs (L) or the endosomes of human
DCs (E) or reach the cell surface and are then recycled. B) Following stimulation by inflammatory
stimuli the DC starts to mature. There is increased synthesis of MHC II and elevated loading in the
peptide-loading compartments (P), CIIV (c) and recycling endosomes. C) In the mature DC the
peptide/MHC II complexes are highly expressed on the cell surface to permit activation of the T-cells.
This occurs following DC migration to lymphoid organs. D) T-cells are activated by interaction of
MHC Il-peptides complexes with T-cell receptor (illustrated in grey with crescent shaped binding
site) and this activation is greatly amplified by interaction of B7 molecules (shown in red) with CD28
(shown in green) on the surface of the T-cell. Figure Adapted from Watts (1997) and Delves and
Roitt (2000).
Moreover, there is also increased expression of costimulatory molecules (e.g.
CD40, CD80) on the cell surface, which are required for the stimulation of T-
cells (reviewed in Banchereau and Steinman, 1998). It is known that DC
populations produce different cytokines in response to different activating
stimuli. However, DC populations are heterogeneous; and it is unclear if the
different types of immunity are generated by different DC subtypes
responding to different PAMPs (i.e. DC1 and DC2 stimulate Thl and Th2 T-
cell responses respectively), or if a single DC type delivers distinct signals (i.e.
different costimulatory molecules) depending on the activating stimulus
(reviewed in Moser and Murphy, 2000).
4.1.7 Measuring Cell Migration
The microchemotaxis chamber designed by Falk et al. (1980) used in this
study allows for rapid assessment of cell migration in multiple wells. The
chamber consists of upper and lower chamber separated by a membrane
filter of defined pore size. The chemoattractive compound is placed in the
lower chamber, cells are added to the top chamber and following a period of
incubation, cells that have migrated towards the chemoattractant are counted
on the lower surface of the filter. Neutrophil migration was assessed after 1
hr incubation, migration of CD4+ cells was assessed after 4.5 hrs and DCs
were analysed following incubation of period of 1.5 hrs. Following the
appropriate incubation period the migration «1 x 105 cells in response to 0.1,
1 10, 100, 1000 and 10000 ng/ml of peptide was assessed. Cell migration was
assessed by counting the number of cells on the lower side of the filter in
three random fields of view (FOV) from each of the three replicate wells.
Experiments were repeated a minimum of three times to ensure
reproducibility and representative experiments are indicated below.
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4.2 Chemoattractant Activity of synthetic murine (3-defensins Defb2
and Defrl
Using a 48-well microchemotaxis chamber, the murine p-defensins Defb2 and
Defrl were tested for their chemotactic properties. The cell types assessed
for chemoattractant activity were peritoneal neutrophils, CD4+ splenic T-
lymphocytes, and immature and mature bone marrow-derived dendritic
cells. Peptides were diluted in chemotactic media (RPMI 1640 + 10% FCS) a
concentrations of 0.1 to 10000 ng/ml. Cells were isolated as described and
also resuspended in chemotactic media at a concentration of 5xl06 cells/ml.
Filters were scored by counting the number of stained cells in random field
of view (FOV). Migration was assessed in three replicates wells and three
FOVs were counted per well. Data is presented both as the mean number of
cells per FOV and also as a migratory index (MI). This represents the fold-
increase of migration by expressing the number of migrated cells per test
sample as a ratio of the number of migrated cells from the control wells
(media alone). Studies were tested for reproducibility in a minimum of three
experiments and representative experiments are illustrated below in Figures
4.1-4.12.
4.2.1 Chemoattractant Activity of Defb2 and Defrl to Neutrophils.
Neutrophils were isolated from the peritoneum and incubated with the
peptide for 1.5 hrs as previously in the materials and methods, filters were
then stained with DiffQuick. Microscopic analysis of the isolated cells
showed that they possessed the typical neutrophil polymorphonuclear
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Figure 4.5: Migration of neutrophils in response to the mouse (3-
defensins Defb2 and Defrl.
Neutrophils were isolated from mouse peritoneum. Cells were incubated in a
48-well chemotaxis chamber for 4.5 hours separated from different
concentrations of Defb2 or Defrl by a 5pm polycarbonate filter. fMLP was
used a positive control. The filter was stained with DiffQuick and three
fields of view were counted in each of three replicate wells. Graph A shows
mean number of cells migrated per field of view form a total of nine random
fields. Graph B shows the migratory index, the number of cells migrated in
each sample divided by the number of migrated cells in the control (media
alone) sample. * represents p< 0.05. Error bars represent the standard
deviation of all nine replicate counts. Experiments were checked for
reproducibility in a minimum of three experiments (i.e. n=3) , and a typical
result is illustrated above.
of the positive control, N-formylmethionyl leucyl phenyalanine (fMLP). The
background level of migration was quite high with an average of »80 cells
having migrated per FOV, but in response fMLP induced a significant
increase in migration (p < 0.05). An average of «180 cell migrated in response
to fMLP, giving a MI of almost 2.5 (Figure 4.5). However, no migration was
observed in response to Defb2 or Defrl above the background level. This
suggests that synthetic Defb2 and Defrl do not induce cellular migration in
neutrophils. Isolated cells were confirmed as neutrophils by morphology
and all populations used were at least 90% pure.
4.2.2 Chemoattractant Activity of Defb2 and Defrl to splenetic
CD4+ T-lymphocytes.
CD4+ T-lymphocytes were isolated from mouse spleens by the magnetic cell
sorting (MACS) as described in the materials and methods and incubated
with the peptides for 4.5 hours after which filters were stained with
haematoxylin and scored. In the control (media alone) sample there was a
low level of migration with approximately 30 cells per FOV (Figure 4.6). In
the presence of 10 ng/ml of the positive control (stromal derived factor-
lalpha (SDFla)), the MI was 4.5, with an average of 135 cells per FOV. CD4+
T-cells showed significant migration in response to Defb2 and Defrl (p <
0.05). The migration induced was concentration-dependent and peaked at
lOng/ml with «145 cells/FOV (MI of 5.0). A concentration of 1 ng/ml of
Defb2 induced a 4-fold increase in migration, with «120 cell/FOV. A
concentration of 0.1, 100 or 1000 ng/ml induced 2.5- 3-fold increase in
migration (approximately 75-90 cell/FOV), and at 10000 ng/ml the MI was
less than 2.0. Concentration-dependent migration was also observed
180
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Figure 4.6: Migration of CD4+ T-lymphocytes in response to the mouse P-
defensins Defb2 and Defrl.
CD4+ T-lymphocytes were isolated from mouse spleens by autoMACs separation.
Cells were incubated in a 48-well chemotaxis chamber for 4.5 hours separated
from different concentrations of Defb2 or Defrl by a 5pm polycarbonate filter.
SDFla was used a positive control. The filter was stained and three fields of view
were counted in each of three replicate wells. Graph A shows mean number of
cells migrated per field of view form a total of nine random fields. Graph B shows
the migratory index, the number of cells migrated in each sample divided by the
number ofmigrated cells in the control (media alone) sample. * represents p< 0.05.
Error bars represent the standard deviation of all nine replicate counts.
Experiments were checked for reproducibility in a minimum of three experiments
(i.e. n=3), and a typical result is illustrated above.
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Figure 4.7: FACS analysis of CD4+ T-lymphocyte surface antigen expression.
CD4+ T-lymphocytes, isolated from mouse spleen using the autoMACS system
(Milteny Biotec), were double stained for CD3 and CD4 expression. A) shows
forward and side scatter and R1 gate used in subsequent analysis. B) Dot plot of
unstained cells. C) shows a dot plot of cells stained for expression of CD3. D)
show a dot plot of cells stained for CD4. E) shows cells double-stained for CD3
and CD4 expression. All antibodies were either PE- or FITC-conjugated as
indicated. Quadrant grid was set using isotype controls. FACs analysis was
performed on all three replicate experiments to ensure reproducibility of the
isolated cells phenotype (n=3).
in response to Defrl, the peak level of migration was seen at 1 ng/ml a lower
concentration than that observed for Defb2. At 1 ng/ml the MI was 4.5 with
an average of «140 cell/FOV, whereas at 10 ng/ml a 3.5-fold increase in
migration was observed compared to the control wells. The migration
induced by 10 ng/ml Defrl was statistically significantly lower than that
induced by the same concentration of Defb2; there were no differences
between Defb2 and Defrl at other concentrations tested. At a concentration
of 100 or 1000 ng/ml migration of approximately 70 cells/FOV was observed,
giving a MI of 2-2.5. Much lower migration was observed with 0.1 or 10000
ng/ml with a MI of only 1.5. The migration induced by Defrl at 1000 or
10000 ng/ml was not statistically significant compared to control.
Isolated cells were analysed for expression of the cell surface markers CD3
and CD4 by fluorescence-activated cell sorting (FACS). Analyses showed
that 92% of cell were double-positives and expressed both CD3 and CD4
(Figure 4.7). This confirms the purity of the isolated cells as CD4+ T-
lymphocytes.
d6iDC d7iDC mD(
Surface Antigen % mean % mean % mean
CDllc 80.70 266.29 94.14 275.21 95.22 319.34
MHCII 63.01 135.90 84.00 309.11 87.68 422.37
CDllc &MHCII 51.48 n/a 62.50 n/a 71.25 n/a
CD54 (ICAM-1) 73.48 443.50 77.33 667.53 86.74 874.74
CD86 95.88 844.04 96.19 979.47 96.78 1124.2
Grl (Ly6G) 25.84 n/a 26.96 n/a 24.74 n/a
CD45 (B220) 5.08 n/a 5.14 n/a 4.98 n/a
Table 4.1: FACS analysis of DC-enriched populations for surface antigens. Percentage of cells
positively stained for each surface antigen is indicated. The mean level of fluorescence of positive






Figure 4.8: Migration of day 6 immature dendritic cells to the mouse P-
defensins Defb2 and Defrl.
Dendritic cells were derived form bone marrow by culture with GM-CSF for 6 days.
Cells were incubated in a 48-well chemotaxis chamber for 1.5 hours separated from
different concentrations of Defb2 or Defrl by a 5pm polycarbonate filter. MIP3a
was used a positive control. The filter was stained and three fields of view were
counted in each of three replicate wells. Graph A shows mean number of cells
migrated per field of view form a total of nine random fields. Graph B shows the
migratory index, the number of cells migrated in each sample divided by the
number of migrated cells in the control (media alone) sample. * represents p< 0.05.
Error bars represent the standard deviation of all nine replicate counts. Experiments
were checked for reproducibility in a minimum of three experiments (i.e. n=3) , and
a typical result is illustrated above.
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Figure 4.9: FACS analysis of day-6 immature dendritic cell surface antigen
expression.
Bone marrow cells were isolated and cultured as previously described. The cells
were double-stained for CDllc and MHCII. A) forward and side scatter and R1
gate used in subsequent analysis. B) Dot plot analysis showing unstained cells. C)
Dot plot shows cells stained for CD1 lc. D) Dot plot analysis showing cells stained
for MHC II expression. E) Dot plot analysis of cells double-stained for CDllc and
MHC II. Percentages indicate the percentage of cells in each quadrant. All
antibodies were either PE- or FITC-conjugated as indicated. Quadrant grid was set
using isotype controls. FACs analysis was performed on all three replicate
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Figure 4.10: FACS analysis of day-6 immature dendritic cell surface antigen
expression.
Bone marrow cells were isolated and cultured as previously described. The cells
were double-stained for CD11c and MHCII. F) Dot plot analysis of cells stained
with the isotype antibody for CD86. G) Dot plot showing cells stained for CD86.
H) Dot plot analysis of cells stained with the isotype of CD54. I) Dot plot analysis
of cells stained for CD86. J) Dot plot analysis of cells stained with the isotype for
Grl. K) Dot plot analysis of cells stained with the Grlantibody. Cells were also
stained for B220 (not shown). Percentages indicate percentage of cells in each
quadrant. All antibodies were either PE- or FITC-conjugated as indicated.
Quadrant grid was set using isotype controls. FACs analysis was performed on all
three replicate experiments to ensure reproducibility of the isolated cells phenotype
(n=3).
4.2.3 Chemoattractant Activity of Defb2 and Defrl to Day-6
immature dendritic cells.
Total cells were isolated from the bone marrow of C57B1/6 mice and cultured
for 6 days in the presence of granulocyte/macrophage colony stimulating
factor (GM-CSF) to generate a dendritic cell-enriched population. These cells
were incubated in the presence of the peptides for 1.5 hrs and then stained
with haematoxylin. Day 6 immature dendritic cells (d6iDC) showed
significant migration in response to the positive control macrophage
inflammatory protein-3alpha (MIP3a) at 1 ng/ml with an almost 4-fold
increase in migration, an average of 75 cells/FOV were observed compared to
«20 in the control wells (Figure 4.8).
Statistically significant (p < 0.05) migration by d6iDC was observed in
response to Defb2 and Defrl (Figure 4.8). The peak activity for Defb2 was
observed to be between 10 and 100 ng/ml with approximately 160 cells/FOV
compared to just under 60 in the control wells giving a MI of 2.75 at 10
ng/ml. At 100 or 1000 ng/ml the MI was 2.0, slightly reduced from the peak.
The lowest migration was observed in response to 0.1 ng/ml with 85 an
average of cells/FOV and a MI of 1.5. The peak migration in response to
Defrl was also observed to be between 10 and 100 ng/ml with approximately
140 cells/FOV at 10/ng/ml the migration at 100 ng/ml was more variable with
»120 cells/FOV; these results give a peak MI of 2.2 to 2.5. The lowest level of
migration was observed at 10000 ng/ml with a MI of «1.5 and 85 cells/FOV
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Figure 4.11: Migration of day 7 immature dendritic cells in response to
the mouse P-defensins Defb2 and Defrl.
Dendritic cells were derived form bone marrow by culture with GM-CSF for 7
days. Cells were incubated in a 48-well chemotaxis chamber for 4.5 hours
separated from different concentrations of Defb2 or Defrl by a 5pm
polycarbonate filter. MIP3a was used a positive control. The filter was
stained and three fields of view were counted in each of three replicate wells.
Graph A shows mean number of cells migrated per field of view form a total of
nine random fields. Graph B shows the migratory index, the number of cells
migrated in each sample divided by the number of migrated cells in the control
(media alone) sample. * represents p< 0.05. Error bars represent the standard
deviation of all nine replicate counts. Experiments were checked for
reproducibility in a minimum of three experiments {i.e. n=3) , and a typical
result is illustrated above.
FACS analysis of the cell population for various dendritic cell surface
markers revealed that 51.5% of the cells were double positive for CDllc and
MHMII, 73.5% expressed CD54 and almost 96% expressed CD86 (Figure 4.9
and 4.10, Table4.1). Contamination from granulocytes was 25% and B-cell
contamination, assessed by B220 expression, was approximately 5%. As
these cell types are the main contaminant, these results suggest that
approximately 70% of the population were dendritic cells. The observed
compositionof the DC-enriched population is in agreement with previous
findings using this culture method (Personal communication, Dr Sarah
Howie, University of Edinburgh).
4.2.4 Chemoattractant Activity of Defb2 and Defrl to day-7
immature dendritic cells.
The migratory response of dendritic cells that had been cultured in the
presence of GM-CSF (d7iDC) was also assessed to investigate if culture-
period or developmental stage of the dendritic cells affected the migration in
response to Defb2 or Defrl. Migration in response to macrophage
inflammatory protein-3 alpha (MIP3a) at 1 ng/ml was increased compared to
the day 6 DCs, with a MI of 4.5, largely as a result of a lower background
migration (Figure 4.5). The peak level of migration of d7iDCs in response to
Defb2 was again between 10 and 100 ng/ml, the MI of 3.0 is marginally
higher than was observed with d6iDCs. The lowest level of migration was
seen at 0.1 and 10000 ng/ml, where an average of just over 30 cells/FOV were
observed compared to 20 in the control wells. The concentration of Defrl
that induced the highest level of migration was 1 ng/ml. This is lower than
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Figure 4.12: Migration of mature dendritic cells in response to the mouse
3-defensins Defb2 and Defrl.
Dendritic cells were derived form bone marrow by culture with GM-CSF for 7
days and matured with LPS. Cells were incubated in a 48-well chemotaxis
chamber for 4.5 hours separated from different concentrations of Defb2 or
Defrl by a 5jam polycarbonate filter. MIP3p was used a positive control. The
filter was stained and three fields of view were counted in each of three
replicate wells. Graph A shows mean number of cells migrated per field of
view form a total of nine random fields. Graph B shows the migratory index,
the number of cells migrated in each sample divided by the number of migrated
cells in the control (media alone) sample. * represents p< 0.05. Error bars
represent the standard deviation of all nine replicate counts. Experiments were
checked for reproducibility in a minimum of three experiments (i.e. n=3) , and
a typical result is illustrated above.
level of migration was also slightly higher than that observed for Defb2, with
a MI of almost 3.5. Defrl at a concentration of 0.1 ng/ml also induced
significant migration with a MI of 2.5. Defrl at a concentration of 1000 and
1000 ng/ml did not induce statistically significant migration; all other
concentrations of Defrl and all concentrations of Defb2 tested did induce
statistically significant migration compared to the control (p < 0.05).
Moreover, there were statistically significant differences in the levels of
migration induced by Defb2 and Defrl were observed at concentrations of 1
ng/ml and 100 ng/ml (p < 0.05).
FACS analysis of the cell population revealed that the percentage of cells
positive for MHMII and CDllc was 69.5; this is significantly higher than was
seen with d6iDC (Table 4.1). Moreover, the percentage of cells that were
positive for CDllc or MHMII and the mean fluorescence were also higher
than for d6iDC, suggesting that level of expression of these surface markers
were also higher. The percentage of cells positive for CD86 or CD54 were
approximately the same as for d6iDC, but the mean fluorescence was in each
case higher, suggesting that the level of expression of the surface antigens
was higher. The level of Grl+ Granulocyte and B-cell contamination were
similar to those seen in the d6iDC populations.
4.2.5 Chemoattractant Activity of Defb2 and Defrl to mature
dendritic ceils.
Bone marrow cells were isolated and cultured as above in section 4.2.4,
except that 24 hrs prior to the experiment LPS was added to the culture
media to induce maturity. Mature dendritic cells (mDC) did not show
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significant migration in response to either Defb2or Defrl (Figure 4.52).
However, in response to the positive control a statistically significant, but
low level, of migration was observed with «85 cells/FOV compared to just
over 40 in the control, giving a MI of 2.0.
FACS analysis was conducted as before (Table 4.1). This revealed a
population that has a higher mean fluorescence in the populations of cells
expressing CDllc or MHC II. A greater percentage of cells that were double
positive for MHC II and CDllc. CD86 and CD54 levels were also elevated
compared to immature DCs, whereas levels of contamination by





Previous studies have revealed that many cationic peptides, such as the
cathelicidin LL-37 and human a- and fl-defensins, possess chemoattractant
properties and can induce migration in a variety of cell types reviewed in
(Yang et al., 2000a; Yang et al., 2001). The first report of a chemotactic activity
of defensins was from an investigation of the monocyte-chemotactic activity
of neutrophils (Territo et al., 1989). Territo et al. showed that the chemotactic
activity of fractionated extracts from neutrophil granules was largely
contained within the a-defensin fraction, and subsequent analyses with the
purified neutrophil a-defensins indicated these to be chemotaxins for
monocytes and to a lesser extent for neutrophils. However, these migratory
responses were not repeated in an in vitro study by Chertov et al. (Chertov et
al., 1996), although this study does record in vivo migration of neutrophils.
The Chertov et al. study was performed with a 48-well chemotaxis chamber,
whereas the study conducted by Territo et al. (1989) is based on assays of the
leading front cells migrating into a filter. It is possible therefore that the
discrepancy is due to technical differences between the two assays.
Subsequent studies have supported and further characterised the range of
chemoattractant activities of defensins. The human a-defensins, human
neutrophil peptides 1-2 (HNP1-2) have been shown to chemoattract naive,
but not memory, CD4+ T-cells and CD8+ T-cells (Yang et al., 2000a). In
contrast the human p-defensins DEFB1 and 2 attract memory, but not naive,
CD4+ T-cells (Yang et al., 1999). In addition human a- and p-defensins have
also been shown to attract monocytes and immature but not mature dendritic
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cells (Yang et al., 1999; Yang et al., 2000a; Garcia et al., 2001a). These previous
studies have been performed with human defensins and to date a
chemoattractant property has not been reported for murine p-defensins.
Although one study showed that Defb2 and Defb3 fused to lymphoma
antigen, sFv, were able to induce migration of immature but not mature
dendritic cells (Biragyn et al., 2001).
4.3.2 Migration ofNeutrophils
This chapter presents data on the ability of synthetic murine p-defensins
Defb2 and Defrl to induce cellular migration in neutrophils, CD4+ T-cells
and dendritic cells in vitro using a 48-well microchemotaxis chamber
(Summarised in Table 4.2). The studies carried out on CD4+ T-cells and
dendritic cells were performed in collaboration with Dr Sarah Howie and
Professor Johnathan Lamb at the University of Edinburgh. The results show
that in vitro Defb2 and Defrl possess the ability to induce migration in CD4+
T-cells, and immature bone marrow derived-dendritic cells but that this
activity is lost upon maturation. Neutrophils were not found to migrate in
response to Defb2 or Defrl (Table 4.2).
Defb2 Defrl
Cell Type Migrn. Peak MI Cone. Migrn. Peak MI Cone.
Neutrophils X - - X - -
CD4+ T-cells V 5.0 10 V 4.5 1
d6iDC V 2.75 10-100 V 2.2-2.5 10-100
d7iDC V 3.0 10-100 V 3.5 1
mDC X - - X - -
Table 4.2: Summary of cell migration induced by murine p-defensins. Migrn. indicates whether
of not the P-defensin induced statistically significant migration of each cell type (p < 0.05). Peak
indicates the maximum migration index (MI) of each cell type, and Cone, shows the concentration of
P-defensin (in ng/ml) that induced the maximum migration.
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Neutrophils contribute to innate host defence in response to inflammatory
signals by migrating along chemoattractant gradients to sites of
inflammation where they phagocytose opsonised particles and degranulate
releasing granule contents, which includes the a-defensins, HNP1-4. In the
current study, the analysis of neutrophil migration in response to (3-defensins
indicates that neither Defb2 nor Defrl are chemoattractants for neutrophils
between concentrations of 0.1 and 10000 ng/ml. This observation is in broad
agreement with previous observations that (3-defensins do not induce
migration of neutrophils; separate studies of DEFB103 and DEFB104 found
that neither possessed chemotactic activity for neutrophils (Garcia et al.,
2001a; Garcia et al., 2001b). As discussed above, a-Defensins have been
shown to induce a low level of migration in neutrophils, in an in vitro assay
purified HNP-2 and -3 caused an approximately 20% increase in migration at
a concentration 0.1 pM (Territo et al., 1989). Furthermore, in a separate study
Chertov et al., showed that a subcutaneous injection of 1 pg of F1NP-1 into
BAFB/c mice resulted in an accumulation of monocytes and neutrophils by 4
hrs (Chertov et al., 1996). It is possible that whilst neither a- nor (3-defensins
are directly chemotactic for neutrophils and thus display little or no such
activity in vitro, whereas in vivo they may induce a cascade of
proinflammatory signals resulting in the accumulation of neutrophils.
Chemokines that do attract neutrophils include interleukin 8 (IL-8); this
specifically attracts neutrophils and has no migratory effect on either
lymphocytes or monocytes. It is interesting to note that IF-8 has been shown
to cause release of the a-defensins from neutrophil granules (Chertov et al.,
1996) and neutrophil defensins have been shown stimulate IL-8 synthesis in
airway epithelial cells (van Wetering et al., 1997b). It may be possible
therefore that the neutrophil chemoattractant activity of HNPs is mediated
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via IL-8, this would explain the observation of chemotaxis in vivo and the
failure of Chertov et al. to observe migration in vitro. For example, in another
study injection of between 4 ng and 4 pg of HNP-1 into the peritoneum of
experimentally K. pneumoniae-infected in mice resulted in a significant
reduction in bacterial survival compared to saline treated controls. This
activity did not appear to be due to the direct antibacterial effect of HNP-1,
but due, at least in part, to the chemotactic response of lymphocytes,
macrophages and granulocytes such as neutrophils (Welling et al., 1998).
Therefore, a subcutaneous injection in mice of Defb2 or Defrl may lead to an
accumulation of neutrophils via secondary signalling roles, even though they
do not possess direct chemoattractant ability for neutrophils in vitro.
4.3.3 Migration of CD4+ T-lymphocytes
CD4+ T-lymphocytes were isolated from mouse spleens and purified using
the autoMACS system (Miltenyi Biotec), this gave raise to a population of
cells at least 90% positive for CD3 and CD4. In the current study,
CD3+/CD4+ T-lymphocytes showed significant levels of migration in
response to both Defb2 and Defrl (Table 4.2). The peak migration in
response to Defb2 was 10 ng/ml, whereas Defrl induced maximal migration
at 1 ng/ml. There was, however, no significant difference between the
maximal level of migration induced by Defb2 and Defrl, both induced a 4.5
to 5-fold increase in migration compared to media alone and this was slightly
higher than the migration induced by the positive control stromal cell-
derived factor 1 alpha (SDFla). This chemokine, which has also been shown
to induce chemotaxis of monocytes and B- and T-lymphocytes, but not
neutrophils, signals through the chemokine receptor CXCR4. The studies
presented here do not investigate which receptor is mediating the CD4+ cell
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migration, and this would be an interesting area of future study. The data
presented in this chapter are in broad agreement with previous data showing
that both human a- and (3-defensins can act as chemoattractants for CD4+ T-
cells. However, in previous studies a dichotomy was observed in the subsets
of T-cells that respond to a and p-defensins. The a-defensins HNP-1 and -2
induced migration in CD4+/CD45RA+ nai've T-cells (Yang et al., 2000a). In
contrast, the p-defensins induced attracted CD4+/CD45RO+ memory T-cells
(Yang et al., 1999). The level of migration of CD4+ memory T-cells in the
Tang et al. study in response to DEFB4 was maximal at 1000 ng/ml, with a 5-
fold increase cell migration compared to media alone. This response is
greater than that seen in this study, however, Tang et al, analyses were
conducted with memory T-cells as opposed to the more mixed population of
CD4+ T-cells used in this study, which would have contained memory and
naive CD4+ T-cells. Therefore, the potential response of the memory T-cells
may have been diluted by the failure of the naive T-cells in the population to
respond.
The data presented in the current study do not distinguish between the
responses of the distinct T-cell subsets and consequently it is unclear whether
Defb2 and Defrl are targeting one subset or both naive and memory T-cells
and further studies are required to investigate this issue. It may however be
possible to identify the subset of CD4+ T-cells that have migrated in situ (i.e.
on the filter itself) by staining with antibodies specific to cell surface markers
that identify the different subsets. If it is necessary to perform chemotaxis
experiments using separate populations of naive and memory T-cells these
can be isolated in several ways, although such studies may be hindered by
difficulties in isolating the sufficient numbers of cells. It may be possible to
separate naive and memory T-cells based on CD62L expression. CD62L (L-
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selectin) is highly expressed on naive murine T-cells, but expressed at much
lower levels on memory T-cells. CD62L is also expressed by B-lymphocytes,
neutrophils, eosinophils and monocytes; therefore, selection for high or low
expression of CD62L would have to be preceded by selection for CD4+ cells
and this may significantly increase the number of animals required. Another
method for isolation of the distinct CD4+ T-lymphocytes populations would
be to use expression of CD45RB; this surface marker is expressed at high
levels on by naive T-cells (CD45RBhi) compared to memory T-cells, which
have the phenotype CD45RB10 (Seder and Paul, 1994). Although selection for
CD4 expression would have to be conducted prior to selection for naive and
memory cells and thus a large number of animals may be required.
Separation of CD4+ T-cells based on CD45/RB expression could be conducted
using fluorescence-activated cell sorting (FACS).
The different responses of memory and naive T-cells to (3-defensins is likely
to be due to expression of distinct chemokine receptors on the different
population subsets. Indeed as was discussed above, p-defensins have been
show to signal through CCR6 in both humans and mice (Yang et al., 1999;
Biragyn et al., 2001), whereas the HNP-1 and -2 do not (Yang et al., 2000a).
Chemokines are small highly conserved molecules, which typically contain
four cysteines and like defensins, they are classified into two subfamilies
depending arrangement of those cysteines. a-Chemokines such as
interleukin-8 (IL-8) and SDFla have a C-X-C motif, where there is an extra
amino acid separating the first and second cysteines. a-Chemokines signal by
interaction with C-X-C chemokine receptors (CXCRs); whereas the p-
chemokines, however, such as MIP3a and MIP3P contain a C-C motif, and
there is no amino acid separating the first and second cysteines, these
chemokines signal through C-C chemokine receptors (CCRs) reviewed in
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(Murphy, 1994). It is interesting to note that the a-defensin consensus
sequence shows the presence of a CXC motif and CC motif, whereas the (3-
defensins consensus sequence contains only a CC motif, Defb2 and Defrl also
have a CC motif, but no CXC motif (Figure 6.8). Moreover, p-chemokines,
like the (3-defensins, do not induce migration in neutrophils, whereas a-
chemokines do. Therefore, it is tempting to speculate that the different
migratory responses of T-cells to a- and p-defensins may not only be due to
different receptors - with the a-defensins signalling via a CXC-receptor and
P-defensins acting by a CC-receptor, such as CCR6 (Yang et al., 1999; Biragyn
et al., 2001). The receptor through which a-defensins signal is yet to be
elucidated, and moreover as a-defensins possess both a CC and CXC motif
they may signal through either CC-receptors or CXCRs. It may be possible
to explore the issue of receptor use by antibody blocking experiments; CD4+
cells or dendritic cells could be incubated with antibodies designed to block
specific chemokine receptors and then exposed to defensins to see if cell
migration still occurs in the absence of a 'free' and functional receptor.
The biological relevance of the observation that the two different subfamilies
of defensins attract different subsets of T-cells also remains unclear. It has
been argued that FINPs are involved in systemic defence, whereas the
human p-defensins DEFB1 and DEFB4 play a role in protecting specific
epithelial tissues (Zhao et al., 1996). It has also been predicted that memory
T-cells recirculate preferentially in the tissues where their immunological
memory was first generated, whereas naive T-cells will circulate more widely
throughout the body (Moser and Loetscher, 2001). This may provide a
possible explanation for the different T-cell subsets attracted by a- and P-















Figure 4.13: a-Chemokines and a-defensins possess a CXC motif. P-ehemokines, P-defensins
and a-defensins possess a CC motif. Cysteines are highlighted in bold and CXC and CC motifs are
underlined. Residues said to be conserved between MIP3a and the P-defensins are highlighted in red,
blue and green. Green and red show the conservation of aspartate and leucine residues (or amino acids
with similar properties) between MIP3aand DEFB1 and 4. Residues in blue are the amphipathic
amino acids that are proposed to be conserved between MIP3a and DEFB 1 and 4 (corresponding
amino acids are shown for Defb2 and Defrl).
role, in conjunction with other more tissue-specific chemokines, in
maintaining a physiological 'through-traffic' of antigen-relevant
memory T-cells for immediate response The a-defensins, which may
play a more systemic role, may act to attract naive T-cells to the site
of inflammation. Therefore, it would be of interest to investigate
whether a particular P-defensin shows an increased capacity to
attract memory T-cells that were generated in a tissue where it is
expressed compared to a tissue where it is not. For example, does
Defrl has more potent chemoattractant activity for memory T-cells
generated in the testis, where it is expressed at high levels, compared
to those generated in the lungs, where Defrl expression is
not detected? As Defrl and Defb2, which have very different patterns
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of expression, induced similar levels of migration, it is perhaps unlikely that
P-defensins play an important or direct role in migration of tissue-specific
memory T-cells; and they may instead play a role in maintaining levels of
more migration of more generalised memory T-cells. However, differences
in the induction of these two genes, may serve to regulate cell migration in a
more specific manner.
4.3.4 Migration ofDendritic Cells
Dendritic cells are professional antigen presenting cells that are found in all
lymphoid and non-lymphoid organs. In an immature state, they constantly
sample the environment by endocytosis and phagocytosis, but antigenic
peptide-MHC II complexes accumulate in the lysosomes. However, upon
exposure to bacterial products such as lipopolysaccharide (LPS) or cytokines
such as tumour necrosis factor alpha (TNF-a), endocytosis is down regulated
and peptide-MHC II expression on the cell surface is up-regulated reviewed
in (Watts, 1997). This means that an immature dendritic cell samples from
the environment but does not display antigen, but on exposure to bacterial
antigens such as LPS results in a massive up-regulation in the expression of
antigen-MHC II complexes on the cell surface.
The work presented in this chapter also analyses the migration of dendritic
cell-enriched populations in response to Defb2 and Defrl (Table 4.2).
Dendritic cells (DCs) were isolated from mouse bone marrow cells and
cultured in the presence of 500 - 1000 U/ml of granulocyte/macrophage
colony-stimulating factor (GM-CSF) following a protocol modified from the
procedure established by Inaba et al (Inaba et al., 1992). This protocol
generated a DC-enriched population, which FACS analysis demonstrated to
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consist of approximately 70% dendritic cells and the main contaminants were
Grl+ granulocytes. This population composition is in broad agreement with
previous studies using this technique.
The DC-enriched populations described above were used to examine the
ability of Defb2 and Defrl to induce migration of dendritic cells. Previous
data on the migration of DCs in response to human a- and P-defensins
showed that dendritic cells lose their responsiveness to defensins upon
maturation (Yang et al., 1999; Yang et al., 2000a). Initially therefore the
migratory activity of DCs in response to Defb2 and Defrl was analysed after
6 days of culture with GM-CSF and termed day-6 immature dendritic cells
(d6iDC). Both p-defensin peptides were observed to induce migration in
d6iDCs, the peak migration was observed between 10 and 100 ng/ml and
resulted in a «2.25 to «2.75-fold increase in migration in response to Defb2
and an approximately 2 to 2.5-fold increase in migration in response to Defrl.
This level of migration was less than that which was observed for CD4+ T-
cells, but is similar to the level of migration seen in the previous defensin-
induced migration of dendritic cells (Yang et al., 1999; Yang et al., 2000a).
Subsequent studies also analysed the migratory responses of immature
dendritic cells cultured for 7 days (d7iDC). The migration induced by
d7iDCs was very similar to that observed with d6iDC, in response to Defb2
the maximal migratory activity, which was induced by 10 to 100 ng/ml.
However, maximal chemotaxis in response to Defrl was induced by 1 to 10
pg/ml and this is lower than the Defrl concentration that induced maximum
migration of d6iDC, suggesting that the sensitivity of DCs for Defrl may
alter with stage of development or age. The peak level of migration by either
d6iDCs or d7iDC in these studies is lower than that observed by Tang et al.
(Yang et al., 1999) who observed a 5-fold induction in chemotaxis in response
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to DEFB4, with background migration levels similar to those seen with
d7iDCs in these studies. However, 10 ng/ml of DEFB4 in the Tang et al. study
induced a 3-fold induction in migration. This is similar to the level of
migration induced by Defb2 in this study. These differences may very well
be due to differences between the activities of the human and murine (1-
defensins, or alternatively could be the result of differences in the DCs used;
for example, Tang et al. used CD34+ progenitor-derived cells, whereas the
cells from the current study were derived from bone marrow cells. The
levels of migration seen in this current study are, however, similar to the
migration of DCs observed in response to a-defensins (Yang et al., 2000a). In
the study by Biragyn et al. they observed a 6-fold induction in migration in
response to 10 ng/ml of Defb2 fused to the sFv lymphoma antigen, but an
adjuvant effect and increased migratory potency in the fusion protein
compared to the native form can not be ruled out (Biragyn et al., 2001).
As discussed above, the fold-induction of migration in response to Defb2 and
Defrl were similar for d6iDC and d7iDC. However, the actual number of
cells that migrated (in terms of mean number of cells per field of view) was
lower for d7iDC than for d6iDC. Therefore, the low background migration
and migratory indices of the d6iDC and d7iDC obscure the fact that d7iDCs
appear to be less migratory in terms of actual numbers of cells migrating.
This may suggest that while d7iDC have a lower migratory potential than
d6iDC, they do however retain the ability respond to defensins by inducing
migration. It must also be acknowledged that the variation between the
replicate studies for both the d6iDCs and d7iDCs was quite high, which not
only made statistical comparison between replicate experiments difficult.
Further replicate experiments, or a more reproducible and rigorous source of
DCs may be required (see below).
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The migratory response of mature dendritic cells (mDCs) was also analysed
as part of this study. Exposure to antigens has been shown to induce
maturation in dendritic cells, and for the purposes of this study, d7iDCs were
matured by culture with 100 ng/ml lipopolysaccharide (LPS) for the 24 hrs
prior to use. The current study found that mDCs did not migrate in response
to either Defrl or Defb2. This is in agreement with previous studies that
demonstrated that upon maturation with TNFa DCs lose their
responsiveness to a- and p-defensins (Yang et al., 1999; Yang et al., 2000a).
mDCs also lost the ability to migrate to Defb2-sFv fusion molecule in the
Biragyn et al. study (Biragyn et al., 2001). It has been suggested that p-
defensin-induced migration of both human and murine DCs is mediated via
CCR6 (Yang et al., 1999; Biragyn et al., 2001). Furthermore, it has been shown
that following maturation, DCs down-regulate expression of CCR6 and up-
regulate expression of another chemokine receptor CCR7, correspondingly
they cease to migrate in response to MIP3a, which signals via CCR6, and
show migratory responses to MIP3P, which signals through CCR7 (Dieu et
al., 1998). Therefore, mDCs, which no longer express CCR6, are also no
longer chemoattracted by P-defensins. This receptor-switch permits mDCs,
which having matured, have massively up-regulated antigen presentation on
their surface to leave the inflamed or infected tissue and, in response to a
different set of chemokines, migrate to the lymph nodes to prime naive T-
cells reviewed in (Banchereau and Steinman, 1998).
The purity of the dendritic cell populations was assessed by FACS using a
panel of antibodies. The cell populations used in this study were analysed
for expression of CDllc and MHC-II, which together are markers of
dendritic cells, and the CD86 co-stimulatory molecule and CD54/ICAM-1,
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which are also markers of DCs; the populations were also analysed for
contaminating granulocytes and B-cells. Generally, all populations used
were found to be in broad agreement with previous studies using this
method (Dr Sarah Howie, University of Edinburgh). The DC populations
used in these studies were shown by FACS analysis to contain approximately
25% of cells positive for the granulocyte marker Grl (Ly6G); this relatively
high level of contamination demonstrates that these populations are
'dendritic cell-enriched populations' rather than a pure dendritic cell
population. Contamination by B-cells was found to be present but at much
lower levels of «5%. The majority of the granulocytes are likely to be
neutrophils, which as described above do not migrate in response to Defb2 or
Defrl so they would not contribute to the chemotaxis. However, the
contribution of B-cells, and other granulocytes such as eosinophils to the
observed migration is not known, although a previous study have indicated
that eosinophils do migrate in response to DEFB104 (Garcia et al., 2001b).
DCs produced by the Inaba et al. method upon which this technique is based
expressed CDllc and MHC class II (Inaba et al., 1992). All DC populations
used in this study expressed both CDllc and MHC-II, moreover, the
expression of both of these molecules increased with the age and maturity of
the DC populations and this finding is also in agreement with previous
findings, as mDCs up-regulate expression of MHC-II on their surface (Inaba
et al., 1992; Yang et al., 2000a). The DCs used in this study did express very
high levels of CD86 and CD54 which are normally only expressed at high
levels following maturation. However, it is important to note that whilst the
percentage of cells expressing these two markers did not increase with
maturation, the mean level of fluorescence did increase which suggests that
cells are expressing these markers at higher levels. The reason for the high
levels of CD86 and CD54 expression remains unknown, the day-6 and day-7
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DCs were still immature as they responded to MIP3a and mature DCs do
not. One possible explanation may be strain differences between the mice
used in the different studies. The Inaba et al. (1992) study used BALB/c, mice
whereas the studies presented in this chapter used C57B1/6 mice. It is
possible that DCs from the two strains develop at different rates are therefore
upon analysis different levels of surface markers are detected.
As was discussed above, the replicate experiments conducted in this study
with bone marrow derived dendritic cells gave quite variable results. This
may have been due to natural variation in the migratory responses of DCs,
but it may also be due to the in vitro culture method employed to generate a
population of DCs. As the DCs are developing from progenitors, they may
develop at different rates from culture to culture and this may lead to
differences in the migration observed in response to the (3-defensins. As was
described in the Material and Methods section, bone marrow cells were
isolated from the tibias and femurs of mice and cultured in the presence of
GM-CSF based on the technique established by Inaba et al. (Inaba et al., 1992).
Culturing bone marrow progenitor cells with GM-CSF stimulates the
development of not only dendritic cells, but also granulocytes (hence the
relatively high levels of contamination) and macrophages (Inaba et al., 1992).
Cultures were established on day 0, and fed on days 3 and 6, with gentle
swirling of the plate to remove non-adherent granulocytes. The granulocytes
are non-adherent cells, the macrophages strongly adhere to the culture dish,
whereas the dendritic cells adhere more weakly, this permits the DCs to be
removed by gentle pipetting.
In the original Inaba et al. method after 4 days of culture, the aggregates of
proliferating less-mature dendritic cells selected away from the stroma and
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returned to culture. Moreover, the Inaba et al. (1992) study and a separate
study by Biragyn et al (Biragyn et al., 2001) depleted contaminating cells prior
to culture of the bone marrows cells with GM-CSF. These steps were omitted
in the current studies, and their re-introduction may increase the purity of
the population. This can be done by incubating freshly isolated bone marrow
cells with cocktails of antibodies against B-cells and MHC II antigens plus
complement (Inaba et al., 1992). Therefore, if the above studies are repeated
using DCs that were selected away from the stroma the result may be a more
pure population of dendritic cells and consequently more reproducible
results. Other techniques for culturing of DCs from mouse bone marrow
have included IL-4 with GM-CSF in the culture media (Yang et al., 2000a;
Biragyn et al., 2001), this was not included in the studies described here and
its incorporation in future experiments may improve the purity of the
population.
4.3.5 (3-Defensins as Chemokines
The observation that Defrl also induced migration in of CD4+ T-cells and
DCs is interesting in light of the fact that Defrl appears to be constitutively
expressed. Although Defrl expression may be induced by an, as yet,
unknown stimulus as the upstream sequence of the gene does contain an NF-
kB binding site (Morrison et al., 2002a). However, the constitutively
expressed DEFB1 has also been shown to induce migration of HEK-293 cells
transfected with the chemokine receptor CCR6 (Yang et al., 1999).
Chemokines can also show constitutive or inducible patterns of expression.
Constitutively expressed chemokines, also referred to as homeostatic
chemokines, function within discrete microenvironments and are thought to
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be specialized for maintaining a low level of immune cells trafficking
through tissues, whereas the inducible or inflammatory chemokines function
to recruit cells in an inflammatory response. It is possible therefore, that
constitutive (DEFB1 and Defrl) and inducible (DEFB4 and Defb2) p-defensins
may show similar patterns of activity. It is also interesting that Defrl
functions as a chemoattractant factor, when it has lost the first canonical
cysteine present in other p-defensins (Morrison et al., 2002a), and also given
that the synthetic form used in these studies is known to exist in dimeric and
monomeric forms. It would be of interest to investigate whether any
differences exist between the chemotactic abilities of the Defrl monomer and
dimer, although the CC motif is present in both structural forms.
The structure and charge distribution of p-defensins has been proposed to be
important for the ability of DEFB1 and DEFB4 to bind the CCR6 receptor
(Bauer et al., 2001; Perez-Canadillas et al., 2001; Hoover et al. 2002). The NMR
structures of the human and murine MIP-3a chemokine, which specifically
binds to the CCR6 receptor, were recently elucidated (Perez-Canadillas et al.,
2001; Hoover et al. 2002). A comparison of the structure of MIP3a with that
of DEFB4 highlighted the presence of a highly symmetric distribution of
positive charges and the conservation of an aspartate and a leucine residue at
the amino termini of the peptides (Figure 4.13, residues highlighted in green
and red). Indeed the authors describe the DEFB4 three-dimensional
structure as a 'simplified form of MIP3a' (Perez-Canadillas et al., 2001). They
suggest that as for the DCCF region of MIP3a, the aspartate-leucine region of
DEFB4 may play a role ion receptor binding, activation and signalling (Perez-
Canadillas et al., 2001; Hoover et al., 2002). The aspartate residue is also
conserved DEFB1, but the leucine is replaced by a valine. However, both
leucine and valine are amphipathic amino acids and the valine may therefore
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retain some of the properties of the leucine residue (Bauer et al., 2001).
Interestingly, some of these features may also be conserved in Defb2 and
Defrl. For example, Defrl retains the aspartate seen in DEFB1 and DEFB4,
but has an isoleucine in the position occupied by leucine in MIP3a and
DEFB4. In Defb2, the aspartate residue is replaced by the amino acid
glutamate, which like aspartate is acidic. However, a histidine residue
replaces the valine and leucine residues in DEFB1 and DEFB4 respectively.
A very recent study compared the structures of DEFB4 and human MIP3a
(Hoover et al., 2002). The authors found that in the three-dimensional
structure of MIP3a the leucine residue is 0.85 nm form the aspartate residue.
Hoover et al. also noted that within the same distance of the aspartate
residues of DEFB1 and DEFB4 there are the amphipathic amino acids
tyrosine (DEFB1) and valine (DEFB4) (Figure 4.13, residues highlighted in
green and blue). They argue that the D-Y and D-V of DEFB1 and DEFB4
respectively are the functional equivalents of the DCCL region in MIP3a. It
is interesting to note that in the corresponding positions in Defrl there is a
valine, whereas in Defb2 there is anther aspartate residue. Elucidation of the
three-dimensional structures of Defrl and Defb2 and subsequent mutational
analysis may help to understand the role of these residues in the interaction
of p-defensins with the chemokine receptor.
It is noteworthy that in comparison with the antibacterial activity of Defb2
and Defrl, the in vitro attractant activities of p-defensins appear to be more
rigorous in that the attractant abilities are not inhibited by either serum or
salt, whereas the antibacterial activities are (Zucht et al., 1998). Furthermore,
lower concentrations of defensins are required for attractant ability, which
are more similar to the concentrations at which they have been detected in
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tissues (Singh et al., 1998; Ganz, 1998). Yang et al. have proposed a two-
concentration model of defensin function (Yang et al., 2000a). At nanomolar
concentrations, defensins act as signalling molecules and chemoattract
molecules as shown by this study and others (Yang et al., 1999; Yang et al.,
2000a). Higher concentrations (in the micromolar range) of a- and (3-
defensins are required for antibacterial function, possibly because high
concentrations permit the formation of higher order structures that may be
required for antibacterial activity (Hoover et al., 2000; Yang et al., 2000a;
Bauer et al., 2001). These observations once again raise the question as to
what are the functions of p-defensins in vivo.
4.3.6 Chemokinesis and Chemotaxis
Standard chemotaxis apparatus, such as the 48-well microchemotaxis
chamber used here, do not permit the establishment of a concentration
gradient. Consequently, therefore, it is not clear whether the migration
reported here is chemotactic (a directed migration in the presence of a
concentration gradient) or chemokinetic (non-directional movement in the
absence of a gradient) and further studies are required to resolve this issue.
Normally checkerboard assays are employed for this purpose (Pereira, 1997).
In an initial study of cell migration, such as the ones reported here, only the
bottom wells of the chemotaxis chamber are loaded with the attractant.
However, in the checkerboard assay there is an increasing amount of
attractant in the lower wells (as per usual); but there is also added an
increasing amount of attractant in the upper wells, which contain the cells.
Thus, in this system a point is reached where there is no longer a
concentration difference between the upper and lower chambers and it is
possible to discriminate between directional and non-directional movement.
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A theoretical example is depicted in Table 4.1 in which number in bold
represent true chemotaxis and those underlined indicate chemokinesis.
Furthermore, a novel system for measuring chemotaxis that uses a series of
microchannels to generate a chemical gradient of a chemoattractant has
recently been described (Jeon et al, 2002) and this system my prove to be
useful in further investigations of chemokinetic/chemotactic migration.
[Defensin] in Defensin concentration in lower wells
upper wells 0 1 10 100 1000
0 25 43 85 120 105
1 26 30 48 79 90
10 28 29 68 85 91
100 27 30 39 53 93
1000 25 32 35 32 45
Table 4.3: Determination of chemotaxis by checkerboard assay. Various concentrations of
defensin peptides are present in both the upper and lower wells and the numbers indicate the number
of migrated cells per treatment. Numbers underline show chemokinesis, and numbers in bold
demonstrate chemotaxis. Taken from Pereira, (1997).
4.3.7 Summary
It would be of great interest to investigate the range of attractant activity of
these murine (l-defensins. These studies have suggested that murine p-
defensins Defb2 and Defrl attract immature, but not mature, DCs, and also
CD4+ T-cells. As was discussed above, further studies are required to
investigate the whether the migratory activity observed in these studies is
chemoattractant or chemokinetic. It would also be of interest to investigate
which subset of T-cells Defb2 and Defrl are acting upon. Furthermore, the
effect of these murine p-defensins on CD8+ T-cell migration and on the
migration and degranulation of mast cells are also worthy of further
investigation.
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Chapter 5: Expression of Human and Murine B-Defensins in
Mammalian Cell Lines
5.1 Introduction
The data presented in Chapters 3 and 4 of this thesis analyses the
antibacterial and chemoattractant activities of synthetic p-defensin peptides
generated by Albachem Ltd. (Edinburgh, UK). Whilst such peptides have
the advantages of convenience and purity and are ideal for in vitro analysis,
their cost is very high and improper folding may compromise activity.
Moreover, natural sources of P-defensins are also unsuitable as the levels at
which p-defensins are produced in tissues are too low to be of use, for
example in one study 136 gg of DEFB1 was purified form 10 litres of urine
and 3.6 mg of DEFB1 from 10000 litres of haemofiltrate (Zucht et al., 1998).
The other main method of production therefore is to use recombinant DNA
technology. This chapter describes an attempt to establish a mammalian cell
line that has been stably transfected to express the p-defensins DEFB1,
DEFB4, Defbl and Defb2.
The problems of cost and incorrect folding associated with the use of
chemically synthesised peptides were introduced above. Further problems
are highlighted by the identification of several different isoforms of human
DEFB1, which were shown to have different spectra of antibacterial activity
(Valore et al., 1998). Valore et al. isolated several different forms of DEFB1
from urine that vary in length due to alternate splicing at the N-terminus.
The peptides varied in length from 36 to 47 amino acids, with the 40- and 44-
residue variants being the predominant forms. Interestingly, the recombinant
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peptides generated using a baculovirus system were shown by subsequent in
vitro analysis to have different levels of microbicidal activity. The 36-residue
variant was the most potent and retained its activity under high salt
conditions, whereas the other forms showed little or no activity in the
presence of high levels of salt. Obviously, the synthetic peptides used in the
studies described in this thesis are sequenced to a defined N-terminus.
Therefore, they may not accurately reflect the natural (3-defensin milieu,
which may be composed of a cocktail of different isoforms varying at the
NTh-termini and each possessing different levels of antimicrobial activity.
The establishment of a system producing recombinant protein may help to
investigate this issue. Indeed, if a detailed analysis of this issue is required it
may be necessary to transfect cells from different tissues, as the spectra of p-
defensin N-terminus isoforms may vary among different tissues. However,
the use of a baculovirus system in an insect cell line may not generate
defensin variants that are relevant to mammalian cells, for example the pool
of DEFB1 peptides generated by the baculovirus in the Valore et al. (1998)
study differed from those isolated form urine in terms of which DEFB1 NH-
terminus variant was predominant.
The potential for incorrect folding of synthetic p-defensin peptides is another
issue associated with their use. For example, the structure of the synthetic
Defrl peptide used in the studies described in this thesis (Morrison et al.,
2002a) was analysed by Dr Perditta Barran (University of Edinburgh, UK)
and was found to exist in both monomeric and dimeric forms. Moreover, as
Defrl lacks the first canonical cysteine the arrangement of the disulfide
bridges was altered from the conserved arrangement found in all other p-
defensins. The monomeric form of Defrl contained three disulfide bridges
but the dimeric form was revealed to be composed of two different forms,
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differing in the cysteine-bonding pattern; one form contained four disulfide
bonds and the other contained five. It is not clear whether these different
structural forms are artefacts of the chemical synthesis or whether they
represent naturally occurring isoforms. The identification and analysis of
Defrl peptide were made after the completion of the studies described in this
chapter and therefore Defrl is not included in the experiments described in
this chapter. However, the issues associated with its structure illustrate well
the need for recombinant production of peptides, and resolution of the Defrl
structural issues may benefit from analysis using such a system.
Several studies have used recombinant peptides produced using baculovirus
system in an insect cell line (Bals et al., 1998b; Singh et al., 1998; Valore et al.,
1998). Both the Valore et al. and the Bals et al. studies report the production
of human p-defensins, which vary in the sequence of the N-terminus. As
described earlier Valore et al. report different levels of activity for the
different recombinant DEFB1 peptide variants. Bals et al. (1998b) used a
baculovirus system to generate recombinant DEFB4 (formerly DEFB2 or
HBD2) peptide, they isolated two different isoforms that differ in length by
three residues at the N-terminus, whereas Harder et al., (1997) only isolated
the shorter 38 amino acid form from the skin. However, these two forms did
not differ in antimicrobial activity and it is not clear whether they represent
an artefact of the insect cell line used, or if they represent genuine structural
variants. In a study of Defbl, antimicrobial activity, Bals et al. (1998a)
successfully produced functional recombinant peptide. A mammalian cell
line was transiently transfected with a construct for Defbl, and the lysates of
the transfected cell had significantly greater antimicrobial activity compared
to the empty vector controls, however, this study did not purify the peptide.
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This chapter describes an attempt to produce a stably transfected mammalian
cell line expressing p-defensins. The establishment of a stably transfected cell
line would add to the convenience of the system, in that p-defensins are
constantly produced and samples can be taken as needed. Two different cell
lines are used in this study, the human bronchial epithelial (HBE) cell line,
which expresses DEFB1 and DEFB4, and the mouse mammary epithelial
C127 cell line, which does not express detectable levels of Defbl or Defbl. The
system used in the studies presented in this chapter utilised the operator
plasmid from the LacSwitch II system (Stratagene). Expression from the
operator plasmid, pOPRSVI/MCS is driven by the Rous sarcoma virus
promoter, and stable transfectants can be selected using geneticin (G418)
resistance (Figure 5.1). There is also the option of using the repressor
plasmid pCMVLacI, this is of use if the inserted gene is toxic as it prevents
transcription until a suitable inducer is added (Figure 5.2). This plasmid uses
the lactose (lac) repressor protein from the Escherichia coli lac operon; the lac
repressor binds to the lac operator in the pOPRSVI/MCS vector and prevents
transcription. When an inducer such as isopropyl p-D-thiogalactopyranoside
(IPTG) is added to the culture media, it binds to the lac repressor causing a
conformational change and reducing its affinity for the operator. When the
repressor is removed from the operator, transcription of the inserted gene
can occur.
In addition to the comparison of the in vitro antibacterial activity of
recombinant peptides with the synthetic peptides, the production of
recombinant P-defensins would permit further experiments that may
otherwise prove to be impractical due to cost. Such experiments would be to
investigate the antimicrobial activity of P-defensins in combination with each
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lysozyme, as previous studies have suggested that the activity of p-defensins
is synergistic with such factors (Bals et al, 1998b).
Production of recombinant peptides in a mammalian cell line may also
permit the analysis of their native structure and N-terminal sequence, as with
synthetic peptides the sequence, and to a certain extent, the structure is
dictated by experimental conditions, and involves a certain degree of
conjecture based on previously identified p-defensins. For example, the
precise sequence of mature Defb2 is not known, however, the sequence of the
form used in this study was predicted based on the reported sequence of
mature Defbl, Defb3 and DEFB4. Using a stably transfected cell line
expressing p-defensins may also permit the analysis of their antimicrobial
activity on a cell monolayer. Unlike the in vitro assays that only measure the
activity of a specific p-defensin in isolation, such an experiment would permit
the analysis of the antibacterial activity of these peptides in conjunction with
living epithelia and may represent a more physiologically relevant
environment. For example, it may be possible to treat cultures of primary
airway surface epithelial cells with the recombinant peptides and then
expose the monolayer to bacteria to investigate the antibacterial activity of




5.2.1 Cloning of complementary DNAs for DEFB1 and DEFB4
A human bronchial epithelial (HBE) cell line was treated with 100 pg of
Escherichia coli Lipopolysaccharide (LPS) for 4 or 24 hrs; RNA was isolated
from these cell lines and an untreated control. Complementary DNA
(cDNA) was synthesised from the isolated RNA and used in reverse-
transcriptase polymerase chain reaction (RT-PCR) reactions to isolate cDNAs
for DEFB1 and DEFB4 (Figure 5.2). DEFB1 was detected at all time points,
but expression of DEFB4 was only in detected in those cell lines pretreated
with LPS. The PCR products were ligated into a pCR II-TOPO cloning vector
to give DEFB2/pTOP-TA and DEEB4/pCR II-TOPO constructs.
Plasmid DNA was isolated from bacteria transformed with the DEEB-1/TOP-
TA or DEFB4/pTOPO-TA constructs and the defensin inserts were sequenced
using the Sp6 and T7 plasmid-contained primer sites to confirm the fidelity
of the PCR (Figure 5.3 and 5.4). Inserts that showed 100% identity to the
DEFB1 or DEFB4 cDNA sequence were selected for further work.
DEFB1 was excised from the pCR II-TOPO vector by the Spe I (5') and Not I
(3') restriction endonuclease sites and subcloned in to the pOPRSVI/MCS
vector to give DEFBl/pOPRSVI. DEFB4 was excised by the Eco RV (5') and
Spe I (3') site and also ligated in to the pOPRSVI/MCS vector. Plasmid DNA
was isolated from transformed bacteria, and the inserts sequenced using the
KS and T3 (DEFB1) and T3 and T7 (DEFB4) plasmid-contained primer sites to




























Figure 5.3: Cloning of DEFB1 and DEFB4 from human bronchial epithelial
cell line.
Human bronchial epithelial cells were treated with 100 jig LPS, RNA was isolated
at 4 and 24 hrs post-treatment and used in RT-PCR analysis for expression of
DEFB1 and DEFB4. The generated PCR products were cloned into pTOPO-TA
vector and sequenced to confirm their identity.
A) DEFB1
12 TCCAAAGGAGCCAGCCTCTCCCCAGTTCCTGAAATCCTGAGTGTTGCCTG
I II I I I I I I I I I I I I I I I I I I! I I I I I I I I I I I I I I I I I II I I I II I II I
tccaaaggagccagcctctccccagttcctgaaatcctgagtgttgcctg
62 CCAGTCGCCATGAGAACTTCCTACCTTCTGCTGTTTACTCTCTGCTTACT
II I I II I II I II I I II I I I II I I I II I I I I I I I II I II I I I I I I I I I I I I
ccagtcgccatgagaacttcctaccttctgctgtttactctctgcttact
112 TTTGTCTGAGATGGCCTCAGGTGGTAACTTTCTCACAGGCCTTGGCCACA
I II I I I II II II I I II I II II I II I I I I I II II II I II II I II I I I II I I
tttgtctgagatggcctcaggtggtaactttctcacaggccttggccaca
162 GATCTGATCATTACAATTGCGTCAGCAGTGGAGGGCAATGTCTCTATTCT
II I I II I I I I II I I II I II II I II II II I II II II I II I II II I I I II II
gatctgatcattacaattgcgtcagcagtggagggcaatgtctctattct
212 GCCTGCCCGATCTTTACCAAAATTCAAGGCACCTGTTACAGAGGGAAGGC
II I I II I I I I II I II I I I I I I I II II II I II II II I II I II II II I II II
gcctgcccgatctttaccaaaattcaaggcacctgttacagagggaaggc
2 62 CAAGTGCTGCAAGTGAGCTGGGAGTGACCAGAAGAAATGACGCAGAAGTG
I I I II I II I I II I II I I I I I I I II II I I II I II II I II I I I I I I II I I II
caagtgctgcaagtgagctgggagtgaccagaagaaatgacgcagaagtg
312 AAATGAACTTTTT




I I II II I I I I II I II I I II II I I I II I II I II I I I I II I II II II I I I II
ccagccatcagccatgagggtcttgtatctcctcttctcgttcctcttca
61 TATTCCTGATGCCTCTTCCAGGTGTTTTTGGTGGTATAGGCGATCCTGTT 110
II II I I II I II I I II I I II II I II I II II II I I I II I II I I I I I I II I II
tattcctgatgcctcttccaggtgtttttggtggtataggcgatcctgtt
111 ACCTGCCTTAAGAGTGGAGCCATATGTCATCCAGTCTTTTGCCCTAGAAG 160
II II I I I I I II I I II II II II II I II I II I I II I I I II II II II II II II
acctgccttaagagtggagccatatgtcatccagtcttttgccctagaag
161 GTATAAACAAATTGGCACCTGTGGTCTCCCTGGAACAAAATGCTGCAAAA 210
II II I I II I I I I I I I II I II I I I I I I I I I I I I I II II I II I I I I II I I II
gtataaacaaattggcacctgtggtctccctggaacaaaatgctgcaaaa
211 AGCCATGAGGAGGCCAAGAAGCTGCTGTGGCTGATGCGGATTCAGAAAGG 260
I I II II I I II I I II II I I I I II I II I II I I II I I I I I II II I I I I I I II I
agccatgaggaggccaagaagctgctgtggctgatgcggattcagaaagg
261 GCTCC 265
I I I II
gctcc
Figure 5.4: Sequencing of (A) DEFB1 and (B) DEFB4 cloned by RT-PCR and ligated into the
pTOPO-TA vector. Comparison to previously PCR products (in lowercase) identified sequences (in




I I I I II I I I I I I I I I II II I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I
cactctggaccctggctgccaccactatgaaaactcattactttctcctg
67 GTGATGATATGTTTTCTTTTCTCCCAGATGGAGCCAGGTGTTGGCATTCT 116
I I I I II I I I I I I I I I I I I I I I II I I II I I I I I I I I I I I I I I I I I I I I I I I
gtgatgatatgttttcttttctcccagatggagccaggtgttggcattct
117 CACAAGTCTTGGACGAAGAACAGATCAATACAAATGCCTTCAACATGGAG 166
I II I I I I I I I 11 I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I II
cacaagtcttggacgaagaacagatcaatacaaatgccttcaacatggag
167 GATTCTGTCTCCGCTCCAGCTGCCCATCTAATACCAAACTACAGGGAACC 216
I II I I I I I I I I I II I I I II I I I I I I I I I I I II I I I I I I I I I I I II I I I I I
gattctgtctccgctccagctgcccatctaataccaaactacagggaacc
217 TGTAAACCAGATAAGCCCAACTGTTGTAAGAGCTGACAGTAGTTTGAAGA 266
I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I II I I I I I I I I I II I II
tgtaaaccagataagcccaactgttgtaagagctgacagtagtttgaaga
267 ATGGACATAAAGGACGAGCGATGGATT 293




II I I I I I I I I I I I II II I I II II I II I I I I I II I I I II I I I I I I I I I I II
ctctctggagtctgagtgccctttctaccagccatgaggactctctgctc
51 TCTGCTGCTGATATGCTGCCTCCTTTTCTCATATACCACTCCAGCTGTTG
II I I I I I I I I I I I I I I I I I I I II II I I I I I I I I I I I I I I I I I II II I I II
tctgctgctgatatgctgcctccttttctcatataccactccagctgttg
101 GAAGTTTAAAAAGTATTGGATACGAAGCAgAACTTGACCACTGCCACACC
I I I I I I I II I I I I I I I I I I I I I I I I I I II I I I I II I I II II I I I I I I I I I
gaagtttaaaaagtattggatacgaagcagaacttgaccactgccacacc
151 AATGGAGGGTACTGTGTCAGAGCCATTTGTCCTCCTTCTGCCAGGCGTCC
I I I I I I II I I I I I I I I I I I I I I II I I I I I I I II I I I II I I I I I II I I I I I
aatggagggtactgtgtcagagccatttgtcctccttctgccaggcgtcc
201 TGGGAGCTGTTTCCCAGAGAAGAACCCCTGTTGCAAGTACATGAAATGAT
I I I I I II I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I II I I I I
tgggagctgtttcccagagaagaacccctgttgcaagtacatgaaatgat
251 TAGAAGGAAGCACATGGAAGTCAAGTGACA
I I I II I I I I I I I I I I II I I I I II I I I I I I I
tagaaggaagcacatggaagtcaagtgaca
Figure 5.5: Sequencing of (A) Defbl and (B) Defb2 previously cloned by RT-PCR and ligated
into the pTOPO-TA vector. Comparison to previously PCR products (in lowercase) identified
sequences (in uppercase lettering) was performed using Bestfit function in GCG
(www.hgmp.mrc.ac.uk).
222
DNAs for Defbl and Defb2 had been previously isolated from mouse tissues
and ligated into the pOPRSVI/MCS vector (Defbl/pORRSVl and
De/F2/pOPRSVI) by Gillian Morrison working in this laboratory and these
constructs were also sequenced using T3 and KS primer sites (Figure 5.5).
Inserts that showed 100% identity to the appropriate defensin cDNA
sequence were used for later studies.
5.2.2 Transfection of mammalian cell lines with defensin-pOPRSVI
constructs
Mouse mammary epithelial C127 cell lines and human HBE cell lines were
transfected with Defbl IpORRSVl, Defbl/pOPRSVI, D£FB I/pOPRSVI, or
D£FB4/pOPRSVI using the calcium phosphate method as described in
material and methods. The cell lines were treated with 500 pg/ml Geneticin
(G418) to select for stably transfected cell lines. After 14-21 days several
G418-resistant clones were visible. Single colonies and groups of colonies
were picked and cultured separately with maintenance of selection. In total,
from two separate transfection experiments, 13 colonies were isolated from
C127 cells transfected with the DEFBl/pOPRSVI construct, 19 colonies from
cells transfected with the DEFB2/pOPRSVI construct, eleven from cells
transfected with Defbl/pOPRSVI and 21 from Defb2/pOPRSVI transfected
cells. Attempts were also made to establish stable cell lines transfected with
the repressor plasmid pCMVLacI, which can they be cultured and
transfected with the defensin/pOPRSVI constructs. Flowever, after several
attempts no stable clones were identified.
Attempts were made to establish stable cell lines transfected with the
repressor plasmid pCMV/LacI, whiuch could then be cultured and
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transfected with the defensin/pOPRSVI constructs. However, after several
attempts no stable clones were identified. Furthermore, repeated attempts to
transfect the HBE cell line with the defensin/pOPRSVI constructs also failed
to generate any G418-resistant clones.
5.2.3 Analysis of expression of defensins by transfected C127 cell
lines
RT-PCR analysis of several of the p-defensin/pOPRSVI transfected clones
was conducted to identify those clones expressing the transfected defensin.
Untransfected C127 cell lines do not express detectable levels of Defbl or
Defb2, however, all transfected-C127 cell lines analysed expressed the
appropriate defensin (Figure 5.5). Eight clones were identified that express
Defbl, 13 clones expressed detectable levels of Defb2, ten that expressed
DEFB1 and eleven that expressed DEFB4. The reproducibility and validity of
the expression was tested by repeating the RT-PCR three times (i.e. n=3)
using separate samples of freshly RNA.
Twelve G418-resistant clones expressing the transfected-defensins (three for
each of the transfected defensin-plasmid constructs) were selected for further
analysis. Further RT-PCR analyses showed that these cell lines expressed
only the defensin with which that cell line had been transfected, expression
of the other (3-defensins was not detected (Figure 5.6).
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5.2.4 Assessment of the antibacterial activity of transfected cell lines
- Microbicidal activity of culture media
In order to investigate if the cell lines expressing p-defensins exhibit
increased antibacterial activity the microbicidal effect of cell culture media
(RPMI + 2.5% foetal calf serum) against Pseudomonas aeruginosa laboratory
strain PAOl and Staphylococcus aureus cystic fibrosis (CF) isolate C1705 was
assessed. The antibacterial activity was assessed by incubating 2.5 x 104
colony-forming units (cfu) in 200 pi of culture media and incubating at 37°C
for 30 min. All experimental results were repeated three times to test for
reproducibility, using different samples of media each time (i.e. n=3).
Culture media from the p-defensin expressing cell lines did not show
increased or reproducible antibacterial activity against either P. aeruginosa
PAOl or S. aureus C1705 compared to the untransfected or empty vector
controls (Figure 5.9A). These experiments were repeated with culture media
that had been dialysed against dFbO to remove inhibitory effects of salt,
which may inhibit antibacterial effects of the p-defensins. However, again
the transfected cell lines did not demonstrate significantly greater
antibacterial activity compared to the controls (Figure 5.9B). The above
experiments were also repeated with lxlO3 cfu; however, significant numbers
of surviving bacteria were isolated from these experiments (data not shown).
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A) Shows results of RT-PCR on RNA from C127 cells transfected with Defb/-containing vector, B)
shows RT-PCR ofRNA from Defb2!POPRSVI transfected C127 cells.
RNA was isolated from G418-resistant C127 cell lines that had been transfected with the (3-
defensin/POPRSVI constructs, and used for RT-PCR analysis as described in materials and methods.
100 ng of vector containing the appropriate P-defensin cDNA was used as a positive control.
Reactions without reverse-transcriptase were set up as an internal control. Letter and number in the
top row represent the name of the P-defensin transfected cell line. Ml= Defbl and M2= Defb2,
Subsequent letters represent the number of the colony at initial subculture. RT-PCR analysis was
repeated three times, using a new sample of freshly isolated RNA each time, to ensure the validity of
the result (n=3).
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Figure 5.7 : RT-PCR Analysis of P-Defensin Transfected C127 Cell Lines
A) shows RT-PCR analysis of cells transfected with D£7?6//pOPRSVI construct and B) represents
expression analysis of cells transfected with the D£F£4/pOPRSVI plamsid.
RNA was isolated form G418-resistant CI27 cell lines that had been transfected with the P-
defensin/POPRSVI constructs, and used for RT-PCR analysis as described in materials and methods.
100 ng of vector containing the appropriate P-defensin cDNA was used as a positive control.
Reactions without reverse-transcriptase were setup as an internal control. Letter and number in the top
row represent the name of the P-defensin transfected cell line. H1=DEFB1 and H2=DEFB4.
Subsequent letters represent the number of the colony at initial subculture. RT-PCR analysis was















































































































































5.2.5 Assessment of the antibacterial activity of transfected cell lines
- Microbicidal activity of cell lysates
The antibacterial activity of cell lysates was also assessed as functional p-
defensin peptides may have been retained within the cells and not secreted
into the culture media. Cell pellets from a 150cm2 culture dish were lysed by
brief sonication, and the antibacterial activity was assessed by incubating 1 x
104 cfu with the lysed cell pellet in 200 gl of phosphate buffer.
No significant reproducible difference was observed between the
antibacterial activity of cell pellets from untransfected or transfected cell line
against P. aeruginosa PAOl or S. aureus C1705 (Figure 5.9C). Dialysed cell
lysates form p-defensin transfected cell lines also failed to demonstrate
significantly increased antibacterial activity compared to the controls (Figure
5.9D). As above these experiments were repeated using 1 xlO3 cfu, but again
significant numbers of bacteria were not isolated from this experiment to
permit valid assessment. All experimental results were repeated three times
to test for reproducibility, using different samples of cell lysate each time (i.e.
n=3).
5.2.6 Assessment of the antibacterial activity of transfected cell lines
- Microbicidal activity of purified culture media and cell lysates
Experiments described above have failed to demonstrate increased
antimicrobial activity of culture media or cell lysates from cells expressing
the P-defensins DEFB1, DEFB4, Defbl or Defb2 compared to untransfected or
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empty vector controls. Therefore, attempts were made to purify cationic
peptides from lysates and culture media following a protocol established by
Dr Gerry McLachlan (University of Edinburgh, UK) based on that of
Diamond et al. (1991). The lysates from ten cell pellets of the various (3-
defensin-expressing cell lines were mixed with 45 ml of media isolated from
the same cell line were purified using a Cis Sep-Pak cartridge as described in
the Materials and Methods. The antibacterial assays described above were
repeated using the purified lysates and media. However, as in previous
studies no significant difference was observed between the antibacterial
activities of p-defensin expressing cell lines compared to that of the controls
(Figure 5.9E). Experiments were repeated three times to ensure



































Figure 5.9: Antibacterial Activity of Culture Media from P-defensin transfected
C127 Cell Lines.
Graph A shows antibacterial activity of media incubated with P. aeruginosa PAOl.
Graph B shows antibacterial activity of media against S. aureus C1705. 2.5 x 104 cfu
were added to culture media and incubated for 30 min. The surviving were bacteria
plated out, incubated overnight at 37°C and the resultant colonies were counted. Letter
and number on the x-axis represent the name of the P-defensin transfected cell line. Ml=
Defbl, M2= Defb2, H1=DEFB1, H2=DEFB4. Subsequent letters represent the number
of the colony at initial subculture. Antibacterial experiments were repeated three time,




























Figure 5.10: Antibacterial Activity of Dialysed Culture Media from 3-defensin
transfected C127 Cell Lines.
Graph A shows antibacterial activity of media incubated with P. aeruginosa PAOl.
Graph B shows antibacterial activity of media against S. aureus CI705. 2.5 x 104 cfu
were added to culture media and incubated for 30 min. The surviving were bacteria
plated out, incubated overnight at 37°C and the resultant colonies were counted. Letter
and number on the x-axis represent the name of the P-defensin transfected cell line. Ml=
Defbl, M2= Defb2, H1=DEFB1, H2=DEFB4. Subsequent letters represent the number
of the colony at initial subculture. Antibacterial experiments were repeated three time,








Figure 5.11: Antibacterial Activity of Lysates from P-defensin transfected C127 Cell
Lines.
Graph A shows antibacterial activity of media incubated with P. aeruginosa PAO1.
Graph B shows antibacterial activity of media against S. aureus C1705. 2.5 x 104 cfu
were added to culture media and incubated for 30 min. The surviving were bacteria
plated out, incubated overnight at 37°C and the resultant colonies were counted. Letter
and number on the x-axis represent the name of the P-defensin transfected cell line. Ml=
Defbl, M2= Defb2, H1=DEFB1, H2=DEFB4. Subsequent letters represent the number
of the colony at initial subculture. Antibacterial experiments were repeated three time,
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Figure 5.12: Antibacterial Activity of Dialysed Lysates from P-defensin transfected
C127 Cell Lines.
Graph A shows antibacterial activity of media incubated with P. aeruginosa PAOl.
Graph B shows antibacterial activity of media against S. aureus C1705. 2.5 x 104 cfu
were added to culture media and incubated for 30 min. The surviving were bacteria
plated out, incubated overnight at 37°C and the resultant colonies were counted. Letter
and number on the x-axis represent the name of the P-defensin transfected cell line. Ml=
Defbl, M2= Defb2, H1=DEFB1, H2=DEFB4. Subsequent letters represent the number
of the colony at initial subculture. Antibacterial experiments were repeated three time,
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Figure 5.13: Antibacterial Activity of Purified Lyates/Culture Media from P-
defensin transacted C127 Cell Lines.
Graph A shows antibacterial activity of media incubated with P. aeruginosa PAOl.
Graph B shows antibacterial activity of media against S. aureus C1705. 2.5 x 104 cfu
were added to culture media and incubated for 30 min. The surviving were bacteria
plated out, incubated overnight at 37°C and the resultant colonies were counted. Letter
and number on the x-axis represent the name of the P-defensin transfected cell line. Ml =
Defbl, M2= Defb2, H 1=DEFB 1, H2=DEFB4. Subsequent letters represent the number
of the colony at initial subculture. Antibacterial experiments were repeated three time,
using a new sample of freshly purified batch of media/cell lysate each time, to ensure the
validity of the result (n=3).
5.2.7 Northern blot analysis of p-defensin expression by transfected
cell lines
The expression of p-defensin mRNA by the transfected C127 cell lines was
also analysed by northern blot. However, expression appropriate transfected
P-defensin could not be detected in any of the cell lines analysed (Figure 5.8).
A signal was detected in the positive control sample, which was 10 ng of the
appropriate defensin cDNA, demonstrating the integrity of the p-defensin
probe. Moreover, expression of p-actin was detected in all the cell lines, thus
confirming the integrity of the mRNA. Northern analysis P-defensin
expression by transfected cell lines was repeated twice, using different
samples of freshly isolated RNA, to ensure reproducibility of the result.
5.2.8 Protein Gel analysis of P-defensin expression by transfected
cell lines
Culture media, cell lysates, and purified media/lysates form all cell lines were
separated on protein gels to investigate if P-defensin expressing cell lines
possessed additional protein bands. However, no additional protein bands
were visible in the p-defensin transfected cell lines compared to the
untransfected or empty vector controls (Figure 5.9 and data not shown). Gel
analysis of the protein content was repeated twice using fresh protein
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Figure 5.14: Northern Blot
Transfected C127 Cell Lines.
Analysis of P-Defensin Expression by
RNA was isolated from the different transfected cell lines; 20 |ag was run on a denaturing gel
and subjected to Northern blot analysis using the appropriate (3-defensin cDNA as a probe.
10 ng of the appropriate (3-defensin cDNA was run in parallel as a positive control for
hybridisation. pMCS is the empty vector control, and C127 the untransfected cell line. Letter
and number in the top row represent the name of the (3-defensin transfected cell line. Ml=
Defbl, M2= Defb2, H1=DEFB1, H2=DEFB4. Subsequent letters represent the number of the
colony at initial subculture. Northern blot analysis was repeated twice, using a new sample of
freshly isolated RNA each time, to ensure the validity of the result (n=2).
Figure 5.15: Protein Gel Analysis of the Protein Content of Culture Media Harvested from P-
Defensin Expressing Cell Lines.
Culture media was harvested form P-defensin-transfected cell lines, boiled for 10 min with sample
buffer and then separated on a Tris-tricine gel. Letter and number in the top row represent the name
of the P-defensin transfected cell line. Ml= Defbl, M2= Defb2, H1=DEFB1, H2=DEFB4.
Subsequent letters represent the number of the colony at initial subculture. Protein gel analysis was
repeated twice, using a new protein sample each time, to ensure the validity of the result (n=2).
Similar analysis were performed on cell lysates and purified media/lysates (data not shown).
Chapter 5.3: Discussion
This chapter describes the establishment and characterisation of mouse
mammary epithelial C127 cell lines stably transfected with murine and
human p-defensins. However, whilst expression of DEFB1, DEFB4, Defbl
and Defb2 could be detected in the appropriate cell lines by 35-cycles of RT-
PCR, no significantly increased or reproducible antimicrobial activity could
was observed in the p-defensin expressing cell lines compared to control cell
lines. This may suggest that recombinant defensin peptides are either non¬
functional or produced at too low a level to be detected the antibacterial
assays. However, the transfected cell lines may express sufficient quantities
of p-defensin peptide to possess chemoattractant abilities or for detection by
more sensitive antimicrobial assays. Although, if the cell lines are producing
such low levels of peptide they may prove to be of little use in further
studies. Moreover, a crude western blot analysis did not reveal the presence
of additional low molecular weight protein bands not present in the
untransfected and empty vector cell lines. If additional protein bands were
present, this may have suggested that p-defensin protein was produced but
remained non-functional; unfortunately, the absence of correctly controlled
antibodies for the p-defensins did not permit more detailed analysis.
Furthermore, a Northern blot analysis of 20 jog of also failed to detect the
presence of P-defensin mRNA, and this further suggests that p-defensins
were not produced at sufficiently high levels to be detectable.
It was not possible to detect expression of Defbl-4 in the murine C127 cell
line, and this permitted easy selection of stably transfected cell lines. In order
to help ensure correct cellular processing of the recombinant p-defensins, it
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was desirable to stably transfect a cell line that naturally expresses p-
defensins. Therefore, attempts were also made to transfect a human
bronchial epithelial (HBE) cell line, however, repeated attempts at
transfection failed to produce any stable transfected clones. This observation
is in agreement with previous findings that the HBE cell line is particularly
resistant to stable transfection (Dr Peter Thorpe, University of Edinburgh). It
is possible to create stably transfected lines of HBE cells using Mitomycin en¬
treated feeder cells. Therefore, it may be suitable to generate stable
recombinant p-defensin-expressing HBE cell lines using this method as such
cells may produce recombinant p-defensins at sufficiently high levels to be of
use in further studies.
It is not clear why the transfected C127 cell lines did not produce detectable
levels of functional p-defensin peptide. Neither cell lysates nor culture
media, even when the potentially inhibitory effects of salt had been removed,
demonstrated significantly increased antimicrobial activity compared to the
controls. It is possible that any cell line that produced high levels of p-
defensin peptide will have been destroyed by cytotoxic levels of the peptide.
Indeed a-defensins have been shown to be cytotoxic to mouse cells
(Lichtenstein et al., 1986). Of more direct relevance is that DEFB1 has been
shown to be cytotoxic to mouse NIH-3T3 cells, although this activity required
quite high concentrations and was inhibited by serum (Zucht et al., 1998). It
is therefore, perhaps unlikely that the failure to generate cell lines producing
high quantities of p-defensins is due to cytotoxicity.
Intriguingly, several studies have suggested that loss of the p-defensin locus
may be implicated in the process of tumourigenesis. A study by Abiko et al.
(1999) demonstrated that some oral squamous cell carcinomas express lower
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levels of DEFB1 and DEFB4, however, it was unclear whether transformation
induced lower levels of expression of DEFB1 and DEFB4, or if the down-
regulation of p-defensin expression caused malignant transformation.
Furthermore, a microarray study of renal carcinomas identified DEFB1 as
having a seven-fold lower level of expression than benign tissue (Young et
al., 2001). In addition, the chromosomal locus of p-defensins (8p23) is within
a region of deletion defined in a loss of heterozygosity study on 96 renal cell
carcinomas (Schullerus et al., 1999). These studies suggest that loss of DEFB1,
and potentially other P-defensins, may enhance or promote tumour
formation. Therefore, it is possible that the growth of the transfected cell
lines may be retarded by the p-defensin peptides, and thus low-expressing
cell lines may have a growth advantage over those expressing higher levels
of the peptide and may grow to dominate the cell cultures.
The potential problems associated with a stably-transfected mammalian cell
line expressing p-defensins discussed above may be partially circumvented if
the C127 or HBE cells are first stably transfected with the pCMVLacI
repressor plasmid (Figure 5.2). Such a system would prevent any expression
of the p-defensin until the isopropyl p-D-thiogalactopyranoside (IPTG)
stimulant is added to the culture media, and may therefore limit any toxicity
or growth-retarding properties. It is interesting to note that a previous and
successful attempt to produce p-defensins in mammalian cells used
transiently transfected cells and this too would avoid many of the problems
that may be associated with stable transfectants. Bals et al. (1998a) transiently
transfected humans SW13 cells with the Defbl cDNA, and then
demonstrated that transfected cells had significantly increased bactericidal
activities compared to empty vector and untransfected controls. However,
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the use of transiently transfected cells is less convenient than a stably
transfected cell line and thus removes one of the advantages of this system.
Since this study was initiated, it has become clear that it is also possible to
produce (3-defensins using virally transfected cells. The recombinant DEFB4
used in the study by Bals et al. (1999) was produced using a baculovirus
system in the Sf9 insect cell line. This generated peptides of two different
lengths, one form was 41 amino acids and the other was 38-residues long.
However, as this peptide was produced in insect cells and not mammalian
cells it is not clear whether the alternative processing represents genuine
differences in cellular processing or is an artefact of insect cells. Therefore, to
ensure correct cellular processing it is most advantageous to use mammalian
cells infected using an adenovirus. This system has been used by Dr Alison
Maxwell, working in this laboratory, to express Elafin in cultures of primary
murine epithelial cells to investigate its antibacterial activity within airway
surface liquid (ASL). It would be of interest to produce (3-defensins using
this system. This would not only permit the analysis of the antibacterial
activity of p-defensins in a more physiologically relevant in vivo
environment, by incubating bacteria on the surface of transfected cultures,
but also to investigate the role of cellular processing on the N-terminal
sequence of the mature peptide. The production of large quantities of
recombinant p-defensin peptide would allow for its purification and
subsequent use in in vitro experiments for antibacterial and chemotactic
activity such as those presented in Chapters 3 and 4 of this thesis, and a
comparison with those obtained with the synthetic peptides. If however,
large quantities of p-defensin are required then it may be more suitable to
produce the peptides using a bacterial system. Such a system that allows the
production of large quantities of easily purified peptide has been described
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(Piers et al., 1993). Whilst this study discusses the problems associated with
producing and the correct folding of the defensins in bacteria it does not
resolve them. However, several recent studies have successful production of
P-defensins in bacteria (Harder et al., 2001; Schibli et al., 2002). A His-tag was
added to the mature peptide sequence to aid purification and prevent
premature activation and this can subsequently be removed by enzymatic
digestion. Such a system allows for the production of large quantities of
microbicidally active p-defensin peptide of a defined sequence and is likely
to prove of great use in future studies, as the method is cost-effective and
relatively rapid.
In conclusion, the data presented in this chapter describes an attempt to
establish a stably transfected cell line expressing the p-defensins DEFB1,
DEFB4, Defbl and Defb2. Transfection of the mouse mammary epithelial
C127 cell line produced several stable cell lines that, according to RT-PCR
analysis, expressed the transfected p-defensin. However, the transfected cell
lines did not demonstrate increased antibacterial activity compared to the
controls, suggesting that either they did not produce functional p-defensin
peptide or did not produce sufficient quantities of p-defensin peptide. It is
possible that the transfected cell lines that produced significant quantities of
p-defensin peptide were killed by the cytotoxic effects of the p-defensins or
their growth was retarded by the p-defensins, which allowed faster growing
cells to dominate the culture. It is clearly advantageous to have a
recombinant source of P-defensin peptides, and these could be produced
either using a bacterial system or by infecting mammalian cells with a viral
construct.
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Chapter 6; Expression Analysis ofNovel Human [3-defensins genes
6.1 Introduction
The main human defensin locus is on chromosome 8p22-p23 (Linzmeier et al.,
1999; Jia et al., 2001). This region contains both the a- and the p-defensins
genes, and it has been suggested that the p-defensins may predate the a-
defensins family (Linzmeier et al., 1999). Despite increasing knowledge
regarding this locus, to date only four human p-defensins have been
described in detail.
All four p-defensin genes show a conserved two exon structure: the first exon
encodes most of the propiece, whereas the second encodes part of the
propiece and the mature peptide. Substantial differences exist in their
primary structures, patterns of expression and spectrums of antimicrobial
activity. DEFB1 is constitutively expressed at high levels in the respiratory
and urogenital tracts (Bensch et al., 1995); whereas DEFB4 is expressed at
high levels in the skin and shows inducible expression in airway epithelial
cells in response to microorganisms or tumour necrosis factor-alpha (TNFa)
(Harder et al., 1997). Expression of DEFB103 is also inducible, but expression
is elevated mostly in response to interferon-gamma (IFNy). DEFB104
expression, however, appears to be mainly confined to the testis (Garcia et al.,
2001b). All p-defensins demonstrate salt-sensitive antimicrobial activity.
DEFB1, DEFB4 and DEFB104 show activity against a range of Gram-negative
and Gram-positive bacteria reviewed in (Lehrer and Ganz, 2002b). However,
whilst DEFB103 shows salt-sensitive antimicrobial activity against Gram-
negative bacteria, such as Escherichia coli, its activity against the Gram-
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positive S. aureus appears to be relatively resistant to the inhibitory effects of
salt (Harder et al, 2001).
It has been proposed that gene duplication and subsequent functional
divergence is one of the most significant processes for the evolution of new
gene function (Yokoyama, 2002; Zhang et al., 1998b). However, it remains
debatable as to whether the divergence occurs by positive selection (or
adaptive evolution), which serves to accelerate fixation of new and
advantageous alleles (Goodman et al., 1975), or by random fixation of alleles,
which only alter gene function following changes in the environment or
genetic background (Dykhuizen and Hartl, 1980). In the latter model the rate
of nonsynonymous nucleotide substitutions (i.e. those that result in an amino
acid change) may be enhanced by relaxation of selective pressure on the
redundant duplicated gene, but the rate will not exceed that of synonymous
nucleotide changes (i.e. those that are silent at the amino acid level). Thus,
the two models can be distinguished by comparison of the rates of
synonymous and nonsynonymous substitution. By showing that the rate of
nonsynonymous substitutions significantly exceeds that of silent
synonymous changes, many proteins have been suggested to have
undergone positive selection (Yokoyama, 2002). Several examples of gene
duplication followed by positive selection have been reported for genes
involved in the immune system, where it is argued that the variability
generated widens the range and spectra of immune responses. Such
examples include the immunoglobulin genes (Ota et al., 2000), and the
primate genes for eosinophil cationic protein (ECP) and eosinophil-derived
neurotoxin (EDN), which are thought to have antibacterial and antiviral
activities respectively. It has also been proposed that a- and |3- defensin
genes display such features (Hughes and Yeager, 1997; Hughes, 1999).
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The sequencing of the human genome has greatly enhanced the identification
of novel genes and the study of gene families. This chapter presents data on
the expression analysis of five novel full-length human p-defensin genes
identified from the draft human genome sequence (Semple et al., 2002).
These candidate genes were identified using bioinformatics techniques by Dr
Colin Semple (MRC Human Genetics Unit, Edinburgh).
Previously identified p-defensin sequences from a variety of mammalian
species (Table 6.1) were used as BLAST queries against the high throughput
genomic (HTG) section of the European molecular laboratory (EMBL)
database of human genomic sequence (15th July, 2001 release). All matches
were in the region 8p22-p23 and consisted of 53 bacterial artificial
chromosome (BAC) sequences; this was deemed to represent the human p-
defensin locus and was used in the subsequent analyses. Hidden Markov
Models were generated (Eddy, 1998) from a CLUSTALW multiple alignment
(Higgins et al., 1996) of known p-defensins, and these models were
subsequently used to search against the 53 BAC sequences that represent the
human p-defensin locus to identify novel human p-defensin sequences.
All known human p-defensin genes were identified as well as the related
epididymis-specific SPAG11 (initially reported as EP2). In addition to these,
two novel genes, termed DEFB105 and DEFB106 (Figure 6.1 and Table 6.2),
were identified; these were incorporated into the Hidden Markov model.
Subsequent searches identified a further three p-defensin genes, named
DEFB107, DEFB108 and DEFB109 (Figure 6.1 and Table 6.2).
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Species P-defensin
Human P-defensin 1, 4,103 and 104
Mouse (Mus musculus) P-defensin 1-11,13,15, 35, Defrl
Rat (Rattus norvegicus) P-defensin 1 and 2
Cow (Bos taurus) P-defensinl-13, TAP, LAP, Enteric P-
defensin
Pig (Sus scrofa) P-defensin 1
Sheep (Ovis aries) P-defensin 1 and 2
Goat (Copra hircus) p-defensin 1 and 2
Rhesus monkey (Macca mulatto) P-defensin 1 and 2
Olive baboon (Papio cynocephalus anubis) p-defensin 1
Chimpanzee (Pan troglodytes) P-defensin 1, 2 and 3

































Table 6.2: The predicted sequence of novel human p-defensins identified by a BLAST search of the
P-defensins locus using hidden Markov models constructed from a CLUSTALW alignment of known
P-defensins. Pept.; peptide sequence. *; STOP codon.
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Figure 6.1: (A) The genomic organisation of novel human P-defensin genes DEFBI05, DEFBI06,
DEFB107, DEFB108 and DEFB109 on 8p22-p23. Arrow heads show direction of gene orientation,
and AF numbers indicate the BAC accession number. (B) A phylogenetic tree of functional human
P-defensins using the prepropeptide sequences they encode. Figure from Semple et al., (2002).
Analysis was rooted using the chicken gallinacin 1 sequence and reproducibility of each branch was
assessed 1000 bootstrap replications.
Novel p-defensin genes have been identified at the genomic level but in to
order verify whether or not they are genuine it is necessary to investigate if
they are expressed in human tissues. In order to do this a panel of human
RNAs were obtained and screened by RT-PCR for expression of the novel p-
defensins, and in this chapter, the results of this analysis are presented.
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Chapter 6.2: Results
Expression analysis of the novel human (3-defensin genes was carried out by
RT-PCR. A range of human RNA samples from 16 tissues (stomach, kidney,
thyroid, lung, skeletal muscle, liver, skin, colon, heart, breast, placenta,
uterus, breast, vulva, ovary and testis) was used for this analysis as detailed
in the Materials and Methods. Subsequent PCR products were analysed by
gel electrophoresis and confirmed by hybridisation to specific internal
probes. PCR products were then sequenced to confirm computational
predictions of the intron-exon boundaries.
6.2.1 Expression Analysis of novel human (3-defensin genes
Expression of all five novel p-defensin genes (DEFB105, DEFB106, DEFB107,
DEFB108, DEFB109) genes was readily detected in the testis (Figure 6.2).
Further analysis revealed expression of DEFB108 and DEFB109 in other
tissues. DEFB109 had the most widely distributed expression with low levels
of expression detected in the placenta, cervix, thyroid and breast. A low
level of DEFB108 was also detected in the liver.
6.2.2 Sequence Analysis of novel human P-defensins
PCR products from the testis RNA sample were sequenced and the results
compared to the sequences identified using the Hidden Markov models to
confirm the sequence predicted by computational studies (Figure 6.3). In the
case of the sequenced DEFB105 PCR product, this was 42 bp longer than the
cDNA predicted from genomic sequences (Figure 6.3 Ai). The result of this
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was to lengthen the predicted peptide by nine amino acid residues (Figure
6.3 Aii). Sequencing of DEFB106 and DEFB107 showed that different splice
sites than those predicted by the computational analysis were used. This
resulted in a 36 base pair (bp) decrease in the predicted coding sequence of
DEFB106, and a nine bp increase in the predicted sequence of DEFB107
(Figure 6.3 Bi and Ci). Consequently, the DEFB106 peptide contains 12 fewer
residues and the DEFB107 peptide is three amino acids longer than initially
predicted (Figure 6.3 Bii and Cii). Sequenced DEFB108 contained three
nucleotide substitutions, two of which (T—»C at position 111 and C—»T at 120)
were silent but the substitution of an adenine for a guanine at position 61,
inserts an arginine (R) in the place of the predicted (K) (Figure 6.3 D).
Strikingly, sequencing of DEFB109 generated two different transcripts. One
form was identical to the predicted DEFB109 cDNA, however the alternate
DEFB109 sequence had a base substitution at position 41, which in the
peptide replaced stop codon with a serine residue. The transcript also had
three additional amino acid substitutions as a result of further nucleotide
changes (Figure 6.3 E). All sequences were confirmed by the existence of at








Figure 6.2: RT-PCR Analysis of novel human P-defensin gene expression
RT-PCR was carried out on a panel of human RNAs. Reactions were set with
either with (+) or without (-) reverse transcriptase. GAPDH was carried out as a
PCR control. RT-PCR was repeated three times to ensure reproducibility of the
result (n=3).
A) DEFB105
i.) Percent Similarity: 98.734
28 tttctatttgctatgttcttcattttggttcaactg 63
I I I I I I I I I I I I I I II I I I I I I I II I I I I I I I I II I
TTTCTATTTGCTATGTTCTTCATTTTGGTTCAACTGCCATCAGGGTGCCA
64 ccatcaggtgagtttgctgtct 85
I I I I I I I I I I I I I I I I I I I I I I
GGCAGGACTTGATTTTTCCCAACCATTTCCATCAGGTGAGTTTGCTGTCT
86 gtgagtcgtgcaagcttggtcggggaaaatgcaggaaggagtgcttggag 135
I I I I I! I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
GTGAGTCGTGCAAGCTTGGTCGGGGAAAATGCAGGAAGGAGTGCTTGGAG
136 aatgagaagcccgatggaaattgcaggctgaactttctctgctgcagaca 185
II I I I I I I I I II I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II
AATGAGAAGCCCGATGGAAATTGCAGGCTGAACTTTCTCTGCTGCAATCA
ii.) Percent Similarity: 100.000
10 flfamffilvql psgefavcescklgrgkcrkecle 45
I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I
FLFAMFFILVQLPSGCQAGLDFSQPFPSGEFAVCESCKLGRGKCRKECLE
46 NEKPDGNCRL 55
I I I I I I I I I I
NEKPDGNCRL
B) DEFB106
i.) Percent Similarity: 100.000
27 cgtgctcttctttctgaccccaggtaaaatgggcatctttacagggaagg 76
I I I I I I I I I I I I I I I I I I I II
CGTGCTCTTCTTTCTGACCCC
77 tgatcggagccaagaatgcattttttgatgagaaatgcaacaaacttaaa 126
I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I II I I I II I I I
AGCCAAGAATGCATTTTTTGATGAGAAATGCAACAAACTTAAA
127 gggacatgcaagaacaattgcgggaaaaatgaagaac 163
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
GGGACATGCAAGAACAATTGCGGGAAAAATGAAGAAC
ii.) Percent Similarity: 100.000
10 vlffltpgkmgiftgkvigaknaffdekcnklkgtcknncgknee 54
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
VLFFLTP AKNAFFDEKCNKLKGTCKNNCGKNEE
Figure 6.3: Sequencing of DEFB105 and DEFB106 novel human p-defensin genes and
comparison to predicted genes
Sequences in lower case letters indicate the predicted sequence generated by computational analysis;
sequence in capital letters represents the sequenced RT-PCR products. The PCR products generated
from the testis RNA sample were cloned and sequenced as detailed in materials and methods. Ai and
Bi represent the DNA sequence of the genes compared to the predicted sequences generated by
computational studies. Comparisons were performed using the Bestfit function in the GCG program at
HGMP (www.hgmp.mrc.ac.uk) with default settings. Aii and Bii show the peptide sequence of the
genes. These are compared to the predicted amino acid sequences based on the novel genes.
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A) DEFB107
i.) Percent Similarity: 98.137
14 tctttattttggctgctctcattcttcttgctcaaattttcca 56
II I I II I I II I I I I I I I II I I I I I II I I I I I II I I I II I I
TCGATTTTTTGGCTGCTCTCATTCTTCTTGCTCAAATTTTCCAAGCCAGG
57 . . agcaattcatagagcactaattagtaagagaatggaaggtcactgtga 104
I II I II I I I I I II I I I I II I I I I I I I I I I I I I I I I I I I I I I II I I I I I
ACAGCAATTCATAGAGCACTAATTAGTAAGAGAATGGAAGGTCACTGTGA
105 agccgaatgtcttacctttgaagtaaagattgggggctgtagagctgaat 154
II I I II II I II II I I II I II II II II II I I II I I I I I I I I I II I I I I I I I
AGCCGAATGTCTTACCTTTGAAGTAAAGATTGGGGGCTGTAGAGCTGAAT
155 tagcaccattttgctgcaaa 174
I I I I I I I I I I II II I I I I I I
TAGCACCATTTTGCTGCAAA
ii.) Percent Similarity: 98.039
8 laalillaqifq...aihraliskrmeghceaecltfevkiggcraelap 54






i.) Percent Similarity: 98.026
8 ttgctgtcctcttcttcaccattttcttctttatgagccaagttctacca 57
I I I I I I I I I I I I I II I I I I I I I I I I I I I I II I I I I I I I I I I I I I I II I I I
TTGCTGTCCTCTTCTTCACCATTTTCTTCTTTATGAGCCAAGTTCTACCA 57
58 gccaagggcaaattcaaggagatctgtgaacgtccaaatggctcctgtcg 107
I I II I II I I I I I I I I I I I I I II I I I I II I II I I I II I I I I I I I I I I I I I
GCCAGGGGCAAATTCAAGGAGATCTGTGAACGTCCAAATGGCTCCTGTCG
108 ggatttttgcctcgaaacagaaatccatgttgggagatgtttaaatagcc 157





ii.) Percent Similarity: 100.000
4 avlfftifffmsqvlpakgkfkeicerpngscrdfcleteihvgrclnsr 53
I II I I I I I I I I I I II II : I I I II I I I II II I I I I II I I I I I I I I I II I I I
AVLFFTIFFFMSQVLPARGKFKEICERPNGSCRDFCLETEIHVGRCLNSR
Figure 6.4: Sequencing of DEFB107 and DEFB108 novel human (3-defensin genes and
comparison to predicted genes
Sequences in lower case letters indicate the predicted sequence generated by computational analysis;
sequence in capital letters represents the sequenced RT-PCR products. The PCR products generated
from the testis RNA sample were cloned and sequenced as detailed in materials and methods. Ai and
Bi represent the DNA sequence of the genes compared to the predicted sequences generated by
computational studies. Comparisons were performed using the Bestfit function in the GCG program at
HGMP (www.hgmp.mrc.ac.uk) with default settings. Aii and Bii show the peptide sequence of the
genes. These are compared to the predicted amino acid sequences based on the novel genes.
254
A) DEFB109
i.) Percent Similarity: 100
2 tgagactccatttgcttctccttattctccttcttttttaaattctctta 51
I I I I I I I I I I I I I II I I I II I I I I I I II I I I I I I II I I I I I I I I I I I I I I
TGAGACTCCATTTGCTTCTCCTTATTCTCCTTCTTTTTTAAATTCTCTTA
52 tccccagtaagaggtggtttgggtcctgcggaaggtcattgtctcaattt 101
I II I II II II I I II I II I I I II I I I I I I II I I I II II I II II II I I I II I
TCCCCAGTAAGAGGTGGTTTGGGTCCTGCGGAAGGTCATTGTCTCAATTT
102 gtctggtgtttgcagaagagatgtctgcaaagtagtagaagatcaaattg 151
II I I I II I I I I I II I II I I II I I I I I I I I I I I I I I II I II II II I II II I
GTCTGGTGTTTGCAGAAGAGATGTCTGCAAAGTAGTAGAAGATCAAATTG
152 gtgcctgc 159
I II I I I I I
GTGCCTGC
ii.) Percent Similarity: 100
2 rlhllllilllf*illspvrgglgpaeghclnlsgvcrrdvckvvedqig 51





B) Alternate 'DEFB109' sequence
i.) Percent Similarity: 97.468
tgagactccatttgcttctccttattctccttcttttttaaattctctta 51
I II I I I I I I II I II I I I I II I I I I II I I II I II I I II II I II II I II I I
TGAGACTCCATTTGCTTCTCCTTATTCTCCTTCTTTTTTCAATTCTCTTA
tccccagtaagaggtggtttgggtcctgcggaaggtcattgtctcaattt 101
II I I I I I II I I II I II II I I I II I I II I II I I I I I I I II I II II III
TCCCCAGTAAGAGGTGCTTTGGGTCCTGCGGAAGTTCATTGTCTCAGTTT
gtctggtgtttgcagaagagatgtctgcaaagtagtagaagatcaaattg 151
I I I I I I I I I I I I I II I I I I I I II I I II I I II I I I II I II I I II II I II II
GTCTGGTGTTTGCAGAAGAGATGTCTGCAAAGTAGTAGAAGATCAAATTG
gtgcctgc 159
I I I I I I I I
GTGCCTGC
ii.) Percent Similarity: 92.308
2 rlhllllilllf*illspvrgglgpaeghclnlsgvcrrdvckvvedqigac53
I I I I I I II I I I I II I I I I II II I II I II • I I I I I I II I II I I I I I I II I
RLHLLLLILLLFSILLSPVRGALGPAEVHCLSLSGVCRRDVCKVVEDQIGAC
Figure 6.5: Sequencing of DEFB109 and alternate DEFB109 novel human P-defensin genes and
comparison to predicted genes
Sequences in lower case letters indicate the predicted sequence generated by computational analysis;
sequence in capital letters represents the sequenced RT-PCR products. Ai and Bi represent the DNA
sequence of the genes compared to the predicted sequences generated by computational studies.
Sequences and alignments were generated as previously described (See Figures 6.3 and 6.4). *






This chapter presents data on the expression pattern of five novel human (3-
defensin genes, DEFB105 - 109. The identification of the genes and
subsequent computational and evolutionary analysis was conducted by Dr
Colin Semple, MRC Human Genetics Unit.
All five of the predicted genes were found to be expressed in the testis and
DEFB108 and DEFB109 were also expressed in other tissues but at much
lower levels. It is not clear whether these levels of expression are functional
and further work would be required to clarify this issue. Moreover, it is not
clear if expression of any of these genes can be induced by inflammatory
stimuli or cytokines, and therefore further analysis is required to investigate
if expression of these novel genes shows inducible expression in other
tissues.
It is interesting to note that expression of all of these novel genes was readily
detected in the testis as this appears to be a common site for expressions of (3-
defensins and p-defensin like molecules. In humans, DEFB103 and DEFB104
show very high levels of expression in the testis (Garcia et al., 2001a; Garcia et
al, 2001b), and DEFB1 is also expressed in the testis, but at much lower levels
(Zhao et al., 1996). Expression of DEFB4 in the testis has not been reported.
Furthermore, in the mouse, Defb3 (Bals et al., 1999) and Defensin-related 1
(Defrl) (Morrison et al., 2002a) also show high levels of expression in the
testis.
Expression of several p-defensin-like genes has also been reported in the
testis. In humans, the androgen-dependent epididymis-specific secretory
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protein SPAG11 (EP2) is expressed in the testis and is suggested to have a
functional role in sperm maturation or storage (Frohlich et al., 2001; Lehrer
and Ganz, 2002b). The SPAG11 gene encodes at least nine mRNA variants; it
has two promoters, eight exons and seven introns. Exons 3 and 6 contain
sequences homologous to p-defensins and it has been suggested that SPAG11
evolved from two tandem p-defensin genes reviewed in (Lehrer and Ganz,
2002b). It is interesting to note that many of the testis-specific P-defensin
genes described in this chapter (i.e. DEFB105-107) are clustered around the
SPAG11 gene in the human genome, and may represent an epididymis-
specific P-defensin region (Yamaguchi et al.r 2002). Furthermore, a p-
defensin-like gene, called Binbl, has also been identified in the rat epididymis
(Li et al., 2001). Binbl has been found to be expressed exclusively in the caput
region of the epididymis and interestingly, this area is responsible for sperm
maturation and storage. The gene is maximally expressed when the rats are
sexually mature and is induced by inflammatory stimuli. It is proposed to
function as an antimicrobial peptide. A p-defensin-like gene has also
identified in the mouse epididymis. The testis-specific p-defensin-like gene
(Tdl), which encodes an 83 amino acid peptide and shows the conserved 6-
cysteine motif of p-defensins, was found to be specifically expressed in the
Sertoli cell-lineage in the seminiferous cords of the male gonads when sexual
differentiation is induced in the developing gonads (Yamamoto and Matsui,
2002). It would be of interest to investigate whether p-defensins expressed in
the testis play a structural role or exhibit a function other than as an aspect of
the immune system.
The PCR products of these novel genes were also sequenced and some
showed striking differences compared to the predicted genes. The
sequenced PCR products for DEFB105 showed a 42 base pair (bp) increase in
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the predicted length of the peptide, most notably this additional sequence
produces an additional cysteine, giving the predicted DEFB105 mature
peptide a total of seven as opposed to the normal conserved six (Figure 6.5).
Moreover, this extra sequence formed an additional exon, giving the
DEFB105 gene three exons compared to the two exons that comprise all other
(3-defensins characterised to date. Exons 1 to 3 of the DEFB105 gene are 70,
42 and 119 bp long respectively. The first intron is only 334 bp long and the
second 1200 bp. In is interesting to note that the genes for the a-defensin
human neutrophils peptides, HNP1-4, are composed of three exons
(Linzmeier et al, 1993).
When the PCR products for the gene DEFB109 were sequenced, two different
sequences were identified. One DEFB109 transcript is identical to the
predicted DEFB109 sequence. This sequence shows a stop codon in the
peptide at position 14, this stop codon was present in three independently
sequenced and overlapping BAC sequences (accession numbers AC068974,
AC087203 and AF252830), and therefore DEFB109 is predicted to be a
pseudogene. However, the alternate transcript amplified by the DEFB109
PCR primers has a serine residue substituted for the stop codon and the
presence of an additional three amino acid substitutions compared to the
predicted sequence for DEFB109. Interestingly, a BLAST search analysis
shows that the alternate transcript of DEFB109 sequence matches exactly to a
gene on the BAC (accession number AC092450), which is localised to
chromosome 12 and therefore termed DEFB-likeChrU (Figure 6.6). This gene is
also composed of two exons and the exonic boundaries match those
predicted for DEFB109. Chromosome 12 does not contain any known (3-
defensin loci, and may represent a new locus of (3-defensins, however this
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region remains poorly characterised in terms of mapping. Repeat sequence
analysis of the PCR products from the testis RNA revealed both DEFB109
and DEFB-likeChrlz clones. Therefore, the expression of DEFB109 detected in
the placenta, cervix, thyroid and breast may be exclusively DEFB109 or
DEFB-likeChr12 or, as in the testis, a mixture of the two different transcripts.
Analysis of the PCR products form these tissues with oligonucleotide probes
designed exclusively to DEFB109 or DEFB-likechr12 transcripts should
distinguish the expression profile of these genes.
The sequence derived from the PCR products of DEFB106 and DEFB107 also
deviated from the predicted sequences. The product for DEFB106 contained
36 fewer nucleotides in the first exon compared to the predicted sequence
due to a different donor site than was predicted (Figure 6.3 Bi), resulting in
12 fewer amino acid residues than in the predicted peptide. In contrast,
DEFB107 contained three extra amino acids due to nine additional base pairs
in the second exon, due to a different acceptor site than the one predicted by
computational analysis. Furthermore, the sequence generated from the
DEFB107 PCR product suggests that the DEFB107 peptide lacks the first
canonical cysteine. This is of particular interest given that it has been shown
that the loss of the first cysteine in the murine Defensin-related-1 peptide
(Defrl) does not result in the loss of antibacterial function. Indeed, Defrl
appears to possess particularly potent antimicrobial activity against P.
aeruginosa and it also shows activity against the normally resistant B.
cenocepacia J2315 (Morrison et al, 2002a). Sequencing of DEFB108 also
showed differences compared to the predicted structures, however, only one
of which resulted in an amino acid change with arginine replacing the
predicted lysine. Interestingly, such a change would retain the overall
charge of the peptide as both lysine and arginine are positively charged
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amino acids, and therefore this change may result in only minor alterations
in the antibacterial activity of the peptide.
tgagactccatgtgcttctccttattctccttcttttttcaattctctta
I I I I I I I I I I I I I I I I I I I II II I I I I I I I I II I I I I I I I I I I I I I I I I
670064 TGAGACTCCATTTGCTTCTCCTTATTCTCCTTCTTTTTTCAATTCTCTTA
tccccaggtaag
I I I I I I II I I I I
670013 TCCCCAG-TAAG
cagtaagaggtgctttgggtcctgcggaagttcattgtctcagtttgtctg
I I II I I I I I I I II II I I I I II I I I I I I I I I I I I I I II I I I I I I I II I I I I I
663164 CAGTAAGAGGTGCTTTGGGTCCTGCGGAAGTTCATTGTCTCAGTTTGTCTG
gtgtttgcagaagagatgtctgcaaagtagtagaagatcaaattggtgcctgc





Figure 6.6: BLAST search of DEFB-likechr12 sequence identifies a gene contained on a BAC
located to chromosome 12. The sequence in lowercase lettering represents the input
sequence of DEFB109an, the sequence in uppercase lettering represents the sequence on
BAC AC068974. The search was conducted using BLAST function at the NCBI website.
While the work presented in this chapter was carried out, Schutte et al.,
published a wide spread analysis of p-defensin genes in the human and
mouse genomes (Schutte et al., 2002). This study was able to identify 28
novel human and 43 novel mouse final exon fragments. Whilst this data
identified the second exons for the genes reported in this chapter, however,
first exon sequences were not identified, and neither were the boundaries of
the second exons elucidated. Moreover, the data presented by Schutte et al.
was not verified by experimental analysis of the patterns of expression. Most
interestingly, however, the novel p-defensin genes identified by Schutte et al.
were found at five different chromosomal locations and these loci were in
syntenic regions on human and mouse chromosomes. A search of the human
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defensin locus at 8p22-23 revealed the five genes presented in this chapter,
Schutte et al. named these DEFB5-9 (in this chapter the nomenclature
established by the Human Genome Nomenclature Committee has been
adopted and the genes referred to as DEFB105-109). Wider searches,
incorporating the novel genes, of the draft human genome identified a
further five p-defensins genes (named DEFB101-4) that located to the region
6pl2, and subsequent searches revealed another 15 p-defensin genes
(DEFB16 - DEFB29) at two more locations: 20qll.l and 20pl3. Finally,
subsequent analysis of the entire genome with a hidden Markov model
incorporating all previously identified genes, revealed the existence of a
further 40 6-cysteine genes. However, in only two cases was the spacing of
the cysteines and the cationic charge consistent with p-defensin genes, these
were named DEFB30 and DEFB31 and these genes were also found to locate
to 8p22-23, although this region was not contiguous with the original cluster
and thus may represent a fifth p-defensins cluster (Schutte et al., 2002). The
same procedure was applied to searches conducted of the mouse genome,
which revealed the existence of 43 novel p-defensins genes on chromosomes
1, 8, 14 and two clusters on chromosome 2. Interestingly, these regions are
syntenic with those previously identified in humans (Schutte et al., 2002),
suggesting that these clusters have a common origin.
A very recent report also identified DEFB105 and DEFB106 (reported as hBD-
5 and hBD-6), confirmed their expression as testis-specific, and the three-exon
structure of DEFB105 was also reported by this study (Yamaguchi et al.,
2002). Moreover, the authors also identified the murine homologues of
DEFB105 and DEFB106 as mBD12 (Defbl2) and mBDll (Defbll) respectively,
which were isolated as partial sequences from the Schutte et al. study (2002)
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and interestingly the Defbl2 gene (homologue of DEFB105) was also found to
be composed of three exons.
As was discussed earlier the five novel p-defensin genes presented here
locate to the region 8p22-23 (Figure 6.1). A phylogenetic tree of human p-
defensins (Figure 6.5) reflects the spatial arrangement of these genes (Figure
6.1). The genes DEFB104-7, which form one a separate cluster from DEFB103
and DEFB4 (Figures 6.IB, 6.7 and 6.8) are clustered in together a group
within region 8p22-23, whereas the other cluster formed by DEFB4 and
DEFB103 are located in a region centromeric to the larger cluster. This may
suggest that this cluster was generated by a series of local duplications and
subsequent divergence. It also appears that DEFB105-109 are more closely
related to DEFB104 than to DEFB4 or DEFB103. Moreover, the spacing of
cysteines in DEFB104 are slightly different to that in DEFB1 and DEFB4, in
that there is one fewer amino acid residue between the fourth an fifth
cysteines. Three of the novel genes, DEFB105, DEFB106 and DEFB108, show
this same spacing of the cysteines, although DEFB105 contains an additional
cysteine (residue 43) and has an unusually long propiece due to the
additional exon (Figure 6.7).
Interestingly, six genes that display high levels of similarity (85-98%) to three
of the novel p-defensins presented in this chapter (DEFB105, DEFB106 and
DEFB107) were recently identified in two olive baboon (Papio cynocephalus
anubis) draft genome sequences (Figure 6.7). These genes also displayed
high levels of similarity to the previously identified p-defensin genes DEFB4,
DEFB103 and DEFB104. It is likely that these genes originate from the
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Figure 6.8: Phylogenetic tree of human and baboon (3-defensin protein sequences. The tree was
rooted with chicken gallinacin 1 (GGGAL1) and the reliability of each branch was assessed using 1000
bootstrap replications, pea = olive baboon (Papio cyanocephalus anubis). Figure taken form Semple
etal.{2002)
As was discussed earlier it has been suggested that the evolution of the
defensins has occurred by duplication with subsequent divergence driven by
positive selection. This pattern of evolution has also been observed for rat,
murine and guinea pig a-defensins and also antimicrobial peptides of ranid
and hylid frog species (Hughes and Yeager, 1997; Duda, et al, 2002). An
analysis of the rate of synonymous (ds) and nonsynonymous substitutions
(div) in the first and second exons of human and baboon (3-defensins was
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conducted, according to the method of Nei and Gojobori (1986), and two
different patterns were revealed (Semple et al, 2002). In the first exon, which
encodes the signal sequence of the peptide, the rates of synonymous
substitution were greater than the rates of nonsynonymous substitutions.
This suggests that they are evolving under neutral or possibly very weak
purifying, selection. In the second exon, however, which encodes the mature
peptide a quite different trend was observed; the rate of nonsynonymous
substitutions exceeded those of synonymous (Table 6.3). Moreover, this
pattern was observed for the human (3-defensins and the orthologous baboon
genes. Significant excesses of dN over ds are seen between DEFB1 and
DEFB104 and also between DEF103 and DEFB107 these comparisons were
statistically significant according to the Z-test, and with the exception of
DEFB103 versus DEFB107 also according to the more rigorous Fischer's exact
test (Table 6.3). However, it is difficult to achieve statistical significance
owing to the short length of these peptides.
This pattern suggests that the duplication events, which gave rise to the
different [l-defensins, were followed by rapid diversification driven for
positive selection for amino acid substitutions. Furthermore, a comparison of
the ratios of radical and conservative amino acid changes (Pr/Pc) in the
second exons of genes showing evidence of positive selection were also
analysed (Table 6.2). Averages for the Pr/Pc assessed across 47 genes were
reported as 0.81 and 0.49 for charge and the Miyata-Yasunaga classification
(polarity and volume) respectively (Zhang, 2000). The rates calculated for
the p-defensin genes suggesting positive selection greatly exceeded the rates
reported by Zhang (2000). Moreover, there appears to have been a
predisposition for amino acid changes that alter charge rather than polarity
and volume (Table 6.3). This suggests that, where there is evidence of
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positive selection, most nonsynonymous changes have tended to result in an
alteration of amino acid charge and retention of polarity and volume, such
substitutions were also seen in the a-defensins and frog antimicrobial
peptides (Hughes and Yeager, 1997; Duda, et al., 2002). The evolution of a-
defensins is marked by a pattern of compensation by the propiece for the
mature peptide. It has been suggested that the anionic propiece serves to
balance the cationicity of the mature peptide and thus maintains a neutral
charge in the propeptide, which serves to prevent premature activation of the
defensin whilst it is stored in the granules of neutrophils (Valore et al., 1996).
DEFBl vs DEFB104 DEFB103 vs DEFB107
Human Olive baboon Human Olive baboon
sa 17.917 ± 1.180 17.167 ± 1.169 16.917 ± 1.165 16.833 ± 1.124
N 48.083 ±1.144 48.833 ± 1.181 49.083 ±1.156 49.167 ± 1.124
s 6.25 ± 1.954 6.25 ± 1.954 4.5 ± 1.796 4 ± 1.767
n 35.75 ±3.482 34.75 ±3.559 27.5 ±3.382 27 ±3.373
ds 0.349 ±0.103 0.364 ±0.106 0.266 ±0.104 0.238 ±0.105
dN 0.744 ± 0.062 0.712 ±0.063 0.560 ± 0.064 0.549 ±0.067
Z-test 0.001 0.005 0.020 0.008
Fisher's 0.012 0.019 0.060 0.023
Chargeb
Pc 0.498 ±0.088 0.535 ±0.102 0.447 ± 0.094 0.409 ± 0.094
P R 0.784 ±0.077 0.830 ±0.086 0.571 ±0.087 0.575 ±0.085
Pr! Pc 1.57* 1.55* 1.28 1.41
M-Yc
Pc 0.577 ±0.116 0.708 ±0.108 0.598 ±0.124 0.581 ±0.124
PR 0.618 ±0.092 0.634 ±0.100 0.467 ± 0.080 0.446 ± 0.082
P R t P c 1.07 0.90 0.78 0.77
Table 6.3: Estimated distances and other parameters for comparisons between the second exons
of human and baboon genes demonstrating positive selection. a Estimates (±SE) of the number of
synonymous sites (S), number of nonsynonymous sites, numbers of synonymous substitutions (s),
numbers of nonsynonymous substitutions (n), the number of synonymous substitutions per
synonymous site (ds) and the number of nonsynonymous substitutions per nonsynonymous site (dN).
The result of a two-tailed Z-test (ds - dN=0), and of a Fisher's exact test are also included. b Rates of
radical (p R) and conservative (p c) changes in amino acid properties, with the ratio of radical to
conservative changes (p R / p c) for residues categorised in terms of their charges. Asterices indicate
where p R is significantly greater than p c. c Rates of radical (p R) and conservative (p c) changes in
amino acid properties, with the ratio of radical to conservative changes (p R / p c) for residues
categorised in terms of the Miyata-Yasunaga classification (M-Y; a combination of polarity and
volume). Figure taken form Semple et al. (2002)
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Moreover, it has been proposed that the evolution of the a-defensins has
occurred in a coordinated fashion to preserve the charge balance between the
propiece and mature peptide; with changes in the net positive charge of the
mature peptide balanced by corresponding changes in the propiece (Hughes
and Yeager, 1997). However, a similar pattern of coordinated evolution is
not seen in the P-defensins, this is most probably because the P-defensins are
not stored in granules prior to release and therefore there is no requirement
for the propiece to neutralise the charge of the mature peptide to inhibit its
activity. Similar patterns of adaptive evolution is often observed in genes
associated with the immune system such as lysozyme (Messier and Stewart,
1997), the major histocompatibility complex (Hughes and Nei, 1988) and also
in amphibian antimicrobial peptides (Duda et al., 2002). However, some of
the highest rates of adaptive evolution are observed in genes associated with
testis function and fertility (Johnson et al., 2001).
In summary, this chapter has presented data on the expression pattern of five
novel P-defensin genes. Expression of all five genes was readily detected in
the testis, and DEFB108 and DEFB109 were also expressed at lower levels in
other tissues. Sequencing of these genes revealed striking differences
compared to the computationally predicted gene structure. The results of
sequencing revealed that the DEFB105 gene is composed of three exons,
whereas all previously characterised p-defensin genes are comprised of two
exons. Sequencing analysis also showed that RT-PCR analysis of DEFB109
actually amplified two different transcripts; one transcript matched the
predicted DEB109, this transcript contains a stop codon and may therefore
represent a pseudogene. The DEFB-likeChrl2 transcript contained a serine
residue in place of the predicted stop codon and three further amino acid
changes compared to the predicted DEFB10912 sequence; a BLAST search
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suggested that this sequence matched exactly to an unknown gene on
chromosome 12. Clearly, further analysis is required to investigate to what
extent the detected expression of DEFB109 is due to the predicted DEFB109
or to DEFB109chn2. One of the novel p-defensin genes, DEFB107, lacks the
first canonical cysteine and this is of particular interest in the light of the
isolation of murine Defrl, which lacks the first cysteine and the observation
that it displays highly potent anti-pseudomonal activity (Morrison et al.,
2002a). Moreover, the predicted DEFB105 peptide contains an additional
cysteine and investigation of the antibacterial activity and structure of these
novel peptides would be of great interest.
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7. Conclusions and Future Studies
Antimicrobial peptides comprise an important aspect of innate immune
system of mammals. The p-defensins are a subfamily of antimicrobial
peptides produced by epithelial tissues. Data presented in this thesis further
supports the notion that P-defensins are a large family of salt-sensitive
antimicrobial peptides, with many members as yet uncharacterised. It has
also been shown that murine p-defensins also have chemoattractant ability in
vitro for cells linked to the adaptive immune system.
This thesis has presented studies investigating the antimicrobial activity of
synthetic murine P-defensin Defb2, the human p-defensin DEFB4 and the
novel murine p-defensin Defrl. All peptides showed broad-spectrum salt-
sensitive antibacterial activity against Gram-positive and Gram-negative
bacteria, but the antibacterial activities were found to vary between different
peptides, in terms of both the spectrum of activity and the degree of salt-
sensitivity. The data presented on the activity of DEFB4 is in broad
agreement with previous studies that DEFB4 possesses high levels of salt-
sensitive antimicrobial activity against the opportunistic and CF pathogen P.
aeruginosa. The synthetic DEFB4 peptide used in this study was also shown
to have weaker activity against another common pathogen S. aureus;
however, activity against E. coli was strain specific. Defb2 demonstrated
lower levels of antibacterial activity compared to DEFB4 against S. aureus
and P. aeruginosa but the activities against E. coli were highly similar. That
DEFB4 tended to be more efficient antimicrobial than Defb2 may be due to
the fact that the pathogens analysed in this study mostly are recognised as
human pathogens. It would be of interest therefore to investigate the
activities of these two peptides against murine specific pathogens.
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Furthermore, it would also be of interest to investigate if the function of
different [3-defensin peptides has become specialised to certain bacteria likely
to invade the tissue in which that (3-defensin is expressed. However, as
DEFB4 is not the orthologue of Defb2 differences in the activities of the two
peptides would be expected and therefore it would be interesting to compare
of the activity of DEFB4 with the murine orthologue Defb4, and likewise for
Defb2 and the human ortholgue if one is identified.
The antimicrobial activity of a second batch of synthetic Defb2 (Defb22nd) was
also analysed as a control for further antibacterial experiments (see below).
The two separate batches of Defb2 showed very similar levels of antibacterial
activity against £. coli and S. aureus, but the activity against P. aeruginosa
differed significantly. The first batch killed P. aeruginosa significantly less
efficiently than the Defb22nd. Structural studies suggested that the different
levels of activity may have been due to differently folded peptides.
The antibacterial activity of the novel murine (3-defensin Defrl was also
analysed; this peptide lacks the first canonical cysteine that is present in all
other (3-defensins and this may have resulted in alteration of the
antimicrobial activity. Defrl showed high levels of antibacterial activity
against S. aureus and E. coli in the absence of salt, however, the activity was
markedly reduced by the presence salt. Interestingly, Defrl demonstrated
highly potent antimicrobial activity against P. aeruginosa. This activity was
salt-insensitive at a peptide concentration of 50 pg/ml, but antimicrobial
activity was inhibited by salt at a lower peptide concentration (5 pg/ml). This
suggests that Defrl is a highly potent anti-pseudomonal agent with levels of
activity comparable to DEFB104 (Garcia et al, 2001b). Of great interest was
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the observation that Defrl showed low levels of antibacterial activity the
opportunistic pathogen B. cepacia whereas neither DEFB4 nor Defb2 activity.
Indeed, this pathogen is resistant to the action of most antibacterial peptides
and only one other defensin, DEFB103, (Garcia et al, 2001a) has been shown
to have antimicrobial activity against B. cepacia. Structural studies indicated
that Defrl exists in both monomeric and dimeric structural forms, whereas
DEFB4 and Defb2 exist only in monomeric form. It is suggested that the
potent antimicrobial activity may be associated due to the dimeric structure;
although further investigation of this issue is required.
In view of the potent antimicrobial activity of Defrl, an interesting line of
future work would be to investigate the relative activities of the monomeric
and dimeric isoforms. It may be possible to isolate the different structural
forms following their electrophoresis on a non-denaturing gel. However, it
may be necessary to establish different conditions for peptide folding to
generate the dimeric and monomeric forms separately. As discussed above,
the Defrl peptide lacks the first cysteine present in other p-defensins and this
has resulted in an altered arrangement of disulfide bridges in the defensin
molecule. Consequently, elucidation of the cysteine arrangement and the
relative antibacterial activity of the different bridge-arrangements is also of
great interest and may help explain the potent microbicidal activity of Defrl.
Furthermore, investigation of the mechanism of antibacterial activity of
Defrl, and indeed other p-defensins such as DEFB4 and Defb2, may also be
served by investigation peptide-membrane interactions. Such studies have
been performed for other antimicrobial peptides using lipid vesicles
composed of known and varied lipid compositions.
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Another fruitful area of research would be mutational studies comparing the
antibacterial activity of the wildtype p-defensin peptides against various P-
defensins with altered residues. This may be possible using p-defensins
produced in bacteria using a His-tag system that has been previously used to
produce recombinant DEFB103 peptides (Schibli et al., 2002) (Harder et al.,
2001). The antibacterial activity and structure of the mutated peptides can be
then be analysed and such studies may generate insights into the role of
specific residues in the antibacterial activity. For example, the normally
conserved cysteine could be introduced into Defrl, or conversely the first
cysteine could be knocked out of Defb2 and the effects of these changes on
antibacterial activity could then be assessed. Such studies may reveal if the
unusual structure of Defrl is connected with it potent antimicrobial activity.
Another possible line of investigation would be to alter the cationicity of P~
defensin peptides, because if the activity of P-defensins is driven by the
overall charge of the peptide, then such alterations are likely to affect
antibacterial activity.
Of particular interest are the observations that whereas Defrl shows potent
and salt-insensitive antibacterial activity against the Gram-negative P.
aeruginosa and weak activity against the highly resistant B. cenocepacia. The
human p-defensin DEFB103 shows potent and salt-insensitive antibacterial
activity against the Gram-positive S. aureus and also shows antimicrobial
activity against an environmental strain of B. cepacia. Clearly therefore, these
two p-defensin peptides have some striking similarities in their activities and
also some interesting differences. Given the innate resistance B. cepacia
complex species to many conventional antibiotics and antimicrobial peptides it
would be of particular interest to investigate the structural similarities
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between these two peptides. Such investigations may aid in the elucidation
of specific structural regions, residues and/or properties possessed by these
peptides that may confer the observed potencies. Moreover, any potential
functional regions can then be assessed using the mutational analysis
described above or peptides could be further altered to generate more
effective antimicrobial peptides that as potential therapeutic agents. These
studies could be conducted using the in vitro assay used in this thesis and
then progress to using in vitro primary cultures of airway epithelial cells
followed by in vivo animal studies.
P-Defensins do not act in isolation in vivo, and therefore investigations of the
interaction of p-defensins with other components of the immune system such
as antimicrobial peptides (including other defensins) and cellular aspects of
the immune response may further elucidate the role of these peptides under
more physiological conditions. In concert with these studies, it would also
be of interest to investigate the concentrations of p-defensins and salt at
various epithelial surfaces; these issues are largely unresolved and clearly
influence the effectiveness of these peptides as innate antibiotics. Moreover,
mouse models in which the p-defensin loci have been knocked out would
also prove enormously useful in further investigation of the function of these
peptides as they would display the sum effects of the loss these peptides.
However, due to the identification of several p-defensin loci the task would
not be trivial. Although, if a complete knockout could be generated it may
be possible to replace the murine p-defensins with human P-defensins as
bacterial artificial chromosome (BAC) transgenes; this would provide a
useful system for investigating the activity of human p-defensins in a
physiological environment.
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This thesis has also presented novel data on the chemoattractant activities of
Defrl and Defb2 for various immune-related cells. Defrl and Defb2 were
shown in vitro to induce migration of CD4+ T-cells and immature dendritic
cells, but not mature dendritic cells or neutrophils. This pattern of responses
is in agreement with that seen with DEFB4 in previous studies (Yang et al,
1999). Cell responses occurred at lower concentrations than the antibacterial
activity (nanomolar as opposed to micromolar) and thus may reflect a more
physiological concentration. However, further studies are required to
investigate if these responses are chemotactic or chemokinetic. Experiments
to address this can be performed using a checkerboard assay, although these
are not ideal and so this issue may be better addressed using the chemotaxis
chamber designed by Jeon et al. (2002) that establishes gradients of
chemoattractant substances. Furthermore, previous studies have suggested
that there is a dichotomy between the subtypes of CD4+ T-cells attracted by
a-defensins (naive T-cells) and p-defensins (memory T-cells) and this is
clearly an area for future investigation. Moreover, the populations of
dendritic cells used in the studies presented here did not have a high level of
purity, which may have adversely affected the observed levels of migration.
Consequently, therefore, it may be necessary to find an alternative source of
dendritic cells that will provide a population of acceptable purity, and this
can be done by depleting contaminating cells from the bone marrow cultures
by antibody-dependent complement-mediated depletion. The migratory
activities of neutrophils, CD4+ T-cells and dendritic cells were analysed in
this thesis and there is clearly much scope to investigate the migration of
other cell types, such cell types could include CD8+ T-cells, B-cells, mast cell
and monocytes/macrophages, and also to investigate which receptor is
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involved in cell migration. Moreover, the effect of Defb2 and Deftrl on other
functions of immune cells (e.g. degranulation, cytokine production) could
also be analysed.
The mutational studies described above can also be used for studies to
investigate the chemoattractant activities of Defrl and Defb2; for example, it
is not clear what form or forms (i.e. monomeric or dimeric) of Defrl acts as
the attractant. For example, a conserved region of DEFB4 has been found
shown to have homology with the chemokine MIP3a, and to mediate the
chemotactic activities of DEFB4 and some of these properties are also
conserved, at least in the nature of the residue, in the murine p-defensins
analysed in this thesis. Therefore, it would be of great interest to introduce
amino acid changes in the corresponding region of Defb2 and Defrl to
investigate if this region plays a role in the chemoattractant for example by
mutating the conserved glutamate residue for a positively charged amino
acid such as arginine.
It would also be of interest to use animal models for the analysis of cell
migration by defensins. Such studies would clearly be of more relevance to
the physiological function of p-defensins as they would incorporate 'indirect
chemotaxis' induced by defensins (e.g. defensins may induce production of a
chemokine such as IL-8, resulting in migration cell type not directly activated
by defensins). It may be possible to deliver p-defensins by subcutaneous
injection or intratracheal instillation and then to investigate the cell types that
are recruited.
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This thesis also described an attempt to establish a stably transfected cell
culture-based system for the production of murine and human p-defensins.
Mouse mammary C127 cell lines were established that stably expressed
various human and mouse p-defensins. However, sufficient levels of p-
defensins were not detected to make this system of use in future work in that
it did not display increased antibacterial activity compared to the
untransfected cell line. Moreover, expression of the defensins was not
detectable by northern analysis, which may further suggest that the P~
defensin were not produced at sufficient levels. It is quite possible that cell
lines that expressed high levels of defensin suffered a growth disadvantage
compared to non-expressing or low expressing lines, which may therefore
have come to dominate the cell culture. Therefore, this work, if repeated
may benefit from use of the repressor plasmid system. However, since the
conception of this aspect of this thesis separate studies have suggested that
sufficient quantities of functional and correctly folded P-defensins can be
produced in bacteria. Such a system would ideal be given that it can produce
sufficient quantities of peptide for analysis of antibacterial activity and also
in light of the future work suggested above in that it can be used in
conjunction with in vitro site-directed mutagenesis system. However, it may
also be advantageous to use virally infected mammalian cell cultures to
produce p-defensins in situ, such studies may generate tissue -specific N-
terminal splice variants of the p-defensins. Moreover, viral-based system
could be used to infect primary cultures of mammalian tracheal cells that
could subsequently be used to analyse the antibacterial activity of p-
defensins produced in situ on a functional epithelial surface.
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Finally, this thesis has presented data on the expression patterns of five novel
human p-defensins. All were found to be expressed at high levels in the
testis and some were also present at much lower levels in other tissues. The
sequence and frequency of potential polymorphisms in these genes needs to
be confirmed by further sequencing. The RT-PCR analysis presented in this
thesis shows that these novels genes are expressed, which may suggest that
they are not pseudogenes. A clear future strand for this project is to analyse
the antibacterial activity of these peptides as for previous P-defensins.
Further characterisation of these genes is required in particular in DEFB109,
which yielded two transcripts and DEFB107 lacks the canonical cysteine and
in light of the striking function of Defrl, investigation of the activity of this
peptide is of particular interest.
In summary, the studies presented in this thesis have demonstrated that p-
defensins possess salt-sensitive antimicrobial activity against Gram-positive
and Gram-negative bacteria. Moreover, they have shown that the loss of the
normally conserved first canonical cysteine in Defrl does not result in loss of
activity. They have also demonstrated that Defrl is a highly potent anti-
pseudomonal agent and has antimicrobial activity against B. cenocepacia - an
opportunistic pathogen that is normally resistant to antimicrobial peptides
and causes severe problems ion cystic fibrosis patients. Furthermore, these
studies have suggested that Defb2 and Defrl are chemoattractants for CD4+
T-cells and dendritic cells and may provide a link between the innate and
adaptive immune system. Finally, this projected has confirmed the
expression of several novel human p-defensins, which further suggest that
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